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Zusammenfassung 
 
Diese bioinformatische Dissertation beschreibt die tumorbiologische Hypothesengenierung, 
insbesondere im Kontext des Kolorektalkarzinoms.  
Hintergrund der Studien ist eine Beobachtung aus der klinischen Praxis. Verschiedene Autoren 
berichten, dass bei der Behandlung mit Inhibitoren des Epidermalen Wachstumsfaktor Rezeptors 
(EGFR), speziell des therapeutischen Antikörpers Cetuximab, eine Minderheit der Patienten die übliche 
Nebenwirkung der Hauttoxizität nicht oder in deutlich verminderter Form zeigt. Bei diesen Patienten 
wird gleichzeitig eine reduzierte Wirksamkeit der Therapie beschrieben. Das Ausbleiben der 
Nebenwirkung wird somit als phänotypischer Biomarker genutzt, um gegebenenfalls die Therapie 
anzupassen. Nachteilig erscheint in diesem Kontext allerdings die präventive Hautpflege sowie die 
Tatsache, dass eine Cetuximab-Behandlung zunächst gestartet werden muss, um eine Information 
über die Wirksamkeit zu gewinnen. Dadurch, dass der zugrunde liegende molekulare Mechanismus 
unbekannt ist, kann keine Vorhersage anhand eines klinischen Test getroffen werden. 
In der vorliegenden Arbeit war es das Ziel, Hypothesen zu generieren, welche Proteine und zellulären 
Signalwege kausal für das unterschiedliche Ansprechverhalten der Patientengruppen sein könnten. 
Ausgehend von der Annahme, dass natürliche Keimbahnvarianten in der Erbinformation der 
Individuen im Behandlungskontext diskriminatorisch wirken, baut die Dissertation auf einem kleinen 
Datensatz von 23 Exomen von Teilnehmern klinischer Studien auf. Diese Sequenzierungsdaten wurden 
in genomische Varianten überführt und auf ihren potentiellen genetisch-mechanistischen Einfluss hin 
untersucht. Gezielte Einschränkungen wurden dabei anhand einer Modellierung des biomedizinischen 
Kontextes des Anwendungsfalls eingeführt, um die reduzierte Datenlage gezielt mit Informationen 
anzureichern. Die so erhaltenen Kandidatengene, welche in nachfolgenden praktischen Arbeiten 
validiert werden müssen, werden im Einzelnen beschrieben und bewertet. 
Methodisch ist das Ergebnis dieser Dissertation die „Molecular Systems Map“, eine in Cytoscape 
modellierte Netzwerkstruktur, die funktionelle Interaktionen zwischen Proteinen interaktiv visualisiert 
und gleichzeitig als Filter auf Basis des biologischen Kontexts dient. Ziel hierbei ist es, einen 
biomedizinisch ausgebildeten Fachanwender bei der Generierung von Hypothesen zu unterstützen, 
indem im Gegensatz zu sonst häufig anzutreffenden tabellarischen Ansichten die Ergebnisse aus der 
Sequenzanalyse in eben jenem funktionalen Kontext dargestellt werden. Darüber hinaus wird so die 
Anwendung von Graphenalgorithmen und die Integration weiterer Daten ermöglicht, z.B. solcher aus 
komplementären ‘omics-Experimenten.   
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Abstract 
 
This bioinformatics thesis describes work and results from a study on a use case in the context of 
colorectal cancer. 
Background of the studies is an observation form the clinical practice. Various authors report that upon 
treatment with inhibitors of the Epidermal Growth Factor Receptor (EGFR), in particular with the 
therapeutic antibody Cetuximab, a minority of patients does not, or in a clearly reduced form, show 
common adverse effects of skin toxicity. For these patients, at the same time a reduced efficacy of the 
therapy is described. The lack of the adverse effect therefore gets used as a phenotypic biomarker for 
inducing a switch of therapy. However, preventive skin care during treatment, counteracting the 
biomarker signal, and the necessity to start the therapy first in order to gain the information, appear 
unfavorable. As the underlying molecular mechanisms remain elusive, predictions ahead of treatment, 
e.g. by a clinical test, are not possible yet. 
In the presented work, the aim was to generate hypotheses, which proteins and cellular signaling 
pathways might be causal for the differentiating response of the patient groups. Starting from the 
assumption that naturally occurring germline variations functionally discriminate individuals in the 
context of the treatment, the thesis builds up on a small dataset of 23 exomes of patients from a clinical 
study context. These sequencing data were processed to genomic variants and analyzed for their 
potential influence on the mechanistic level. Targeted restrictions were introduced by modeling the 
biomedical context of the use case in order to enrich the sparse individual data with further 
information. The obtained candidate genes, which are necessary to be validated in practical studies, 
are described and evaluated in detail. 
Methodologically, the result of the thesis is the „Molecular Systems Map“, a network data structure 
modeled in Cytoscape, interactively visualizing the functional interactions of proteins and 
simulatenously filtering the called variants upon the biological context. Here, the aim is to enable 
biomedical domain experts, beyond scrolling tabular information on called variants, to review their 
experimental data in the functional context and support them in the hypothesis generation process. 
Additionally, this provides the opportunity to apply graph algorithms and integrate further data, e.g. 
such from completary ‘omics experiments.
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1. Introduction 
This thesis is set at the intersection of computer science, biology and medicine. From a clinical of view, 
the subject of interest is colorectal cancer, which for a relevant amount of patients is treated using 
therapeutic antibodies targetting the Epidermal Growth Factor Receptor (EGFR), being a key molecular 
factor promoting tumor growth. However, for a minority of patients, anti-EGFR treatment fails, 
indicated by missing skin toxicity reactions, which are a usual adverse effect. Meanwhile, the rationals 
for this observation, subsequently named “skin rash phenomenon”, remains elusive. In terms of tumor 
biology, this raises the question for the underlying molecular mechanisms. Although in cancer settings 
plenty of knowledge has been collected over the years, a transparent model allowing prediction of 
treatment success upon any measurement does not yet exist. Therefore, this thesis targets a small 
number of patient-derived next-generation sequencing datasets and aims to bring the individual 
variations into a general mechanistic context derived from literature. For the latter, a number of 
considerations were made on potentially involved proteins and mechanisms from cellular signaling, 
immunology and cell adhesion.  
Taken together, the following sections provide deeper insights into the factors building grounds for 
this thesis. Starting clinically from CRC and its treatment (Section 1.1), tumor biology with a focus on 
EGFR signaling is highlighted (Section 1.2). Section 1.3 is based to a larger extend on a review on the 
skin rash phenomenon by Mario Lacouture [Lacouture 2006] and related work. These publications in 
particular, and a range of more general knowledge, formed ground for the basic assumptions and 
rationals (Section 1.4). Finally, as the integrative target data structure and user interface has been 
decided to be a visual network, a short corresponding review and argumentation is given in Section 
1.5. 
 
1.1 Epidemiological and clinical aspects of colorectal cancer 
Colorectal cancer (CRC) as third most diagnosed cancer in both women and men [Siegel et al. 2012] is 
an epidemiologically important factor among cancer cases worldwide, accounting for >1.2 Mio. 
diagnoses per year, 520,000 of them registered in the western hemisphere [Ferlay et al. 2010]. In 
Germany, every seventh diagnosed cancer is CRC. Mortality rates are decreasing, ranging from 35% to 
50% [Moriarity et al. 2016]. With 26,000 deaths per year in Germany due to CRC, absolute numbers 
are still high, meanwhile, 478,000 new cases were detected [Robert Koch-Institut 2015]. 
Approximately, every second patient is diagnosed to already suffer from metastatic CRC (mCRC), 
lowering chances for recurrence-free curation [Tjandra & Chan 2007]. 
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Considering these numbers and the fact that in both the US and Germany every fourth death is caused 
by cancer [Siegel et al. 2012; Robert Koch-Institut 2015], effective treatment of CRC is a crucial factor 
in health care. 
CRC typically originates from benign tumors forming polyps. Symptoms like longer lasting diarrhea, 
cramping pain, rectal bleeding etc. occur late in tumor development and are ambiguous for other 
diseases and intolerances, too. Consequently, definite diagnoses are often made in late stages, in 
which the cancer has already grown into the surrounding tissue and even metastasized to other organs 
[NIH-NCI 2016a]. 
Following the American Cancer Society’s guidelines [NIH-NCI 2016b], standard of care for both stages 
0 (no growth of the tumor through the colon’s inner lining) or I (penetration, but no growth beyond 
the colon wall or nearby lymph nodes) is resection of the polyp and, if necessary, parts of the colon. 
While for stage II (spreading to nearby tissues, but not lymph nodes), adjuvant chemotherapy after 
surgery may be considered in order to avoid recurrences, it is the standard treatment for stage III CRC. 
In this stage, nearby lymph nodes are affected, but no other organs. Potentially detached cancer cells 
may be targetted by radiation therapy. 
For stage IV CRC, cancer cells have metastasized into other organs and tissues most likely to liver, lungs, 
the peritoneum or distant lymph nodes. In this systemic setting, surgery is regarded as unlikely to be 
useful. Neoadjuvant chemotherapy may be a treatment option to weaken and shrink cancerous sites 
first, improving chances for curative surgery. Apart from selected chemotherapeutics and often 
combined like 5-Fluorouracil (5-FU), oxaliplatin, irinotecan and other cytostatic drugs, targeted 
therapies invoking monoclonal antibodies (mAbs) have entered the clinical practice. Recently, a 
notable positive effect of these new biologic drugs has been described, as quality of life (QoL), 5-year 
and overall survival have been significantly improved for advanced CRC [Wen & Li 2016]. The 
combination therapies are subject to recent clinical studies on effectiveness in the context of the stage, 
molecular status and even location of the tumor (comp. e.g. [Ciliberto et al. 2018]). Additionally, 
decisions for or against a certain medication depend on the patient’s health parameters as well as on 
the personal genomic background [Ab Mutalib et al. 2017; Patel et al. 2018]. Anyhow, although 
pharmacogenetics/-genomics have been described as a hope for individualized medicine some years 
ago (comp. [Ma & Lu 2011]), practically applied knowledge appears sparse.  
Nowadays, the signaling pathways of two growth receptors are primarily tackled, namely these of 
Epidermal Growth Factors (EGF and similar) and the Vascular Endothelial Growth Factor (VEGF). Both 
are classical representatives for two of the popular ‘cancer hallmarks’ [Hanahan & Weinberg 2000, 
2011]. In the case of a de-regulated EGF receptor (EGFR) pathway, primarely proliferative signaling is 
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sustained, enabling the hallmark ‘self-sufficiency in growth signals’, a basic feature of tumorous 
growth. However, the EGFR pathway also stimulates another five of the six cancer hallmarks of the 
first model of Hanahan and Weinberg: independence of growth signals, insensitivity to growth-
inhibitory signals, resistance to programmed cell death, angiogenesis, and metastasis [Gazdar 2009]. 
VEGF induces and sustains the more advanced hallmark of angiogenesis, which describes the 
formation of local blood vessels through vasculogenesis (de novo) and angiogenesis (from pre-existing 
vessels). In the context of cancer, tumors of a size beyond 1-2 mm require dedicated ingrowth of 
capillaries, as the process of diffusion of oxygen and nutrients through tissues gets insufficient for 
further progress of the malignant cell mass [McDougall et al. 2006]. Gaining a mutation that enables a 
tumor to overexpress VEGF therefore is denoted as ‘angiogenic switch’ and marks an important point 
in tumor development. In turn, therapeutic shutdown of VEGF signaling (e.g. ligand blocking using the 
therapeutic antibody Bevacizumab [Ohhara et al. 2016]) is intended to inhibit the formation of new 
vessels, to abolish immature ones and to decrease the vascular wall’s perfusion rates. Consequently, 
the blood-derived supply with oxygen and nutrients is impaired, tumors which already facilitated the 
angiogenic switch may shrink [Willett et al. 2004]. 
 
1.2 EGFR signaling and Cetuximab 
The epidermal growth factor receptor (EGFR), discovered 1978, is a transmembrane receptor tyrosine 
kinase and a prototypic representative for both the ErbB receptor family as well as the superfamily of 
receptor tyrosine kinases (RTKs) [Carpenter et al. 1978; Wells 1999; Seshacharyulu et al. 2012]. RTKs 
are cell surface receptors, which show high affinity to growth factors, cytokines and hormones 
[Robinson et al. 2000], and encompass also the VEGF receptor (VEGFR). In general, those molecular 
on/off switches forward signals from the cell’s surface to downstream cascades by phosphorylation of 
the intracellular thyrosine kinase domain, resulting in variation of gene expression. 
The ErbB family consists of four known members in humans (ErbB1/EGFR/HER1, ErbB2/HER2/Neu, 
ErbB3/HER3 and ErbB4/HER4) [Seshacharyulu et al. 2012], of which the first two are known to be 
overactive in various solid tumors [Cho & Leahy 2002]. For EGFR, at least seven different activating 
ligands are known, including EGF, transforming growth factor-alpha (TGFα) and heparin-binding EGF 
(HB-EGF) [Linggi & Carpenter 2006]. These trigger various dimerizations of ErbB family member 
monomers [Schlessinger 2002], reflecting the general ability of RTKs to expand both the spectrum of 
bindable ligands and the diversity of recruited downstream pathways [Holland et al. 2003]. 
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Cellular target mechanisms of EGFR signaling are as diverse as important. They include protein 
secretion, cell motility, the balance between mitogenesis or apoptosis as well as differentiation and 
dedifferentiation. In cancer settings, the ability of the EGFR pathway to promote survival and growth, 
is an important factor for tumor progression, tissue invasion and metastasis [Wells 1999]. 
Although the reported percentage of tumors (CRC, but also lung, head and neck, and gliomas) varies 
between 25% and 82% [Krasinskas 2011], a majority of cancer cases is reported to overexpress EGFR, 
showing an association with progression to malignancy, more advanced tumor stages, poor 
differentation, worse histologic grade, lymph vascular invasion and finally, poor prognosis [Yarom & 
Jonker 2011; Grandis & Sok 2004]. EGFR as a target for cancer therapy was already focussed in the 
1980s [Aboud-Pirak et al. 1988], resulting in the first therapeutics fifteen years later. All those 
inhibitory drugs belong to either the class of tyrosine kinase inhibitors (TKIs) or monoclonal antibodies 
(mAbs) [Melosky et al. 2009]. TKIs in general are small molecules, acting on the intracellular kinase 
domain, blocking downstream signaling. In contrast, therapeutic antibodies act on the extracellular 
receptor domain. Additional to blocking EGFR signaling, it is assumed that immune responses against 
the mAB’s tail, e.g. via the complement system, may also contribute an effect [Holubec et al. 2016]. 
Gefitinib was the first TKI, approved for the treatment in non-small cell lung cancer (NSCLC) since 2002 
in Japan [evaluate.com 2002], 2003 in the US [NIH-NCI 2011] and 2009 in Europe [EMA 2009], 
respectively. Erlotinib, another TKI, received approval in 2005. In 2004, with Cetuximab the first 
antibody directed against EGFR entered the market [NIH-NCI 2013a], followed by Panitumumab in 
2006 [NIH-NCI 2013b]. Both were dedicated to CRC first [Ohhara et al. 2016]. For both TKIs and 
antibodies, further molecules became available and for most of them the range of application was 
iteratively extended to other cancer entities with overexpression of EGF(R).  
Shortly after those new drugs had entered the market and clinical practice, conditionals in treatment 
emerged. On the one hand, genetic factors like target variations in the tumor (e.g. EGFR mutations 
[Paez et al. 2004; Lynch et al. 2004]) or ethnical background (e.g. Asian or European origin), but also 
further epidemiologic parameters like environmental influences (smoker or not) show an effect on 
treament efficacy [Gazdar 2009; Stuart & Sellers 2009]. On the other hand, the treatment procedures, 
especially the combination and sequence of options (radiation, various chemotherapeutics, TKIs, 
mAbs), are subject of intensive discussions and clinical studies. While (neo-)adjuvant chemotherapy 
plus blockade of EGFR are intended to be more effective than monotherapy [Yazdi et al. 2015], other 
authors decline any effect in adjuvant settings and a controversial one in neo-adjuvant treatments, 
where the aim is to shrink the tumor in order to allow resection [Schmiegel et al. 2008]. Also common 
mutations in functionally connected genes are accepted to be crucial for certain decisions – for 
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example, activating KRAS mutations exclude the application of EGFR inhibitors, as proliferation signals 
are generated downstream of EGFR in this setting [Karapetis et al. 2008]. 
While KRAS mutations are known to be the causal reason for a lack of therapeutic effect, mechanistic 
backgrounds of side effects remain elusive. Consequently, the occurrence of skin rash as an adverse 
effect of Cetuximab application can be used as a predictive biomarker for treatment efficacy, but not 
predicted itself. 
 
1.3 Cetuximab, skin rash and anti-tumor efficacy 
Even before FDA’s approval of EGFRIs, their dermatologic side effects were reported [Herbst et al. 
2003] and became subject to various intensive discussions, dedicated to classification, treatment 
guidelines, the patient’s psycho-social discomfort and the urgent need for mechanistic understanding.  
Skin toxicity as an adverse effect in EGFRI treatment describes a variety of symptoms affecting the 
epidermis, hair follicles and periungual tissues [Lacouture 2006]. Usual symptoms are papulopustular 
rash in sun-exposed areas like head (scalp and eyelashes), chest (V-shaped area) and legs, dry and itchy 
skin, pruritus, abnormalities of hair and nails, up to pain in extreme cases [Robert et al. 2005]. The 
pathology overall has often been named as ‘acne-like’ by various authors, although there are no shared 
features in terms of histopathology and pharmacologic response (reaction to anti-inflammatory drugs, 
but not anti-acne agents; [Lacouture 2006]). By observation, there is a certain sequence of symptoms 
observed in the majority of patients (comp. Fig. 1). 
In the affected areas, tissues are constantly growing, triggered by EGF signaling. The activation of EGFR 
leads to a controlled sequence of cell proliferation, migration and differentiation, primarely for 
keratinocytes [Jost et al. 2000]. Consequently, the skin shows a high degree of self-organization when 
viewed in cross section (comp. Fig. 2). Generally, the skin subdivides into multiple layers: hypodermis, 
dermis (both contain blood vessels), epidermis and finally the stratum corneum. The basement 
membrane, separating dermis and epidermis, is the location of undifferentiated, basal keratinocytes, 
which in turn make up the major epidermal cell type [Lacouture 2006]. Most importantly, 
developmental physiology of the skin depends on keratinocyte maturation, which includes a migratory 
movement towards the skin surface and ends in apoptosis [Candi et al. 2005]. The terminal 
differentiated cells are designated as corneocytes. Maturation as well as the fragile balance between 
migration and adhesion is highly regulated [Fuchs & Raghavan 2002]. Although the EGFR pathway 
orchestrates these mechanisms, the molecule itself is expressed in keratinocytes of the basal and 
suprabasal layers only [Nanney et al. 1990]. 
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Fig. 1 - Sequence of rash events in EGFRI-treated patients. While skin-related effects occur immediately in the first week 
upon EGFRI application, disturbances of (slower growing) hair and nails take weeks to manifest. Xerosis, presumably through 
hypofunction of sebaceous glands, also appears as late symptom. In between, crusting and visibly dilated vessels in the skin 
appear (from: [LoRusso 2009]). 
 
 
Fig. 2 - The structure of the skin and EGFR location. The multilayer model of the skin from Lacouture 2006. While below the 
basement membrane dermis and hypodermis are supplied by bloods vessels, the epidermis consists to approximately 90% of 
keratinocytes. At hair follicles, the basement membrane is invaginated, but continuous. Here, like everywhere immediately 
at the epidermal side of the basement membrane, undifferentiated keratinoycytes are constantly proliferated from stem 
cells. These basal keratinocytes express EGFR. On their way to the skin’s surface, EGFR expression gets lost soon. However, 
activation of the EGFR pathway triggers the differentatiation of keratinocytes to terminal corneocytes. During the progression 
from epidermis to the stratum corneum, keratohyalin is massively expressed and stored in granules. Meanwhile, the cell 
undergoes apoptosis. The final anucleated corneocytes make up the protective layer against the outside.  
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Vice versa, inhibition of EGFR disrupts the skin’s integrity by accelerating the maturation of 
keratinocytes by arresting growth and migration (comp. Fig. 3). Premature keratinocytes proceed to 
terminal differentiation too early, reducing the epidermal thickness and impairing the stratum 
corneum. Simultaneously, EGFR blockade triggers recruitment of immune cells, causing local 
inflammation, apoptosis, tissue damage and dilated vessels [Lacouture 2006]. While the skin’s barrier 
function to the extracorporal environment is affected overall, simultaneously bacteria and other 
microbes can enter the skin, further amplifying the immune cell’s reactions [Eilers et al. 2010]. 
 
 
Fig. 3 - Flowchart model of EGFRI-induced reactions of the skin according to Lacouture 2006. Inhibition of EGFR leads to 
arrest of growth and migration, apoptosis as well as chemokine expression immediately. Consequently, inflammatory cells 
get locally recruited, amplifying cutaneous injuries. These include tenderness of the skin and rash, at hair follicles and nail. 
Longterm effects like xerosis, pruritus and macroscopic disturbances of hair and nails rely on persistent abnormal maturation 
and differentiation of the skin tissues. 
 
Although for the majority of patients the EGFRI side effects are mild, <15 % develop severe toxicities 
[Melosky et al. 2009], which significantly lower the quality of life. In these cases, dose modifications 
(three quarters of cases), treatment delays or even discontinuation of therapy is the consequence for 
a third of the patients [Lacouture 2009].  
Therefore, rash management is key during EGFRI treatment, supporting the patient tolerance and 
compliance [Lacouture & Melosky 2007]. Consequently, over the last decade dermatology-driven 
recommendations for preventative/prophylactic and reactive treatment of skin toxicities have been 
published (e.g. [Lacouture et al. 2011]). As most of the clinical study reports use the National Cancer 
Institute’s Common Terminology Criteria for Adverse Effects (NCI CTCAE; current version is 5.0 [NIH-
NCI 2017]), classifiers for reactive treatment start from a diagnosed grade of toxicity, ranging from mild 
(grade 1) over moderate (grade 2) up to severe (grade 3/4) adverse effects. Usual treatments are 
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topical application of moisturizers, suncream and hydrocortisone, systemic reactions are counteracted 
with Minocycline or Doxycycline orally. 
However, the CTCAE to date is not primarely designed for classifying EGFRI-induced skin toxicities, 
leading to underreported severity and consequently underadjustment of therapy. In turn, the 
Multinational Association for Supportive Care in Cancer (MASCC) offer their EGFRI Skin Toxicity Tool 
(MESTT) [Lacouture et al. 2010]), correlating well with CTCAE in grading, and providing a more precise 
catalogue of adverse effects in order to support the still subjective classification [Lacouture et al. 2011]. 
This subjectivity may be one major source for varying fractions of patients with a certain grading when 
comparing multiple studies. 
Despite all discomfort, there is a positive aspect on skin rash as an adverse event: similar to the early 
description of EGFRI-induced skin reactions, a correlation between its severity and positive treatment 
outcome was reported even before FDA approval of Gefitinib [Herbst 2003]. Clinically similar 
observations have been made shortly after also for anti-EGFR antibodies, first in Cetuximab [Peréz-
Soler & Saltz 2005; Lacouture 2006]. Anyhow, considering the two classes of EGFR-targeted classes of 
EGFRIs (mAbs and TKIs), differences with regard to incidence, severity and onset have been claimed 
[Melosky et al. 2009] so that this thesis, except as otherwise stated, relates to mAbs in general and 
Cetuximab in particular. 
To date, the oncology community is deeply interested in this repetitively described connection 
between adverse effect intensity, drug activity and survival [Petrelli et al. 2013; Lupu et al. 2015]. For 
years now, skin toxicity is not only regarded as an undesired adverse effect, but also as pleasant 
phenotypical surrogate biomarker: the more severe the skin rash symptoms, the stronger anti-tumor 
effects, the better survival and the less progression [Petrelli et al. 2013]. Ultimately, these observations 
support decisions on optimized dose adaptions or switch of therapy [Leporini et al. 2013], while not 
requiring further invasive testing. Consequently, it is being used in the daily clinical practice – but to 
date, no full mechanistic link could be drawn on the molecular level. In other words: the regulative 
network and its molecular players remain hidden. While certain somatic alterations of EGFR itself, HLA-
A and ABCG2 in the SR-negative patients have been described [Kozuki 2016], those are only 
explainatory for subpopulations of patients.  
Apart from the academic question, the described implications show an important drawback for 
patients: neither drug efficacy nor skin rash severity are predictable, as this visual biomarker appears 
on treatment with EGFRIs only. Additionally, SR may be covered/silenced in the setting of preemptive 
skin care treatments [Leporini et al. 2013]. Therefore, patients have to suffer from likely discomfort 
and possibly severe skin reactions in order to be sure to undergo the appropriate treatment. There is 
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no clinical test at baseline yet, which could identify a priori the roughly 10% of patients who do not 
show any rash or only very mild forms and are likely to be EGFRI-resistant. For those patients, a 
treatment with EGFRIs is suggested as not beneficial [Petrelli et al. 2013], while valuable treatment 
time is lost. 
However, several pieces of knowledge from dermatology, cancer research and immunology are 
already given, providing traces for shedding further light on the molecular genetic background, 
resulting in the stratification of patients into distinct reaction types. 
 
1.4 Basic assumptions and rationals 
In terms of biological tissues, both skin and colon are boundary layers to the environment and share 
some features. They separate the body and the outside, with digestion products being ‘outside’ by 
definition. Both show a constant directed growth in layers and dedicated aging from ‘inside’ to 
‘outside’. Accordingly, skin and colon are immunologically compentent and highly regulated. Diseases 
following a pathologic de-regulation of the respective mechanisms are well-known for both skin (e.g. 
psoriasis [Lowes et al. 2014]) and colon (inflammatory bowel diseases (IBD) [West & Jenkins 2015]), 
often being related to chronic inflammation.  
Meanwhile, molecular mechanisms of inflammation are well known to be involved in carcinogenesis 
in general [Hanahan & Weinberg 2011; Pesic & Greten 2016]. For both skin [Sherwani et al. 2017] and 
colon [Kang & Martin 2017], knowledge on the interaction with the surrounding microbiota is 
accumulating: while the microbe composition influences the balance of immune system cycles, it gets 
increasingly recognized as important factor in the development of cancer as long-term progression of 
chronic inflammation. Even more, in several cancer settings a state of chronic inflammation has been 
reported to be triggered by the tumor itself or its microenvironment, supporting malignant growth 
including successful metastasizing [Smith & Kang 2013]. 
In turn, immunological reactions and carcinogenesis are closely connected to several cell adhesion 
mechanisms. These are highly regulated by pathways, including EGFR signaling. Like for the immune 
system (but also several other regulative molecular networks), only proper balancing of input signals 
prevents the system from pathologic states. Psoriasis may serve as a good example for pathologic 
misregulation of the skin, where immune reactions disturb proper cell adhesion. Interestingly, the 
EGFRI-induced skin rash symptoms are similar to such of autoimmune diseases like psoriasis [Peréz-
Soler & Saltz 2005]. Conversely, for certain autoimmune diseases like systemic lupus erythematosus, 
drug induction has been described [Antonov et al. 2004; Vihinen et al. 2011]. Cetuximab being a strong 
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silencer of EGFR can be regarded as an extrinsic introducer of misregulation. Due to its systemic 
application, non-pathologic tissues in which EGFR plays a major role (like skin, hair and colon), are also 
affected. 
Skin-located cancer cells are excluded as the cause of the rash as metastasizing from colon to 
cutaneous sides is very rare [Saladzinskas et al. 2010]. Although colon and skin share also a similar 
tumor biology, clinical phenotype, morphology, molecular patterns, and defects in cancer-related 
pathways [Berman 2004], there is no knowledge about direct connections between skin and colon 
tumor. However, the correlated clinical observations indicate Cetuximab to be responsible for both 
skin rash and antitumor effects on colon cancer lesions. Therefore, the different grade of skin rash 
between patients is assumed to be caused by minor naturally occurring germline variants somatically, 
not exclusively in the tumor sites (according to Kozuki 2016). Generally, this meets the concepts of 
pharmacogenetics/-genomics, considering individual genetic variance having an influence pathology 
as well as treatment reaction (genome-disease and genome-drug interactions), rising hope for 
individualized medicine [Ma & Lu 2011]. However, while in the light of ‘omics data such knowledge is 
rapidly accumulating for tumor variations, especially in relatively well-studied entities like CRC 
[Bignucolo et al. 2017], systemic consideration of germline variations remains elusive. Interestingly, 
for general drug-induced skin adverse reactions (SCARs), genetic associations the major 
histocompatibility complex (MHC) genes have been reviewed very recently, although with the aim to 
support SCAR prevention [Gerogianni et al. 2018]. 
In a nutshell, the focus is set to naturally occurring germline variants in proteins and pathways which 
are expected to belong to one or more of three major functional groups: signaling, immune system 
and cell adhesion. The investigations aim to identify candidate variations potentially causing the skin 
rash phenomenon in Cetuximab-treated patients on the scale of molecular mechanisms. 
 
1.5 Molecular networks and visualization 
In the given setting, an unknown complex molecular mechanism regulates tissue reactions upon drug 
application, experienced as adverse effects. For a minority of patients, this mechanism is changed, 
resulting in an alternate behaviour. In terms of modeling, functional players (= proteins) and their 
relations (functional interactions) translate best into a network of nodes and edges. Within this 
regulated network, subsets of nodes and relations make up “pathways”, mostly understood as 
signaling cascades utilizing a set of molecules, triggering certain effects upon certain signals. As 
regulation occurs via many cross-reactions between those pathways, the isolated view on defined 
pathways has to be taken as artificially simplified according to biology [Villaveces et al. 2015]. While 
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this may be applicable in tightly sketched scenarios on well- known pathways, incomplete knowledge 
on signaling cascades requires a more general strategy. Here, networks on curated protein-protein 
interaction (PPI) data offer a more complete view, although they do not take into account pathway 
knowledge [Villaveces et al. 2015]. For example, while two proteins A and B are interacting as well as 
B interacts with another protein C, there is no information contained whether A signals to C through B 
in any situation (= no transitivity). Such information has to be inferred from secondary resources like 
measurements or common knowledge. 
Several approaches deal with quantitative data (mostly gene expression; e.g. [Lamb et al. 2006]), 
enabling mathematical modeling and the computation of dedicated scores (e.g. [Li et al. 2009b]). 
Furthermore, weighting of interactions may depend on e.g. assay ratings, probability estimations from 
empirical lab data and voting systems, as multiple references might be taken into account. In turn, 
various databases for interaction data1 take into account multiple resources at a time (incl. biochemical 
assays, association studys and text mining on literature). Accordingly, a current trend in data analysis 
is the integration of various, case-specific high-throughput measurements, coining the term of “multi-
omics” approaches [Huang et al. 2017]. 
Despite the arising complexity, those highly data-driven models appear attractive in terms of precision 
and exact mechanistic decription, and furthermore, they carry the chance to detect connections de 
novo. Anyhow, in the given use case, they are neither applicable nor necessary. This is on the one hand 
simply due to the given amount and type of data: exome data of 23 patients does not provide 
quantitative information. On the other hand, the aim is anyhow to support non-computer scientists in 
hypothesis generation. Here, field expert’s background knowledge is intended to compensate the 
sparse information on the data level, designating this human-driven approach to act on level of high 
abstraction. In contrast to mathematical models, interfacing data and human experts is of central 
importance. Intuitively, the better data is presented, the easier it can be interpreted by connection 
with learned knowledge and personal experience (conclusions/inference). The concept of unconscious 
inference as central element in human visual perception has been introduced already in the 19th 
century and matters of making assumptions and conclusions from incomplete data, depending on prior 
knowledge [Helmholtz 1867]. Accordingly, proper visualization is key for hypothesis generation upon 
sparse data, which is anyhow expected to contain hidden patterns. For humans as visual-centric 
species [Nat. Methods Editorial 2005], the brain’s perception capacities are exhausted soon in the case 
of serial information like full text, lists or tables [Duke et al. 2015]. In contrast, images can carry much 
                                                          
1 For an extensive list, compare https://omictools.com/ppis-category  
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more information of high complexity [Few 2013]. Despite all intuitivity, the role of visual perception in 
particular has been formal subject of research, aiming for effective data visualization [Dastani 2002]. 
Apart from the applicability of graph algorithms in network analysis, networks instantly serve as easy 
and powerful visualizations. While the representation of entities and relations is intuitive, visualization 
complexity increases with the network’s size, although various techniques like node filtering or layout 
algorithms to counteract this phenomenon [Villaveces et al. 2015]. Taken together, terms like “visual 
analytics” or “visual data mining” become common, independent of the particular subject of study 
(e.g. asthma [Bhavnani et al. 2014], gastric cancer [Pastrello et al. 2014] or Parkinson’s disease [Porras 
et al. 2015]). Recently, in the face of the publically available masses of interaction data, awareness for 
usecase-specific manual curation rises, focussing on e.g. a disease or a particular gene of interest 
[Porras et al. 2015]. Aims may be the discovery of new biomarkers [Bhavnani et al. 2014], drug design 
[Sukumar & Krein 2012] or generally the extrapolation of relevant information from data [Pastrello et 
al. 2014]. In other words,: hypothesis generation. Here, interactivity is tremendously important. 
Recently, in a cancer genomics setting it could be proofed that there is a significant positive effect in 
enabling clinicians to interact with genomic reports, resulting in increased user satisfaction and 
improved data interpretation [Gray et al. 2018]. The authors clearly state to integrate interactive 
reports into electronic healthcare records, effectively facilitating the implementation of precision 
oncology. Analogously, from the perspective of future funding efforts for the use of big data in general 
health research, awareness of the importance of visualization has recently been demonstrated 
[Auffray et al. 2016]. Here, for progressing from time-consuming ranking lists and incomprehensible 
“hairball” networks to serious clinical decision support system, disease-specific maps have been 
explicitly suggested to be a considerable way. 
 
  
13 
 
1.6 Aim 
The causal relation between adverse effects and anti-tumor drug efficacy in Cetuximab-treated CRC 
cases is still unknown, but of elevated interest in the context of clinical practice. Starting from a small 
set of selected patients, their somatic sequencing data should be mapped to a disease-specific 
network, depicting protein interactions. This map, being both graphically visualized and interactive, 
aims to support clinical field experts to develop hypotheses on candidate genes and mechanisms to 
investigate further. Beyond the biomedical interpretation of the overall results, the principle of the 
general “Molecular Systems Map” (MSM) and its usecase-specific application represents the core of 
this thesis.  
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2. Materials & Methods 
The strategy for the overall work (Fig. 4) starts at two separate points: on the one hand, this is the 
patient-related exome sequencing data, which has to be converted into gene-centric variation 
information. This process is facilitated in Galaxy (comp. Section 2.3), GEMINI (comp. Section 2.4) and 
a range of custom shell commands and scripts (comp. Sections 2.5 and 2.6). On the other hand, the 
mechanistic context of the usecase from the literature has to be formalized into a network model, 
which is called Molecular Systems Map (MSM; comp. Subsection 2.7.1). This modeling as well as all 
subsequent steps are implemented in Cytoscape. Being the intercept point of the two initially disjoint 
branches, the mapping of the genes annotated in the variant calling to the MSM is the central step 
(comp. Subsection 2.7.2). The in such way populated MSM enables both visual inspection by a field 
expert and the application of graph algorithms, making up the basis for interactive hypothesis 
generation (comp. Section 4.3ff). 
 
2.1 Patient overview 
For the performed analyses, data of patients from two clinical studies where used. Overall, 7 and 16 
patients were selected from the CIOX (or Fire2; [Moosmann et al. 2011]) and FIRE3 [Heinemann et al. 
2014] study, respectively. Apart from clinical and epidemiologic parameters, exome datasets (raw 
paired end short reads in FASTQ format) from 23 patients were provided and used for the initial data 
analysis and generation of the model (MSM; comp. Section 2.7).  
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Fig. 4 - Depiction of the thesis overall workflow. Two branches, processing the NGS data to gene-centric variants of interest 
(left) and modeling the mechanistic context of the usecase according to public knowledge (but also discussion with field 
experts; right), are joined by mapping variant-affected genes to the newly developed central data structure, the Molecular 
Systems Map (MSM; middle). Major components of the left branch are Galaxy for NGS short read processing, GEMINI for 
genomic variant storage and querying, as well as a set of shell commands and custom scripts, primary in awk, but also R. A 
reference genome is necessary. The right branch and all subsequent steps, especially the user-driven ones, are hosted by 
Cytoscape, ultimately supporting interactive hypothesis generation, taking into account both actual NGS datasets and 
functional relations of mechanisms of interest. Basis for the modeling phase is pathway information from Reactome. 
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Tab. 1 - Overview on study patients. Exome data had been generated from the following patients (case report forms/CRFs 
for identification) out of two mCRC studies [Moosmann et al. 2011; Heinemann et al. 2014], where Cetuximab has been 
applied. Skin rash (SR) grades following NCI CTCAE v3.0 [Trotti et al. 2003]. Lab ID and CRF are equal for Fire3 patients, while 
individual labels exist for CIOX. SR = 0/1 indicates for ‘negative’, SR = 2/3 for ‘positive’ group. PFS = progression-free survival, 
OS = overall survival, ORR = overall response rate. 
Study  CRF Lab ID SR grade  Age  Sex  KRAS WT  PFS [months] OS [months] ORR 
CIOX 22 111 2  66  m  no  6.3  30.2  0 
CIOX  67 155 3  56  m  yes  7.0  36.0  1 
CIOX  110 014 3  68  m  yes  8.6  19.4  1 
CIOX  114 072 0  66  f  yes  4.6  17.0  0 
CIOX  129 036 0  71  m  no  1.9  4.9  0 
CIOX  163 125 0  51  f  yes  2.8  11.0  0 
CIOX  167 137 3  75  m  no  5.5  17.9  1 
FIRE-3  20 020 1  71  m  no  2.9  13.6  0 
FIRE-3  90 090 3  57  f  unknown  15.3  63.0  1 
FIRE-3  213 213 3  42  m  yes  61.1  63.5  0 
FIRE-3  281 281 1  68  f  no  1.4  19.2  0 
FIRE-3  344 344 3  73  m  no  63.1  63.1  1 
FIRE-3  375 375 1  67  f  no  1.5  5.0  0 
FIRE-3  406 406 1  65  f  yes  28.4  55.6  0 
FIRE-3  428 428 1  73  m  yes  3.7  3.7  0 
FIRE-3  566 566 3  64  m  yes  14.5  14.7  1 
FIRE-3  586 586 1  59  f  yes  1.9  12.9  0 
FIRE-3  598 598 3  56  m  yes  28.5  28.5  1 
FIRE-3  624 624 3  73  m  yes  3.9  14.2  0 
FIRE-3  638 638 3  61  f  yes  4.9  30.9  0 
FIRE-3  708 708 3  43  m  yes  12.5  27.2  1 
FIRE-3  750 750 1  67  f  no  1.5  4.3  0 
FIRE-3  796 796 1  73  f  yes  1.4  16.0  0 
 
2.2 Exome data 
Generation of exome data has been performed ahead of the presented work, but dedicated to 
uncovering the reasons for the skin rash phenomenon. Between April and December 2012, the data 
were produced at the LMU Gene Center, applying an Illumina Genome Analyzer IIx, which received a 
capacity upgrade in this period. Therefore, multiplexing was introduced for later samples. In 
consequence, the single datasets slightly differ in terms of coverage and quality (comp. Tab. 2). For 
exome targeting, the Agilent SureSelect Human all exon 50Mb kit was used. Raw data sets are listed in 
Tab. 2, a basic depiction of sequence count vs. read lengths in Fig. 5. 
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Tab. 2 - Raw datasets generated at the LMU Gene Center. Data were generated between April and December 2012 as paired-
end reads on overall four chips. In between, the device was upgraded in terms of sequencing capacity, enabling multiplexing. 
Therefore, on later chips samples were distributed across multiple lanes (three or five, respectively), the resulting FASTQ files 
simply concatenated into one each. Descriptive statistics apply for those combined files. Theoretical coverage has been 
calculated assuming an equal distribution of sequenced bases (read count * read length) on 50 Mb target sequence. 
Pat. 
ID 
Lab 
Sequencing 
date 
Chip ID No. 
of 
lanes 
forward/ 
reverse 
[F/R] 
total 
sequence 
count 
read 
length 
[bp] 
GC 
content 
[%] 
theo. 
coverage 
111 2012-04-10 
HWUSI-
EAS632R_00054 
1 
F 49,357,115 85 46 84x 
R 49,357,115 85 46 84x 
155 2012-04-10 
HWUSI-
EAS632R_00054 
1 
F 50,868,088 85 47 86x 
R 50,868,088 85 47 86x 
014 2012-04-10 
HWUSI-
EAS632R_00054 
1 
F 47,536,362 85 51 81x 
R 47,536,362 85 51 81x 
072 2012-05-31 
HWUSI-
EAS1783R_00005 
1 
F 65,239,385 76 50 99x 
R 65,239,385 84 50 110x 
036 2012-04-10 
HWUSI-
EAS632R_00054 
1 
F 50,578,517 85 48 86x 
R 50,578,517 85 48 86x 
125 2012-05-31 
HWUSI-
EAS1783R_00005 
1 
F 49,236,313 76 48 75x 
R 49,236,313 84 48 83x 
137 2012-05-31 
HWUSI-
EAS1783R_00005 
1 
F 57,888,647 76 43 88x 
R 57,888,647 84 43 97x 
020 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 31,002,461 76 49 47x 
R 31,002,461 84 49 52x 
090 2012-11-29 
HWUSI-
EAS1783R_00018 
3 
F 21,603,701 76 46 33x 
R 21,603,701 84 46 36x 
213 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 24,779,449 76 46 38x 
R 24,779,449 84 46 42x 
281 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 29,490,809 76 46 45x 
R 29,490,809 84 46 50x 
344 2012-11-29 
HWUSI-
EAS1783R_00018 
3 
F 21,585,819 76 46 33x 
R 21,585,819 84 46 36x 
375 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 27,631,902 76 48 42x 
R 27,631,902 84 48 46x 
406 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 33,694,938 76 50 51x 
R 33,694,938 84 50 57x 
428 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 30,022,010 76 48 46x 
R 30,022,010 84 48 50x 
566 2012-11-29 
HWUSI-
EAS1783R_00018 
3 
F 24,328,044 76 46 37x 
R 24,328,044 84 46 41x 
586 2012-11-29 
HWUSI-
EAS1783R_00018 
3 
F 21,175,515 76 45 32x 
R 21,175,515 84 45 36x 
598 2012-11-29 
HWUSI-
EAS1783R_00018 
3 
F 22,767,044 76 46 35x 
R 22,767,044 84 45 38x 
624 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 22,403,986 76 46 34x 
R 22,403,986 84 46 38x 
638 2012-11-29 
HWUSI-
EAS1783R_00018 
3 
F 24,637,690 76 45 37x 
R 24,637,690 84 45 41x 
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708 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 23,165,578 76 46 35x 
R 23,165,578 84 46 39x 
750 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 25,770,359 76 46 39x 
R 25,770,359 84 46 43x 
796 2012-12-13 
HWUSI-
EAS1783R_00020 
5 
F 23,058,518 76 46 35x 
R 23,058,518 84 46 39x 
 
As shown, both read count and GC content are equal when comparing forward and reverse read sets 
of a single patient. Read count and lengths were sufficient, and FastQC warnings could be overcome 
by the first, QA-related steps of the processing pipeline (comp. Section 2.3), maily due to simply using 
the quality-based trimmer. Taken together, data were considered to be valid for further use. 
 
 
Fig. 5 - Read count vs. read length plot for all forward and reverse datasets, separated by chip. Except for one chip (green), 
where they are equal, read lengths for forward reads are 8 bp shorter than for reverse ones, presumably by lab design. For 
the older chips, a single lane delivers roughly double the data compared to the newer, multiplexed ones, although they use 
three or five (shared) lanes per sample, respectively. Meanwhile, the lengths are equal or higher for the non-multiplexed 
chips. 
 
2.3 From raw reads to variant calling 
For input datasets, where reads from exome sequencing of a biological sample were distributed across 
multiple files (due to multiplexing via DNA barcoding), collections of forward and reverse raw reads, 
respectively, were merged first. The simple merges are used as input datasets in the variant calling 
pipeline. 
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In a multistep process, the collected paired-end raw reads were translated into variants. This pipeline, 
set up in the local Galaxy [Afgan et al. 2016] instance of the Medical Faculty of the Ludwig Maximilians 
University Munich (“NGS-FabLab” [Schaaf et al. 2014]), principally consists of a quality assurance and 
control (QA/QC), a short read mapping to the human reference genome hg19, a variant calling using 
three algorithms and a final genomic annotation of the variants. For raw and trimmed reads (forward 
and reverse each), initial bwa mapping and final re-alignment of reads, FastQC was applied in order to 
receive summary reports on quality measures (comp. Fig. 6). For the finally re-aligned reads, Picard’s 
‘Collect Alignment Summary Metrics’ module2 was applied additionally. Variant calls were performed 
using VarScan2 (SNP and InDel algorithm each [Koboldt et al. 2012]) and GATK’s HaplotypeCaller3, 
merged afterwards and finally annotated with SNPeff [Cingolani et al. 2012] (comp. Fig. 7). Most of the 
applied modules are part of either the samtools [Li et al. 2009a], Picard4 or GATK v2.85 toolboxes.  
By application of the pipeline, for each patient one Variant Call Format (VCFv4.16) file was generated, 
containing three technical samples each (one sample column per variant caller result).  
For an exact listing of command lines executed by Galaxy, refer to Boxes Box A2 to Box A4 in the 
Appendix. For those commands applied for generating the QC plots shown in Section 3.2, refer to Boxes 
Box A5 to Box A8. 
 
Fig. 6 - Galaxy workflow view (1/2) on exome variant calling pipeline applied to patient samples (continued in Fig. 7). 
Quality-based trimming of ends was followed by mapping to the hg19 reference genome, reordering, duplicate marking and 
indel re-alignment. Outputs of modules with yellow stars underwent quality control using FastQC. 
 
                                                          
2 https://broadinstitute.github.io/picard/command-line-overview.html#CollectAlignmentSummaryMetrics  
3 https://software.broadinstitute.org/gatk/documentation/tooldocs/3.8-0/ 
org_broadinstitute_gatk_tools_walkers_haplotypecaller_HaplotypeCaller.php  
4 http://broadinstitute.github.io/picard/  
5 https://github.com/broadgsa/gatk-protected/tree/2.8  
6 https://samtools.github.io/hts-specs/VCFv4.1.pdf  
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Fig. 7 - Galaxy workflow view (2/2) on exome variant calling pipeline applied to patient samples (continuation of Fig. 6). 
The ‘Indel Realigner” box is the same like in Fig. 6, linking both figures. After re-alignment and base recalibration, in one 
branch GATK’s Haplotype Caller, in the other branch both VarScan’s SNP and InDel implementations are applied. Results of 
all three variant caller runs are merged and annotated with SNPeff. Outputs of modules with yellow stars underwent quality 
control using FastQC, Picard’s ‘Collect Alignment Summary Metrics’ module was applied to the last version of the BAM-
formatted mapping data (orange star). 
 
2.4 Post-processing of VCF files 
For the centralized and queriable storage of called variants, GEMINI v0.18.2 [Paila et al. 2013] was 
chosen. According to the official manual7, VCF files were separately decomposed (Box 1) and 
normalized (Box 2) with ‘vt’ [Tan et al. 2015], followed by sorting by genomic position (VCFTools v0.1 
[Danecek et al. 2011]) and indexing (tabix v0.2.58; from samtools; Box 3) in order to merge all files (Box 
4). After merging, decomposition and normalization was repeated. 
 
Box 1 - Looped, 'vt'-based decomposition of patient VCF files. 
 
                                                          
7 https://gemini.readthedocs.io/en/latest/#new-gemini-workflow  
8 http://www.htslib.org/doc/tabix.html  
$ cd exome_vcf/ 
$ mkdir -p preprocessing/decomposed 
$ for f in `ls -1p | grep -v "/"`; do 
    vt decompose -s $f -o preprocessing/decomposed/$f 
  done 
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Box 2 - Looped, 'vt'-based normalization of decomposed VCF files. 
 
Box 3 - Looped sorting, zipping and indexing of decomposed and normalized patient VCF files. 
 
Box 4 - Merging of all pre-processed patient-related VCF files, followed by additional decomposition and normalization. 
 
 
The GEMINI database was loaded (initialized) in two ways: on the one hand once with every pre-
processed patient VCF (resulting in 23 separate DBs), on the other hand with the merged VCF file 
(resulting in one DB containing data of all patient variants). While the 23 separate patient DBs were 
used for QC purposes (see Section 2.5) only, all other analyses were performed using the complete 
merged database holding all patient samples.  
The background is that the measure of comparing the VCF ‘QUAL’ column with the sample-specific 
quality value (‘gt_quals’ in GEMINI corresponding to VCF ‘GQ’ tag) on a per-sample basis is impossible 
after merging, as the “QUAL” value is averaged across all included samples. Therefore, comparing 
QUAL to sample-specific values requires separate DBs. 
$ mkdir -p preprocessing/normalized 
$ for f in `ls -1 preprocessing/decomposed/`; do 
vt normalize -r [path]/hg19.fa $f \ 
> preprocessing/normalized/`basename $f` 
  done 
$ PERL5LIB=/home/galaxy/galaxy/tool_dependencies/vcftools/0.1.11/\   
   devteam/package_vcftools_0_1_11/710efaae2ff8/vcftools/lib/\ 
   perl5/site_perl:$PERL5LIB 
$ export PERL5LIB 
$ wd=preprocessing/sorted_zipped_indexed 
$ mkdir -p $wd 
$ cd $wd 
$ for f in `ls -1 ../normalized/*.vcf`; do 
    outname=`basename $f .vcf`.sorted.vcf 
    echo $outname 
    vcf-sort $f > $outname 
    gzip $outname 
    tabix -p vcf ${outname}.gz 
  done 
$ dir=../merged 
$ mkdir -p $dir 
$ vcf-merge *.gz > $dir/all_merged.vcf 
$ cd $dir 
$ vt decompose -s all_merged.vcf \ 
   -o `basename all_merged .vcf`.decomposed.vcf 
$ vt normalize -r /EasyRaid/share/genomes/links/hg19.fa \ 
`basename all_merged .vcf`.decomposed.vcf \ 
> `basename all_merged.decomposed.vcf .vcf`.normalized.vcf 
$ cd ../../ 
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Box 5 - GEMINI loading and annotation of sample information 
 
 
2.5 Quality control of called variants by visual inspection 
In order to identify failed samples, abnormal analyses and other outliers due to biological or technical 
artifacts, a series of XY scatterplots was generated from the GEMINI databases. 
First, supportive attributes were chosen, namely the chromosomal ‘start’ position (‘POS’ in VCF) and 
‘quals’ (VCF: ’QUAL’), both being variant-specific, as well as sample-specific ‘gt_depths’ and ‘gt_quals’ 
(VCF ‘DP’ and ‘GQ’ field, respectively). As the output of one variant caller results in trailing sample 
column each within the patient-specific VCF file, “sample” means “variant caller” in the given setting. 
Second, for all cross-pairings collections of images were generated by applying a self-developed R 
script, which queries the database and processes the outputs. The resulting plot collections were 
pasted together making up panels with chromosomes (23; X axis) vs. patients (23; Y axis). For sample-
specific attributes, marks were color-coded according to the samples (with “sample” again meaning 
“variant caller”). Parts of the plot collections were additionally generated with logarithmic scales. 
According to the plots and referring to the meaning of the PHRED score, minimal thresholds for 
‘gt_depth’ and ‘gt_quals’ were chosen to be 5 and 13, respectively. That is, a variant site has to be 
covered by five or more short reads, with a variant being detected at a 95% accuracy or higher (variant 
caller internal statistic). These relatively permissive values take into account the overall coverage and 
quality of the initial NGS data, which is in comparison to nowadays datasets relatively low. 
 
$ export PYTHONPATH=[PATH_TO_ANACONDA]/lib/python2.7/:$PYTHONPATH 
$ mkdir gemini_DBs 
$ # create sample-specific DBs 
$ for f in `ls -1 preprocessing/normalized/*.vcf`; do 
echo "PROCESSING FILE "$f"...";  
gemini load --cores 12 -v $f -t snpEff \ 
gemini_DBs/`basename $f.db` 
gemini amend --sample all_pats_training.ped \ 
gemini_DBs/`basename $f.db` 
  done 
$ # create complete DB from merged samples 
$ gemini load --cores 12  
  -v preprocessing/merged/all_merged.decomposed.normalized.vcf  
  -t snpEff gemini_DBs/all_merged.decomposed.normalized.db 
$ # annotate sample information via PED file 
$ gemini amend --sample \  
 all_pats_training_more_info_varcaller_triple.ped \  
 gemini_DBs/all_merged.decomposed.normalized.db 
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2.6 Pre-candidate selection: imbalance measure and gene mapping 
In order to overcome statistical limitations considering the small number of patients, the simple 
approach of detecting a variant, which is distributed between both patient groups in an imbalanced 
manner, was chosen.  
 
2.6.1 Statistical assumptions on imbalanced variants 
Statistically expressed, the basic assumption is that a variant’s appearance in patients is assumed to 
occur in a uniform and independent pattern. By regarding this setting as a series of trials (patients of 
a group), one can describe a general Bernoulli process, knowing the states ‘success’ (variant present) 
and ‘failure’ (variant absent) – independent from the exact pattern/sequence across individual 
patients. Consequently, for a k describing the number of occurrences of a variant within a group of 
patients, a binomial distribution can be modelled, depending on n (the number of patients) and m (the 
allele frequency). Taken together, the probability B can be formalized as: 
𝐵( 𝑘 | 𝑚, 𝑛 ) =  (
𝑛
𝑘
) 𝑚𝑘(1 − 𝑚)𝑛−𝑘      for   𝑘 = 0,1, … , 𝑛 
 
For the imbalance overall, the probability P(imb) is conditionally cummulative, summing up the 
products of probabilies for every possible number of variant-affected patients of the one condition 
with every other possible variant-affected patient count in the other group. Here, the imbalance 
criterion t restricts the set of accepted cases by expressing a minimal difference in success (presence) 
counts between the groups: 
𝑃(𝑖𝑚𝑏, 𝑡) = ∑ ∑ 𝑥𝑖,𝑗
𝑝
𝑗=0
𝑛
𝑖=0
                         where 
𝑥𝑖,𝑗 =  { 
𝐵(𝑖 | 𝑏, 𝑛) ∙ 𝐵(𝑗 | 𝑏, 𝑝)         |𝑖 − 𝑗| ≥ 𝑡
0                                               otherwise
 
with n and p being the number of patients in the SR-negative and SR-positive group, respectively.  
Following this probability model, for detected variants their imbalance measures, Minor Allele 
Frequencies (MAF; a) and genotypes were used to plot distributions (comp. Fig. 16 and Fig. 17), with 
their maxima depicting the minimal probabilities for coincident appearance of an imbalanced variant 
(i.e., considered to be insignificant for the SR use case). 
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𝑏 = {
𝑎2                                homozygous variant
 2𝑎 ( 1 − 𝑎 )  + 𝑎2                        otherwise
 
 
While the two alleles A’ and A’’ of a gene in diploid organisms can be assumed to be independent, the 
MAF a is to be squared when considering homozygous variants, making up the first case for b. When 
including also heterozygous variants (which in turn would require to be of dominant trait when 
considering them to be phenotypically effective), the probabilities for both the case that A’ is altered 
while A’’ is not and vice versa have to be considered, making up the second case for b.  
 
2.6.2 Imbalance measure on called variants and proceeding to genes 
For retreiving the variants and their distribution in the patient groups, SQL statements were 
formulated in order to query the GEMINI database. The statements join information from both the 
‘variants’ and the ‘gene_detailed’ table, achieving to include information about affected transcripts 
and both IDs from HGNC and Entrez for later gene symbol normalization. Considering optional 
restrictions to homozygous variants and the filtering of low impact variants (like intronic), four queries 
were executed (comp. Box 6 to Box 9). 
 
Box 6 - Detection of imbalanced variants (Set 1): heterozygous included, all variants independent of impact strength. 
 
 
  
$ gemini query --header -q \ 
  "SELECT v.variant_id, v.chrom, v.start, v.ref, v.alt, v.rs_ids, \ 
   v.aaf_1kg_all, v.impact_so, v.impact_severity, v.gene, \ 
   g.transcript, g.is_hgnc, g.hgnc_id, g.entrez_id, \ 
   (gt_quals).(phenotype==0), (gt_quals).(phenotype==1), \ 
   (gt_depths).(phenotype==0), (gt_depths).(phenotype==1), \ 
   (gt_types).(phenotype==0), (gt_types).(phenotype==1), \ 
   (gts).(phenotype==0), (gts).(phenotype==1) \ 
   FROM variants v, gene_detailed g \ 
   WHERE v.chrom = g.chrom AND v.gene = g.gene \ 
   ORDER BY v.gene ASC, v.variant_id ASC" \    
   ../gemini_dbs/all_merged.decomposed.normalized.vcf.db | \ 
   awk -v offset=14 -v minq=13 -v minc=5 \ 
     -f gemini_imbalance_detector.awk \ 
     >> imbalance_7_HET_final.ssv 
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Box 7 - Detection of imbalanced variants (Set 2): heterozygous included, variants annotated as 'LOW' impact by SNPeff are 
ignored. 
 
 
Box 8 - Detection of imbalanced variants (Set 3): homozygous only, all variants independent of impact strength. 
 
  
$ gemini query --header -q \ 
  "SELECT v.variant_id, v.chrom, v.start, v.ref, v.alt, v.rs_ids, \ 
   v.aaf_1kg_all, v.impact_so, v.impact_severity, v.gene, \ 
   g.transcript, g.is_hgnc, g.hgnc_id, g.entrez_id, \ 
   (gt_quals).(phenotype==0), (gt_quals).(phenotype==1), \ 
   (gt_depths).(phenotype==0), (gt_depths).(phenotype==1), \ 
   (gt_types).(phenotype==0), (gt_types).(phenotype==1), \ 
   (gts).(phenotype==0), (gts).(phenotype==1) \ 
   FROM variants v, gene_detailed g \ 
   WHERE v.chrom = g.chrom AND v.gene = g.gene \ 
   AND impact_severity != 'LOW' \ 
   ORDER BY v.gene ASC, v.variant_id ASC" \ 
   ../gemini_dbs/all_merged.decomposed.normalized.vcf.db | \ 
   awk -v offset=14 -v minq=13 -v minc=5 \ 
     -f gemini_imbalance_detector.awk \ 
     >> imbalance_7_HET_noLOW_final.ssv 
$ gemini query --header -q \ 
  "SELECT v.variant_id, v.chrom, v.start, v.ref, v.alt, v.rs_ids, \ 
   v.aaf_1kg_all, v.impact_so, v.impact_severity, v.gene, \ 
   g.transcript, g.is_hgnc, g.hgnc_id, g.entrez_id, \ 
   (gt_quals).(phenotype==0), (gt_quals).(phenotype==1), \ 
   (gt_depths).(phenotype==0), (gt_depths).(phenotype==1), \ 
   (gt_types).(phenotype==0), (gt_types).(phenotype==1), \ 
   (gts).(phenotype==0), (gts).(phenotype==1) \ 
   FROM variants v, gene_detailed g \ 
   WHERE v.chrom = g.chrom AND v.gene = g.gene \ 
   ORDER BY v.gene ASC, v.variant_id ASC" \ 
   ../gemini_dbs/all_merged.decomposed.normalized.vcf.db | \ 
   awk -v offset=14 -v rfilter=1 -v minq=13 -v minc=5 \ 
     -f gemini_imbalance_detector.awk \  
     >> imbalance_7_HOM_final.ssv 
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Box 9 - Detection of imbalanced variants (Set 4): homozygous only, variants annotated as 'LOW' impact by SNPeff are 
ignored. 
 
 
The ‘gemini_imbalance_detector’ has been written in awk [Aho et al. 1988], providing an easy, line-
wise processing of the query outputs at a maximum performance. For this tool, the minimal thresholds 
for coverage/depths (‘minc’) and quality (‘minq’) are pre-configured, although configurable. 
The detector takes three consecutive columns per patient and acknowledges a variant if at least one 
of the three variant callers passes the depth and quality filters. Outputs are space-separated files (.ssv). 
Further documentation is provided within the script itself. 
As indexes and databases of bwa, the variant callers and SNPeff may not be up to date compared to 
subsequent tools (esp. ReactomeFI; comp. 2.7.1), gene symbols were updated by comparison to a 
recent HGNC [White et al. 1997] excerpt. By using the HGNC ID, preferred/approved names were 
appended as additional column to the imbalance detector outputs, performed by the 
‘HGNC_approver’ script (comp. Box 10). From here on, all files are tab-separated (.tsv). 
In a subsequent two-step process, the GEMINI database outputs were further processed by merging 
lines according to (1) transcripts and (2) genes. The ‘line_merger’ script takes columns (by name) to 
check for equality in consecutive lines. For those line sets, the contents of columns configured to 
merged are pasted together, using a configurable separator symbol. 
For collecting transcripts (and e.g the respective predicted effects), lines with both the same variant ID 
and gene were merged, resulting in comma-separated lists for transcript-specific attributes. 
Afterwards, lines referring to the same gene were merged according to the variant information, as one 
gene may be affected by multiple variants according to SNPeff. For later steps, a per-gene treatment 
of data is necessary. 
$ gemini query --header -q \ 
  "SELECT v.variant_id, v.chrom, v.start, v.ref, v.alt, v.rs_ids, \ 
   v.aaf_1kg_all, v.impact_so, v.impact_severity, v.gene, \ 
   g.transcript, g.is_hgnc, g.hgnc_id, g.entrez_id, \ 
   (gt_quals).(phenotype==0), (gt_quals).(phenotype==1), \ 
   (gt_depths).(phenotype==0), (gt_depths).(phenotype==1), \ 
   (gt_types).(phenotype==0), (gt_types).(phenotype==1), \ 
   (gts).(phenotype==0), (gts).(phenotype==1) \ 
   FROM variants v, gene_detailed g \ 
   WHERE v.chrom = g.chrom AND v.gene = g.gene \ 
   AND impact_severity != 'LOW' \ 
   ORDER BY v.gene ASC, v.variant_id ASC" \ 
   ../gemini_dbs/all_merged.decomposed.normalized.vcf.db | \ 
   awk -v offset=14 -v rfilter=1 -v minq=13 -v minc=5 \ 
     -f gemini_imbalance_detector.awk \ 
     >> imbalance_7_HOM_noLOW_final.ssv 
27 
 
In order to have explicit information of the number of merged lines, the ‘line_merger’ script (Box 10) 
was configured to append the columns “affectedTranscriptCount” and “variantsCountForGene”, 
respectively. 
 
Box 10 - Processing of the imbalanced GEMINI outputs (with variable ‘$file’ standing for the four outputs of Box 6 to Box 9). 
Normalization of gene symbols according to HGNC, merging of variant lines affecting multiple transcripts as well as merging 
variants affecting the same gene (per-gene representation). 
 
 
# normalize to HGNC-approved name (appends column “approved_name”) 
$ awk -F $'\t' -f HGNC_approver.awk HGNC_all.tsv $file \ 
   >> $normed_file; 
 
# merge lines by variant: each line contains a variant and  
#  all transcripts being affected by it (attributes of the  
#  latter in a comma-separated list per 'merge' field) 
$ awk -F $'\t' \ 
      -v merge="transcript,impact_so,impact_severity" \ 
      -v check="variant_id,gene" \ 
      -v delim=";" \ 
      -v cntcol="affectedTranscriptCount" \ 
      -f line_merger.awk \ 
      $normed_file >> $merged_file1 
 
# merge lines by gene: one line carries a gene and all variants  
#  affecting it (attributes of the latter in a pipe-separated  
#  list per 'merge' field))  
# Define columns to check for equality first 
$ check="chrom,gene,approved_symbol,is_hgnc,hgnc_id,entrez_id"; 
 
# Afterwards, construct a comma-separated list of all other  
#  columns to merge 
$ merge=`head -n1 $file | awk -v check=$check \ 
          'BEGIN{ split( check, ccols, "," );  
                  for( c in ccols ){store[ccols[c]] = "T"};  
                  sep=""  
          } 
          { for( i=1; i<=NF; i++){  
              if(length(store[$i]) < 1){  
                printf("%s%s", sep, $i);  
                sep="," } 
              } 
          }  
        END{ print "\n" }'` 
 
# Finally, merge by using the line_merger script again, using  
#  pipe ('|') as separator 
$ awk -F $'\t' \ 
      -v merge=$merge \ 
      -v check=$check \ 
      -v delim="|" \ 
      -v cntcol="variantsCountForGene" \ 
      -f line_merger.awk \ 
      $merged_file1 >> $merged_file2; 
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2.7 Molecular Systems Map (MSM) 
In a first step, the map is generated by collecting pathway (interaction) data, depending on the use 
case and joining the items to a network. In a second step, the MSM gets ‘populated’, i.e. those genes 
are identified, which are hit by at least one variant (‘affected genes’). 
 
2.7.1 Generation of a blank MSM 
As platform for the integration of pathway data and visualization, Cytoscape v3.4.09 [Shannon et al. 
2003] was chosen. Additionally, the plugins ReactomeFIViz (v5.1.0.beta, [Wu et al. 2014]) and 
AllegroLayout v2.2.210 were installed via the integrated app manager. For shortest path detection, 
Pesca (v3.0.811; [Scardoni et al. 2015]) was used. 
From a ‘Reactome Pathways’ [Croft et al. 2014] session, diagrams were selected corresponding to the 
defined major topics “signaling”, “immune system” and “cell adhesion”, plus “cellular stress”. Within 
the hierarchically organized tree structure of Reactome’s interaction event collection, the outmost 
diagrams (leafs) of interest were selected and converted into a FI networks, each containing functional 
interaction data from Reactome and further sources [Wu et al. 2010; Wu et al. 2014] like KEGG. Those 
networks (pathways) were merged iteratively ‘bottom-up’, making up subsets, sets and finally 
supersets of interest (further details and description see Tab. 3). In order to track the origin or 
membership of nodes and edges, for each of the initial Reactome-derived networks, as well as any 
derived set, boolean columns were introduced and filled up with ‘true’ values. Therefore, nodes and/or 
edges can be selected in merged networks (incl. the MSM itself) according to annotated pathways. 
  
For particular networks, nodes of excessively high degree were removed, if the expected biological 
impact for the given analysis was low. This affects in the very first line the multiple immuneglobulin 
chains and their respective gene loci. Those items are close to fully connected with each other and few 
further nodes, providing only generic information. Additionally, these loci are anyhow somatically 
altered in immune cells. Technically, the number of the adjacent edges to these nodes make up the 
vast majority of edges within the graphs and slow down Cytoscape to an unserviceable level. For a full 
list of these removed nodes refer to Tab. 4. 
In a final step, the resulting three supersets together with the “cellular responses to stress” set were 
merged to the blank (means: carrying no sample-specific genetic data) MSM. The complete network 
                                                          
9 http://www.cytoscape.org/release_notes_3_4_0.html  
10 became recently unavailable, compare https://groups.google.com/forum/#!topic/cytoscape-helpdesk/122pCTu_0AI  
11 http://apps.cytoscape.org/apps/pesca30  
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was re-ordered with AllegroLayout, using the Fruchterman-Reingold algorithm [Fruchterman & 
Reingold 1991] and default parameters (2,000 iterations, independent component processing, scale 
and gravity at 100% each). Finally, a functional clustering was calculated using the ReactomeFI plugin’s 
internal feature (spectral partition based network clustering; [Newman 2006]), resulting in functional 
groups (“modules”). The session was saved as ‘molecular_map_with_history.cys’ plus a copy in which 
for performance reasons all non-MSM networks were removed (‘molecular_map_only.cys’).  
30 
 
Tab. 3 - Selected pathways according to ReactomeFI. Entries providing no diagram in Cytoscape's ReactomeFI app are printed 
in grey. Sets in italics show more subordinate pathways in Reatome, but not all have been extracted for the MSM. Supersets 
do not have correspondently named diagram in ReactomeFI. Classifications of mechanisms as sets, subsets etc. corresponding 
to relative depths within the hierachy. ReactomeFI diagrams which could not be further resolved to any subdiagrams were 
labeled as “pathway”. Consequently, the subset level may be left empty. 
Superset Set Subset Pathway 
Signal- Signaling by EGFR 
 
 
transduction Signaling by FGFR  Signaling by FGFR1    
Signaling by FGFR2  
  Signaling by FGFR3  
  Signaling by FGFR4 
 
Signaling by VEGF   
 
Signaling by ERBB2   
 
Signaling by ERBB4   
 
PIP3 activates AKT 
signaling 
  
 
MAPK family signaling 
cascades 
MAPK1/MAPK3 signaling RAF/MAP kinase cascade 
RAF-independent MAPK1/3 activation 
 
 MAPK6/MAPK4 signaling 
 
 
Signaling by Rho GTPases 
  
 
Signaling by TGF-beta 
Receptor Complex 
  
 
Signaling by Wnt 
 
WNT ligand biogenesis and trafficking    
Degradation of beta-catenin by the destruction complex    
TCF dependent signaling in response to WNT    
Beta-catenin independent WNT signaling 
Immune 
System 
Adaptive Immune System 
 
TCR signaling 
Costimulation by the CD28 family    
Signaling by the B Cell Receptor (BCR)    
Class I MHC mediated antigen processing & presentation    
MHC class II antigen presentation    
Immunoregulatory interactions between lymphoid and non-
lymphoid cells 
 
Innate Immune System 
 
Toll-like Receptors Cascades    
Complement cascade    
Nucleotide-binding domain, leucine rich repeat containing 
receptor (NLR) signaling pathways    
Defensins    
Fcgamma receptor (FCGR) dependent phagocytosis 
 
Cytokine signaling in 
Immune system 
 
Interferon Signaling 
Signaling by Interleukins    
Growth Hormone Receptor Signaling    
Prolactin Receptor Signaling    
TNFRSF mediated non-canonical NF-kB Pathway    
ROS, RNS Production in Response to Bacteria 
Cell 
Adhesion 
Extracellular matrix 
organization 
Collagen formation Collagen biosynthesis and modifying enzymes 
Assembly of collagen fibrils and other multimeric structures    
Fibronectin matrix formation    
Elastic fibre formation   
 Laminin interactions   
 Non-integrin membrane-ECM interactions    
ECM proteoglycans 
  
Degradation of the 
extracellular matrix 
Activation of Matrix Metalloproteases 
Collagen Degradation    
Integrin cell surface interactions 
 
Cell-Cell communication 
 
Cell junction organization    
Nephrin interactions 
 
Vesicle-mediated 
transport 
Membrane trafficking Gap junction trafficking and regulation 
Stress Cellular responses to 
stress 
 
Cellular responses to hypoxia 
Detoxification of Reactive Oxigen Species 
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Tab. 4 - List of nodes removed due to excessive interconnection and expected low impact for the scientific question. Nodes 
were detected in and removed from Reactome’s pathways ‘RAF/MAP kinase cascade’, ‘Signaling by the B Cell Receptor (BCR)’, 
‘Immunoregulatory interactions between lymphoid and non-lymphoid cells’, ‘Complement cascade’ and ‘Fcgamma receptor 
(FCGR) dependent phagocytosis’. 
Class Gene symbols 
Immunoglobulin heavy 
chains 
IGHD, IGHE, IGHG[1-4], IGHM, IGHV, IGHV3-23, IGHV7-81 
Immunoglobulin kappa 
constant chains 
IGKC, IGKV1D-16, IGKV4-1, IGKVA18 
Immunoglobulin lambda 
constant chains 
IGLC[1-7] 
Immunoglobulin lambda 
variable chains 
IGLV, IGLV1-36, IGLV1-40, IGLV1-44, IGLV10-54, IGLV11-55, IGLV2-11, 
IGLV2-18, IGLV2-23, IGLV2-33, IGLV3-12, IGLV3-16, IGLV3-22, IGLV3-
25, IGLV3-27, IGLV4-3, IGLV4-60, IGLV4-69, IGLV5-37, IGLV5-45, 
IGLV7-43, IGLV7-46, IGLV8-61 
Ig [heavy lambda kappa] 
chain […] region [XYZ] 
multiple (117) 
Proteasome complex 
subunits 
PSMA[1-8], PSMB[1-11], PSMC[1-6], PSMD[1-14], PSME[1-4], PSMF1 
 
 
In order to map the relations between cluster modules and biological pathways, the MSM’s node table 
was exported, reduced to those columns which indicate for name as well as membership to a module 
and pathways, respectively (‘Node_assignment_table_MSM.tsv’). After re-formatting the column 
names for improved readability, node and edge files were generated by applying two custom scripts 
(Box 11). 
  
Box 11 - Conversion of MSM node table contents to nodes and edges for a new graph associating modules with pathways. 
 
 
$ awk -v FS=$'\t' \ 
      -f node_builder.awk \ 
      Node_assignment_table_MSM_formatted.tsv \ 
      >> nodes_formatted.tsv 
$ awk -v FS=$'\t' \ 
      -f edge_builder.awk \ 
      Node_assignment_table_MSM_formatted.tsv \ 
      >> edges_formatted.tsv 
32 
 
In a new Cytoscape session (‘modules2pathways.cys’), edges where imported, making up the network. 
Node attributes were imported afterwards. Colors and sizes of both nodes and edges were set 
according to the count of underlying MSM nodes and their memberships, respectively. In a session 
copy (‘modules2pathways_max_reduced_allegro.cys’), nodes representing (super-)sets were 
removed, improving readability. Finally, the Allegro layout “spring electric” was applied with default 
parameters. 
 
2.7.2 Populating the MSM 
As nodes in the MSM represent genes/proteins, all additional information has to be referred to the 
HGNC approved symbol. As this has been done in the post-processing of the detected imbalanced 
variants (Box 10), data could be easily appended as table import, matching the ‘approved_symbol’ 
column from the data table with the ‘shared name’ column from Cytoscape’s Node Table panel. This 
step was performed for each of the variant tables resulting from the performed GEMINI queries (Box 
6 to Box 9), leading to the populated MSM versions.  
Annotations not matching a node in the MSM are not used, in turn nodes with no additional 
information from the imported data table receive empty fields for the added columns. Consequently, 
the variant lists are filtered for entries which are not annotated to affect genes of interest (means: the 
MSM) and visualized in the functional context at the same time.  
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3. Results 
The following sections describe first the MSM specifically generated for the SR usecase, subsequently 
the sets of variants called from NGS data and their processing, finally the population of the MSM with 
the filtered candidate variants. 
 
3.1 Description of the Molecular Systems Map 
At the end of the process of data from Reactome [Croft et al. 2014], the MSM12 (Fig. 8) included 2,261 
nodes (genes/gene products) and 37,769 edges (functional interactions). This refers to 18.57% of 
12,177 nodes and 16.47% of 229,300 edges in Reactome overall. 
By applying the ReactomeFI clustering (spectral partition based network clustering; [Newman 2006]), 
55 modules with between 2 and 420 member genes each were generated. 16 of them showed a size 
of 24 genes or more (“major modules”). For approving wether those modules are biologically 
meaningful, a mapping to Reactome’s biological pathways was plotted as shown in Fig. 9. Using this 
mapping, the 16 auto-generated modules with most member nodes could be labeled with biology-
oriented descriptions as listed in Tab. 5.  
Taken together, genes associated with cell adhesion (collagen, integrin, extracellular matrix; module 
1, green) are concentrated in the MSM’s lower left region, while WNT-associated cell adhesion 
mechanisms are separately located in the upper right. A series of dense clusters form a tight half ring 
around the core region (remaining open at its bottom side).  
Most immunology-related mechanisms can be found (e.g. MHC class I (module 2, violet) and class II 
(module 3, olive)), but also GPCR signaling (module 5, yellow) and nuclear processes (module 6, pink; 
e.g. pore complex). In the periphery regions, several receptor-related upstream mechanisms are 
located, like TGFβ signaling (module 10, maroon) and WNT (modules 8, 11, 13 in dark green, green 
blue and light pink, respectively), but also the complement cascade (module 15). 
Interestingly, EGFR as a (semantically) central molecule in this use case, was located right in the center 
of the MSM’s layout. Here, in the core region, most genes (including EGFR) are accounted for the 
biggest module 0 (blue), making up the signaling core of most pathways. Signaling includes shared 
components like PIP3, AKT1 and MAP kinases, but also major parts of e.g. the FGFR, VEGF and the 
other ERBB pathways.  
                                                          
12 For a high-resolution print, please refer to the foldable inlay map at the end of this thesis. For a zoomable vector graphic, please refer to the digital contents. 
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Fig. 8 - Blank Molecular Systems Map. ReactomeFI’s clustering algorithm calculated functional modules (indicated by colors 
for the 14 modules with most members), while layout was performed by Allegro. Small clusters and single nodes unconnected 
to the majority of nodes are sorted to the bottom of the map.  
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Tab. 5 - Description of clustered modules according to pathway memberships of included nodes. Restriction to the 16 
modules with most member nodes (“major modules”), colors following Fig. 8 and Fig. 9 (auto-generated by Cytoscape). 
Module ID # Nodes Color Description 
0 420  Growth factor signaling, cytokines 
1 227  Extracellular matrix mechanisms 
2 208  MHC class II signaling (adaptive immunity, extracellular) 
3 203  MHC class I signaling (adaptive immunity, intracellular) 
4 189  TLR/Interleukin/TNF/LRR signaling (innate immunity, extracellular) 
5 149  Rho-GTPases/GPCR signaling 
6 127  Nucleus mechanics (nuclear pore complex, chromatin) 
7 89  Cell interaction/junction upon Rho/TGF beta 
8 75  WNT signaling 
9 73  EGFR/ERBB/FGFR downstream signaling (e.g. mTOR) 
10 69  TGF beta signaling 
11 63  WNT signaling (downstream) 
12 46  Immunoregulatory phagocytosis (Fc Gamma) 
13 35  WNT signaling (biogenesis/trafficking) 
14 32  DNA replication, cell cycle 
15 30  Complement Cascade 
16 24  ROS/RNS and signaling 
 
 
 
 
 
 
 
 
 
 
Fig. 9 - Mapping of clustering modules to biological pathways (next page). Numbered boxes represent MSM modules 
clustered automatically by ReactomeFI plugin, while all other boxes represent biological pathways. Genes of the MSM can be 
member of multiple pathways, but only one module. Layout has been performed by applying Allegro with edge weighting. 
The box size linearly depends on member count for modules or pathways. Width of connecting edges indicates for the number 
of genes shared by adjacent boxes. Color codes for modules 1-14 are used as in Fig. 8, other modules are kept in grey. Colors 
for pathway boxes are chosen by membership to a superset (blue = signal transduction, red = immune system, green = cell 
adhesion, grey = stress). Edge coloring follows the adjacent module node. Full graphical details available in the original image 
file (supplementary materials). 
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3.2 NGS quality control: raw reads, mapping and variant calling 
Starting with the given input data, quality was checked in major steps of the processing pipeline. Raw 
reads Kmer contents were indicated by FastQC to be suboptimal due to homopolymeric sequences of 
A and T and showed a slight, expected drop of quality from 5’ to 3’ end. After quality-based trimming 
on both ends, empty reads remained, triggering QC errors for over-represented sequences (empty 
string) and a suspicious sequence length distribution. 
After mapping the reads to the reference genome, additional warnings for GC content were reported. 
Integrating read re-ordering, duplicate marking and re-alignment fixed all issues, with a remaining 
warning of sequence length distribution referring to kept empty reads. Keeping empty reads appeared 
to be necessary for compatibility reasons in later stages of the pipeline, as some tools cannot cope 
with missing pair members in paired-end datasets. 
Regarding the mapping itself, FastQC reported no critical issues, although some parameters on 
qualities (base and sequence level) were marked as being not optimal. An exception is the dataset of 
patient 072, where quality values were noted as being insufficient, mainly due to average PHRED 
scores around 18 for both per-base and per-sequence statistics. The other datasets show values 
around 25, with 20 being a common lower limit. However, as this particular patient is of the group of 
interest (SR-negative), which is anyhow smaller than the SR-positive one, and coverage was highest 
among the whole cohort, the patient’s dataset was kept for subsequent analyses. 
For gaining insights in comparability of patient’s samples and the results of the three applied variant 
callers, a visual inspection was introduced by systematically querying the loaded GEMINI database and 
plotting the results (comp. chapter 2.5). Except for dataset 072, the X-Y scatterplots appeared 
uniformly for any chromosome when comparing various attribute combinations (for examples refer to 
Figs. Fig. 10 to Fig. 12, for the overview to the digital supplements). Regarding dataset 072, two major 
observations were made: called variants are much more dedicated to exonic positions, and the quality 
value distributions do not show a difference to the other datasets (Fig. 13), supporting the decision to 
work further on with these data. Taken together, the raw data and their processings were considered 
to be valid. 
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Fig. 10 - Genomic position vs. VCF quality ('QUAL') example plot. Qualities of all called variants, independent of any filtering, 
were plotted according to their start position (VCF ‘POS’) on a particular chromosome for one patient each (here: chr1 for 
individual 014) for visual inspection. The VCF ‘QUAL’ column averages all sample measurements here: (sample = variant 
caller). Exonic calls are obviously of higher quality in average. Red = intronic/intragenic call, green = exonic call. The gap in 
the middle marks the centromer. Left: linear scales; right: log scale for quality. 
 
 
Fig. 11 - Genomic position vs. variant caller quality ('GQ') example plot. Qualities of all called variants, independent of any 
filtering, were plotted according to their start position (VCF ‘POS’) on a particular chromosome for one patient each (here: 
chr1 for individual 014) for visual inspection. The VCF sample columns carry a field ‘GQ’ (‘gt_quals’ in GEMINI) indicating for 
a non-averaged quality value dedicated to a particular (here: sample = variant caller). Blue = GATK Haplotype Caller, green = 
VarScan SNP, red = VarScan InDel. The gap in the middle marks the centromer. Left: linear scales; right: log scale for quality.  
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Fig. 12 - Variant coverage vs. variant caller quality ('GQ') example plot. Qualities of all called variants, independent of any 
filtering, were plotted against according to their start position (VCF ‘POS’) on a particular chromosome for one patient each 
(here: chr1 for individual 014) for visual inspection. The VCF sample columns carry a field ‘GQ’ (‘gt_quals’ in GEMINI) indicating 
for a non-averaged quality value dedicated to a particular (here: sample = variant caller). Both tools hit their maxima (GATK: 
255; VarScan: 100) with several variants. Blue = GATK Haplotype Caller, green = VarScan SNP, red = VarScan InDel. Top left: 
linear scales; top right: log scale for quality; bottom: log scale for both. 
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Fig. 13 - Plots of outlying dataset 072. Ranges and distributions appear in all three perspectives like they were found in 
other datasets (top left: comp. Fig. 10, right panel; top right: comp. Fig. 11, right panel; bottom: comp. Fig. 12, bottom 
panel). Exception is the low number of intronic variants and a consequently low density overall. 
 
  
41 
 
3.3 Filter assessment and imbalance detection 
Principally, both applied filtering mechanisms (SNPeff impact class and zygosity of a variant) should be 
independent. In order to estimate both their effects, the sets defined by the 2x2 cross-table presented 
in Tab. 6 were analyzed for their overall filtering on those variants passing both the coverage (>= 5x) 
and quality/confidence (Phred >= 13; ≙ 95%) filter in at least one sample, without any restriction on 
imbalance criteria (‘baseline’). 
 
Tab. 6 - Filtering effects on baseline variants according to impact class and zygosity (cross-table). While ignoring 
heterozygously called variants cuts down the list by ~60%, filtering for an impact class of ‘MED’ or ‘HIGH’ leaves just 10% of 
the initially called variants. These numbers hold relatively independently of whether the other filter is set or not. The 
combined application (Set 4) yields in just 4.2% of the initial Set 1. 
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In the actual GEMINI calls (filtering by imbalance >= 7) for sure the number of remaining variants 
dropped dramatically, but in parallel for all three sets on a logarithmic scale (comp. Fig. 14). 
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Fig. 14 - Candidate count according to filtering steps applied in the order of application to all four sets. Sets according to 
Tab. 6. X axis reads as progress in data processing. Labels in columns define filters applied, resulting in the depicted number 
of remaining candidates. Columns one and two indicate for variants, three and four to affected genes. Filtering effects 
obviously apply homogeneously to all sets. 
 
Subsequently, using the approved HGNC gene names, the four separate variant sets were each 
converted to gene-centric sets (comp. Tab. 6). Those could then be assigned to a copy of the MSM 
each (comp. Section 3.4).  
While querying the database for significantly imbalanced variants resulted in 1,629 variants overall, 
545 of those were reported to be homozygous (Tab. 7). The exclusion of variants classified as being 
low impact by SNPeff reduced the number of candidate variants even more (84 with 34 being 
homozygous). Low impact filtering excludes all intergenic and intronic variants. Applying impact and/or 
zygosity filters did not change the numerical relation to affected transcripts or genes, as indicated by 
a high R² for both genetic elements (Fig. 15). 
 
Tab. 7 - Sets of detected imbalanced variants across all patients. Relation of variants to affected functional genetic elements 
(transcripts and genes) according to SNPeff annotation. Low impact variants are mainly intronic. HOM = homozygous, HET= 
heterozygous. 
Set genotype LOW 
impact 
initial variant 
count 
imbalanced 
variants 
affected 
transcripts 
affected 
genes 
1 All (HOM + HET) included 514,099 1,629 10,578 1,104 
2 HOM only included 219,182 545 4,350 448 
3 All (HOM + HET) excluded 57,869 84 571 70 
4 HOM only excluded 21,540 34 272 32 
 
 
Coverage >= 5
Quality >= 13
Imbalance >= 7
genes affected
MSM member
1
10
100
1000
10000
100000
1000000
C
an
d
id
at
e 
co
u
n
t
Set 1
Set 2
Set 3
Set 4
43 
 
 
Fig. 15 - Imbalanced variants vs. affected genetic elements. Count relations and linear fit indicate no principal change by 
applying low impact or zygosity filtering. Values from Tab. 5. Data points correspond to „ All (HOM + HET)“, „ HOM only“, „All 
(HOM + HET), LOW impact excluded“ and „HOM only, LOW impact excluded”, respectively, read from left to right. 
 
In terms of patient assignments, the imbalanced variants appeared more often in the SR-negative 
individuals (Tab. 8). This refers to the higher number of imbalanced variants assigned to the SR-positive 
group, a consequence of the unequal group sizes (11x negative, 12x positive). 
 
Tab. 8 - Imbalanced variants accounted for individual patients. Again, 072 appears as an outlier. 
SR-negative 
patients 
imbalanced 
variants 
SR-positive 
patients 
imbalanced 
variants 
036 614 014 663 
072 12 111 1317 
125 307 137 1245 
020 226 155 1327 
281 363 090 1342 
375 204 213 1302 
406 190 344 1298 
428 327 566 1341 
586 631 598 1363 
750 602 624 1171 
796 502 638 1360 
  708 1323 
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Runtimes were unexpectedly long; GEMINI is a database system, although implemented in SQLite, so 
SELECT statements of the given complexity should not take hours. Even when not formulating the 
explicit JOIN on variants and gene_detailed table, a substantial speed-up could not be 
observed, so GEMINI remained a bottleneck. Finally, the generation of Sets 1 and 3 took 8h 47min and 
8h 45min, respectively. For the more restricted Sets 2 and 4, in which low impact variants are already 
excluded with the database call, query time was at 1h 38min and 1h 45min, respectively. 
When projecting the called variants onto the statistical model, distributions in Fig. 16 (all variants) and 
Fig. 17 (homozygeous variants only) show the relation between minor allele frequency (MAF according 
to 1000 Genomes Project [Auton et al. 2015]) and the probability to occur in the measured imbalanced 
manner in the given patient cohort, following the model. In both plots, those variants being specifically 
detected for the patient group of interest (SR-negative) where highlighted in order to compare visually 
the distribution of this sub-population. 
  
Fig. 16 - Distribution of called variants according to the statistical model of imbalance.  48 out of 59 variants being specifically 
overrepresented in the SR-positive group show a minor allele frequency (MAF) of 0.5 or lower (red dashed vertical line), 36 
out of 59 variants are rated with a MAF of 0.25 or lower (black vertical dashed line). Focussing to the 7 of those SR-positive 
specific variants, which are annotated to be medium (MED) or high (HIGH) impact by SNPeff, 5 or 2 of them are listed with a 
MAF of 0.5 or lower and 0.25 or lower, respectively. Lines underlying the points of the four imbalance classes with >= 4 
detections are splines smoothing the distribution. 
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Fig. 17 - Distribution of called homozygous variants only, according to the statistical model of imbalance. 3 out of 24 variants 
being specifically overrepresented in the SR-positive group show a minor allele frequency (MAF) of 0.5 or lower (red dashed 
vertical line), 1 out of 24 variants is rated with a MAF of lower than 0.25. Focussing to the 6 of those SR-positive specific 
variants, which are annotated to be medium (MED) or high (HIGH) impact by SNPeff, none of them is listed with a MAF below 
0.5. Lines underlying the points of the three imbalance classes with >= 4 detections are splines smoothing the distribution. 
 
3.4 Joining imbalanced variants with the MSM: populating the map 
After having mapped the called and filtered variants to the genes they are predicted to affect, those 
genes could be located within the MSM if anyhow present. Consequently, the MSM’s filtering function 
was used in order to finally reduce the remaining candidates to those being of potential mechanistic 
interest. 
In average, 15% of the affected genes were assigned to be part of the MSM, while around 18% of all 
known genes are represented in Reactome’s database. Simultaneously, the fraction of MSM-located 
genes specificially hit in the SR-negative group increases with the degree of filtering from less than 2% 
up to 50% (comp. Tab. 11). 
  
 
 
Tab. 9 - Variants detected to occur imbalanced specifically in the SR-negative group. Sorting by genomic position. All impacts on multiple transcripts were predicted to be equal in terms of type and 
severity. Entries printed in bold are part of the MSM (see Section 2.7). 
chrom Start 
[bp] 
Ref. 
allele 
Alt. 
allele 
rs IDs [dbSNP] MAF 
[1kg 
project] 
Impact type 
[Sequence 
Ontology (SO)] 
Impact 
severity 
[SO] 
SR 
neg. 
count 
SR 
pos. 
count 
diff Exclusive 
for SR neg. 
group? 
Affected 
gene 
Number of 
affected 
transcripts 
chr1 43305752 G A rs12034000 0.260 intron_variant LOW 8 0 8 YES ERMAP 5 
chr1 204159607 GC G - - frameshift_variant HIGH 8 1 7  KISS1 1 
chr1 204159610 CT C rs71745629 0.222 frameshift_variant HIGH 8 1 7  KISS1 1 
chr1 216824504 C G rs10863261 0.134 intron_variant LOW 8 1 7  ESRRG 23 
chr2 73339707 G A rs1864488 0.521 synonymous_variant LOW 9 2 7  RAB11FIP5 6 
chr2 107460473 T G rs12473361 0.256 5_prime_UTR_variant LOW 10 3 7  ST6GAL2 5 
chr2 239010718 T C rs36066915 0.609 synonymous_variant LOW 7 0 7 YES ESPNL 5 
chr4 983808 C T rs4690221 0.389 synonymous_variant LOW 7 0 7 YES SLC26A1 4 
chr6 13010090 TG T - - intron_variant LOW 7 0 7 YES PHACTR1 13 
chr6 13010091 GCCA G rs142689950 0.967 intron_variant LOW 7 0 7 YES PHACTR1 13 
chr6 13010091 GCCACCA G - - intron_variant LOW 7 0 7 YES PHACTR1 13 
chr6 44151764 G A rs13209117,rs386432577 0.311 3_prime_UTR_variant LOW 8 0 8 YES CAPN11 6 
chr7 26678855 A G rs57000259 0.397 synonymous_variant LOW 8 1 7  C7orf71 1 
chr7 30634660 C G rs1049402 0.649 missense_variant MED 7 0 7 YES GARS 9 
chr7 122769615 T C rs13243580 0.221 intron_variant LOW 8 1 7  SLC13A1 4 
chr7 132248810 C CTGT rs147358337 - intron_variant LOW 7 0 7 YES PLXNA4 5 
chr7 152544636 T C rs386622381,rs940262 0.808 intron_variant LOW 8 1 7  ACTR3B 6 
chr8 6500543 C T rs1057091 0.244 missense_variant MED 8 1 7  MCPH1 7 
chr9 86585678 A G - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86585690 A G - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86585714 A G - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
 
 
chr9 86586983 G T - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86586990 A G - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86586999 T A - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86587002 G T - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86587008 G T - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86587059 G A rs200783060 - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86587065 A G - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 86587080 C T - - synonymous_variant LOW 7 0 7 YES HNRNPK 12 
chr9 126128252 G C rs1105222 0.316 missense_variant MED 8 0 8 YES CRB2 4 
chr11 1093451 G A rs34136803 - synonymous_variant LOW 9 2 7  MUC2 4 
chr11 2869187 C T rs11601907 0.083 synonymous_variant LOW 8 1 7  KCNQ1 6 
chr11 45230861 C A rs3781705 0.255 intron_variant LOW 8 1 7  PRDM11 6 
chr11 63767185 A G rs709594 0.428 synonymous_variant LOW 10 2 8  MACROD1 8 
chr11 63767248 C T rs11600062 0.171 intron_variant LOW 8 1 7  MACROD1 8 
chr12 1019943 G A rs2023944 0.987 3_prime_UTR_variant LOW 8 1 7  WNK1 21 
chr12 6938022 C CG - 1.000 frameshift_variant HIGH 7 0 7 YES P3H3 13 
chr13 113158859 AC A - - intron_variant LOW 8 1 7  TUBGCP3 6 
chr13 113158860 CATAT C rs3832905,rs397840783 0.282 intron_variant LOW 8 1 7  TUBGCP3 6 
chr13 113158860 CAT C - - intron_variant LOW 8 1 7  TUBGCP3 6 
chr13 113158860 C CAT - - intron_variant LOW 8 1 7  TUBGCP3 6 
chr14 103879023 G A rs4900574 0.703 intron_variant LOW 9 2 7  MARK3 26 
chr15 28090172 C T rs12592307 0.283 synonymous_variant LOW 7 0 7 YES OCA2 5 
chr16 1393019 G A rs2235632 0.352 splice_region_variant MED 10 3 7  BAIAP3 16 
chr17 41465914 GTC G - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465918 CAAGATAT C - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465926 CATCA C - - exon_variant LOW 7 0 7 YES LINC00910 7 
 
 
chr17 41465936 G GCA - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465938 A G - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465940 A G - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465941 C CG - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465943 A G - - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 41465949 A C rs140897052 - exon_variant LOW 7 0 7 YES LINC00910 7 
chr17 80275252 T C rs3176829 0.887 intron_variant LOW 7 0 7 YES CD7 7 
chr19 58898192 C T rs975947 0.314 exon_variant LOW 7 0 7 YES MIR4754 1 
chr20 2594189 C T rs10485601 0.090 intron_variant LOW 7 0 7 YES TMC2 2 
chr20 62318855 G C rs6062490 0.718 intron_variant LOW 7 0 7 YES RTEL1 11 
chr22 36623147 T C rs132759 0.514 3_prime_UTR_variant LOW 8 1 7  APOL2 9 
chrX 41530654 A AT rs199561120 0.112 intron_variant LOW 7 0 7 YES CASK 15 
 
Tab. 10 - Homozygous variants detected to occur imbalanced specifically in the SR-negative group. Sorting by genomic position. All impacts on multiple transcripts were predicted to be equal in terms 
of type and severity. Entries printed in bold are part of the MSM (see Section 2.7). 
chrom Start 
[bp] 
Ref. 
allele 
Alt. 
allele 
rs IDs [dbSNP] MAF 
[1kg 
project] 
Impact type 
[Sequence 
Ontology (SO)] 
Impact 
severity 
[SO] 
SR 
neg. 
count 
SR 
pos. 
count 
diff Exclusive 
for SR neg. 
group? 
Affected 
gene  
Number of 
affected 
transcripts 
chr1 26310393 A G rs2275102,rs386486547 0.547 intron_variant LOW 9 2 7  PAFAH2 7 
chr1 72740633 G A rs7549792 0.397 intron_variant LOW 7 0 7 YES NEGR1 6 
chr2 54122955 A G rs698856 0.823 intron_variant LOW 7 0 7 YES PSME4 10 
chr3 13368891 G A rs2271509 0.396 synonymous_variant LOW 7 0 7 YES NUP210 4 
chr3 13383539 A G rs2271504 0.577 synonymous_variant LOW 7 0 7 YES NUP210 4 
chr3 13395578 C A rs2280084 0.575 missense_variant MED 7 0 7 YES NUP210 4 
chr3 13407555 T C rs3732671 0.579 missense_variant MED 7 0 7 YES NUP210 4 
chr3 13415145 G T rs6810356 0.517 intron_variant LOW 7 0 7 YES NUP210 4 
 
 
chr3 13418085 C A rs6442377 0.512 intron_variant LOW 7 0 7 YES NUP210 4 
chr3 13421149 C T rs7628051 0.517 missense_variant MED 7 0 7 YES NUP210 4 
chr3 13421319 T C rs7625586 0.520 intron_variant LOW 7 0 7 YES NUP210 4 
chr3 14551443 A G rs9845816 0.710 missense_variant MED 7 0 7 YES GRIP2 7 
chr3 134322741 A G rs2293293 0.684 synonymous_variant LOW 10 2 8  KY 5 
chr3 134331979 C T rs9838119 0.683 intron_variant LOW 8 1 7  KY 5 
chr5 54830379 A G rs11745331 0.856 intron_variant LOW 8 0 8 YES PLPP1 6 
chr5 140955776 C T rs2302103 0.641 intron_variant LOW 8 1 7  DIAPH1 18 
chr5 141016287 T G rs1421896 0.656 intron_variant LOW 8 1 7  HDAC3 16 
chr7 5427719 A G rs4724663 0.999 missense_variant MED 9 2 7  TNRC18 10 
chr7 16504177 A T rs4506094 0.669 intron_variant LOW 8 1 7  SOSTDC1 2 
chr7 132248810 C CTGT rs147358337 - intron_variant LOW 7 0 7 YES PLXNA4 5 
chr10 134981689 T C rs2998152 0.669 intron_variant LOW 8 0 8 YES KNDC1 6 
chr10 134981836 T C rs2998151 0.667 intron_variant LOW 8 0 8 YES KNDC1 6 
chr12 1019943 G A rs2023944 0.987 3_prime_UTR_variant LOW 8 1 7  WNK1 21 
chr12 6938022 C CG None 1.000 frameshift_variant HIGH 7 0 7 YES P3H3 13 
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Tab. 11 - Filtering effects on gene-centered variant sets by applying the MSM. Percentages for MSM-located genes express 
the relation to affected genes overall. Percentages of SR-negative genes in turn refer to fractions in MSM-located genes. 
Set genotype LOW impact affected genes 
overall 
genes located 
within MSM 
genes assigned to 
SR-negative group 
1 All (HOM + HET) included 1,104 167 (15.12%) 3  (1.8%) 
2 HOM only included 448 70 (15.63%) 5  (7.1%) 
3 All (HOM + HET) excluded 70 7 (10,00%) 1  (14.3%) 
4 HOM only excluded 32 6 (18.75%) 3  (50.0%) 
 
 
 
Fig. 18 - Relation of MSM filtering effect across sets. A strong trend shows 15% of affected genes remaining when applying 
the MSM as a pathway-driven filter on the different sets. 
 
For the maps displaying also LOW impact data (Sets 1 and 2; Fig. 19 and Fig. 20, respectively), overviews 
were generated in order to get an impression of the topological distribution of affected genes. For 
both sets, an accumulation of events specific for SR-positive cases could not be observed in any area 
of the map. Despite the quite low number, for Set 1 events specific for SR-negative cases could only 
be located in and between core and lower left area. 
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Fig. 19 - Distribution of genes affected by any kind of imbalanced variant. Green: genes specifically hit in the SR-positive 
patient group. Red: genes specifically hit in the SR-negative patient group. Violet: EGFR. 
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Fig. 20 - Distribution of genes affected by imbalanced MED or HIGH impact variant. Green: genes specifically hit in the SR-
positive patient group. Red: genes specifically hit in the SR-negative patient group. Violet: EGFR. 
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When reducing the affected genes to those being hit by at least one medium (MED) or high (HIGH) 
impact imbalanced variant, it becomes feasible to compute the sets of shortest paths (SP clusters) to 
EGFR.  
For Set 3 (Fig. 21), seven of those genes occurred. Six are assigned to the SR-positive patient group, 
with OBSCN (module 5) and STUB1 (module 3) being linked to EGFR with a distance of two functional 
interactions. CDH11 (module 7), COL4A4 (module 1), NUP210 (module 6) and TLR5 (module 4) show a 
distance of three. The single gene specific for SR-negative patients, P3H3 (module 1), has a distance of 
four and is directly linked to COL4A4. For those two collagen-associated genes, most pathes lead over 
PDGFA/B, NCAM1 or ITGB3 and few over ADAM10/17, connecting straight to the signaling-associated 
core of the MSM. 
For Set 4 (Fig. 22), for five genes the SP cluster and shortest pathes to EGFR were computed. Again, 
P3H3 was hit and accounted for the SR-negative patient group. Here, NUP210 was assigned to this 
group, and not to the SR-positive group like in Set 3. The third gene, GRIP2 (module 2), shows a distance 
of two functional interactions to EGFR, with all shortest pathes leading via AP2 subunits (A1/2, B1, M1, 
S1). For the SR-positive group, two out of three specifically hit genes are related to clusters of 
differentiation: CD86 (module 0) is located in the MSM’s center and closely connected to EGFR 
(distance = 2; same module). C3 (module 15) is connected to EGFR with several shortest pathes of 
distance three, and all these go via CD19. The third gene for this patient group is CCNK (module 10), 
connected exclusively via SMAD2/3/4 with SP distance 3. 
 
3.5 Final candidate lists 
When reviewing the variants detected by the pipeline, for some outputs minor allele frequencies 
(MAFs) appear to be greater than 0.5, effectively designating them to be the most common alleles for 
these loci. Conversely, the reference alleles are less common and by definition minor alleles. In 
contrast to the pipeline, dbSNP already lists the reference alleles’ frequencies (MAFreference) as official 
MAFs. For the most frequent case of two known alleles in a locus, this is simply 1 – MAFalternate. From a 
variant calling point of view, for these pipeline outputs the assignment of uncommon variants to a 
patient group has to be inverted: i.e., for C3’s variant rs2287845 in Tab. 14, the less common ‘G’ allele 
with a MAF of 0.268 (= 1 - 0.732) has to be assigned to the SR-negative group. 
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Fig. 21 - Clusters of Shortest Paths (SP) between affected genes of Set 3 and EGFR, each. Computed SPs are of a distance of 
two (OBSCN, STUB1), three (CDH11, COL4A4, NUP210, TLR5) and four (P3H3), respectively. Nodes on the SPs to EGFR are 
plotted with thick green borders, the connecting edges in blue. Further nodes linking all affected genes with each other via 
shortest pathes (= SP cluster) are painted in their respective module color (comp. Tab. 5), while respective edges stay grey. 
Green nodes with thick borders: with variants specifically observed in SR-positive cases. Red nodes with thick borders: with 
variants specifically observed in SR-negative cases. Violet node: EGFR. 
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Fig. 22 - Clusters of Shortest Paths (SP) between affected genes of Set 4 and EGFR, each. Computed SPs are of a distance of 
two (CD86, GRIP2), three (C3, CCNK, NUP210) and four (P3H3), respectively. Nodes on the SPs to EGFR are plotted with thick 
green borders, the connecting edges in blue. Further nodes linking all affected genes with each other via shortest pathes (= 
SP cluster) are painted in their respective module color (comp. Tab. 5), while respective edges stay grey. Green nodes with 
thick borders: with variants specifically observed in SR-positive cases. Red nodes with thick borders: with variants specifically 
observed in SR-negative cases. Violet node in center: EGFR. 
 
Tab. 12 - Reverse mapping from MSM to variants (Set 3). After restricting the set of genes affected by imbalanced medium or high impact variants of any type to those being part of the MSM, the 
following variants of interest remain. For pipeline outputs with minor allele frequencies (MAFs) greater than 0.5 (underlined), alternate alleles according to the reference have be considered as 
major alleles. The variant on P3H3 has been officially listed as rs57050687 recently and does not appear with this ID in the pipeline outputs. SO = Sequence Ontology. 
Gene Variant Imbalance 
approved 
symbol 
[HGNC] 
HGNC Entrez affected 
transcript 
count 
genomic 
position 
ref alt rs IDs 
[dbSNP] 
MAF 
[aaf_1kg_all, 
dbSNP] 
Impact [SO] Severity 
[SO] 
SR 
neg. 
SR 
pos. 
Assignment 
to SR group 
Value exclusive 
in group 
CDH11 1750 1009 18 chr16:65025717 G A rs35195 0.182 missense_variant MED 3 10 + 7 NO 
COL4A4 2206 1286 2 chr2:227915831 G A rs1800517 0.547 missense_variant MED 4 11 + 7 NO 
NUP210 30052 23225 4 chr3:13361286 C T rs354478 0.612 missense_variant MED 3 12 + 9 NO 
OBSCN 15719 84033 15 chr1:228494789 G A rs435776 0.269 missense_variant MED 3 10 + 7 NO 
P3H3 19318 10536 13 chr12:6938022 C CG 
None 
(rs57050687) 
1 frameshift_variant HIGH 7 0 - 7 YES 
STUB1 11427 10273 11 
chr16:732284 AG A None -1 splice_region_variant MED 2 10 + 8 NO 
chr16:732286 GC G 
rs3216838, 
rs397766974 
0.622 splice_region_variant MED 2 10 + 8 NO 
TLR5 11851 7100 6 chr1:223284527 A G 
rs386599677, 
rs5744174 
0.29 missense_variant MED 1 8 + 7 NO 
 
Tab. 13 - Distribution of Set 3 variants across patients. For further information, refer to Tab. 12, using genomic position, reference (ref) and alternate (alt) alleles as key. “0” (green) codes for 
homozygous reference alleles, “1” (yellow) for one alternate allele detected, “3” (red) for homozygous alternate allele. “2” (grey), observed for chr16:732284 AGA (in NUP210), codes for an 
unknown allele combination. Here, the genotypes are “AG/.”, indicating for a mssing allele in the referring samples. All genotype codes follow the GEMINI convention. 
Variant Skin rash negative patients Skin rash positive patients 
genomic 
position 
ref alt 020 036 072 125 281 375 406 428 586 750 796 014 090 137 155 111 213 344 566 598 624 638 708 
chr16:65025717 G A 0 3 0 0 0 0 0 1 1 0 0 1 0 1 0 3 1 1 1 3 1 3 1 
chr2:227915831 G A 0 0 0 1 0 0 0 1 1 3 0 1 1 1 3 1 3 1 1 1 1 0 1 
chr3:13361286 C T 0 3 0 0 0 3 0 0 1 0 0 3 1 3 3 3 3 1 1 3 1 1 1 
chr1:228494789 G A 3 1 0 0 0 0 0 3 0 0 0 1 3 1 3 1 1 1 0 1 0 1 1 
chr12:6938022 C CG 3 0 0 0 3 3 3 3 3 3 0 0 0 0 0 0 0 0 0 0 0 0 0 
chr16:732284 AG A 0 0 0 0 0 0 0 0 0 2 1 1 2 0 1 2 1 2 0 1 1 1 1 
chr16:732286 GC G 0 0 0 0 0 0 0 0 0 3 1 1 3 0 1 3 1 3 0 1 1 1 1 
chr1:223284527 A G 0 0 0 0 0 3 0 0 0 0 0 1 1 1 1 1 0 0 1 1 0 0 1 
 
 
Tab. 14 - Reverse mapping from MSM to variants (Set 4). After restricting the set of genes affected by imbalanced medium and high impact homozygous variants to those being part of the MSM, 
the following variants of interest remain. For pipeline outputs with minor allele frequencies (MAFs) greater than 0.5 (underlined), alternate alleles according to the reference have be considered as 
major alleles. The variant on P3H3 has been officially listed as rs57050687 recently and does not appear with this ID in the pipeline outputs. Entrez ID of GRIP2 (in italics) added manually, as not 
part of the offline database of SNPeff. SO = Sequence Ontology. 
Gene Variant Imbalance 
approved 
symbol 
[HGNC] 
HGNC 
ID 
Entrez 
ID 
affected 
transcript 
count 
Position ref alt rs IDs 
[dbSNP] 
MAF 
[aaf_1kg_all] 
Impact [SO] Severity 
[SO] 
SR 
neg. 
SR 
pos. 
Assignment 
to SR group 
Value exclusive 
in group 
C3 1318 718 18 chr19:6696596 G A 
rs2287845, 
rs386490580 
0.732 splice_region_variant MED 3 10 + 7 NO 
CCNK 1596 8812 9 chr14:99961829 T C rs2069492 0.447 splice_region_variant MED 0 7 + 7 YES 
CD86 1705 942 9 chr3:121825196 G A rs2681417 0.868 missense_variant MED 4 12 + 8 NO 
GRIP2 23841 80852 7 chr3:14551443 A G rs9845816 0.71 missense_variant MED 7 0 - 7 YES 
NUP210 30052 23225 4 
chr3:13368891 G A rs2271509 0.396 synonymous_variant LOW 7 0 - 7 YES 
chr3:13383539 A G rs2271504 0.577 synonymous_variant LOW 7 0 - 7 YES 
chr3:13395578 C A rs2280084 0.575 missense_variant MED 7 0 - 7 YES 
P3H3 19318 10536 13 chr12:6938022 C CG 
None 
(rs57050687) 
1 frameshift_variant HIGH 7 0 - 7 YES 
 
Tab. 15 - Distribution of Set 4 variants across patients. For further information, refer to Tab. 14, using genomic position, ref and alt alleles as key. “0” (green) codes for homozygous reference allele 
and “3” (red) for homozygous alternate allele. All genotype codes follow the GEMINI convention (“0” = homozygous reference; “3” = homozygous alternate). 
Variant Skin rash negative patients Skin rash positive patients 
Position ref alt 020 036 072 125 281 375 406 428 586 750 796 014 090 111 137 155 213 344 566 598 624 638 708 
chr19:6696596 G A 3 0 0 0 0 0 3 0 0 0 3 3 3 3 3 3 3 3 3 0 3 3 0 
chr14:99961829 T C 0 0 0 0 0 0 0 0 0 0 0 3 0 0 3 0 3 3 0 0 3 3 3 
chr3:121825196 G A 0 3 0 3 0 3 3 0 0 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
chr3:14551443 A G 3 0 0 0 3 3 0 3 3 3 3 0 0 0 0 0 0 0 0 0 0 0 0 
chr3:13368891 G A 3 0 0 3 3 0 3 3 0 3 3 0 0 0 0 0 0 0 0 0 0 0 0 
chr3:13383539 A G 3 0 0 3 3 0 3 3 0 3 3 0 0 0 0 0 0 0 0 0 0 0 0 
chr3:13395578 C A 3 0 0 3 3 0 3 3 0 3 3 0 0 0 0 0 0 0 0 0 0 0 0 
chr12:6938022 C CG 3 0 0 0 3 3 3 3 3 3 0 0 0 0 0 0 0 0 0 0 0 0 0 
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4. Discussion 
Skin rash as an undesired, nowadays often preventively treated side effect, has been used as a 
phenotypic biomarker for drug efficacy of Cetuximab (and other EGFRIs) by oncologists for years now. 
A minority of patients, who more or less lack a skin toxicity reaction, are reported to be low responders 
to Cetuximab. Although this repeatitively reported correlation is still under investigation and not finally 
confirmed, in practice SR-negative patients are subject to switch of therapy.  
However, molecular mechanisms potentially connecting these two observations causally, are still 
unknown. Apart from scientific motivation, deeper knowledge may support optimized treatment 
strategy selection by earlier decision for alternate medications. 
As hypothesis generation is an important first step, exome data from eleven SR-negative CRC patients 
and twelve SR-positive controls, treated in first line with Cetuximab each, were used as the basis for 
this work. After state-of-the-art variant calling from raw NGS data, two approaches were combined for 
finding candidate genes. First, following an assumption that relevant affected genes should be 
significantly, inequally distributed between both patient groups, the ‘imbalance’ was set up as a 
statistical model. Second, by restricting the subsequent analyses to a set of biologically promising 
mechanisms, candidate genes should be filtered massively. Therefore, a usecase-specific ‘Molecular 
Systems Map’ (MSM) was created, while the MSM principle itself is generic. The MSM has been 
implemented in Cytoscape, which is most commonly used in bioinformatics. Here a focus is on 
molecular and genomic interactions in curated, uncurated as well as custom made networks, which 
can be visualized and analysed simultaneously in a graph-oriented and semantic-aware manner [Fitts 
et al. 2016]. 
 
4.1 Variant calling and the imbalance criterion 
In previous analyses, performed by the NGS data-producing lab, no simple relation between a single 
gene and the observed phenotype could be found. Consequently, for this work two central 
assumptions were made:  
 Not a single gene is responsible for the phenotype across all affected patients, but maybe a 
functionally connected subset. 
 Exome data in fact is enriched for exons by design, but the given short reads may be generated 
from further loci or exceed the target regions, carrying additional information. 
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Therefore, no BED file was used for the short read mapping, leading to a larger number of called 
variants in intronic or even intergenic regions. Here, functional elements like promoters, various 
binding motifs and splice sites are expected to occur, having influences when changed by somatic 
variations. Calling technical artefacts is considered to be compensated by the removal of read 
duplicates. 
 
4.2 Evaluating the skin rash MSM 
The MSM provides a visual, interactive representation of those mechanisms and a topologic 
representation of the detected genes, e.g. their direct interaction partners, connection to EGFR and 
membership to functional units (pathways, clusters of functional interactions). Apart from gaining 
deeper insights in the biological meaning of the NGS-derived results, hypothesis generation by domain 
experts (physicians, geneticists) will be supported. 
For the given use case of skin rash in Cetuximab treatment, the MSM fulfilled the attributes stated 
above and delivered reasonable structures when considering the data-driven layout and clustering 
compared to the biological backgrounds. In the layout (for a detail shot depicting the following 
paragraphs refer to Fig. 23), dense clusters represented tightly connected functional units, which are 
simultaneously accounted for respective modules by ReactomeFI’s algorithm. Much more important, 
modules can be assigned easily for biological functions. For sure, on the one hand, as Reactome’s 
pathway annotations are manually curated and follow the biological knowledge, these observations 
meet an expectation. But, on the other hand, the generated MSM layout follows this principle 
expectations, although Reactome data is most often used in a pathway-centered way.  
Furthermore, the central, but less tightly clustered modules are distributed in the core region (module 
0; growth factor signaling and cytokines) or even across major parts of the MSM (module 7; cell 
interaction/junction upon Rho/TGFβ), showing their connective character. This makes biologically 
sense, as growth factors share multiple components and perform intensive cross-talk [Holland et al. 
2003], acting more as a reaction network – in turn underlining the artificial character of the ‘pathway’ 
concept. 
Generally, the top left quarter of the core region shows the close interaction of components from 
both immune system and growth factor/GPCR-related signaling pathways, all primarely related to 
sensing conditions from the cell’s environment (extracellular space). In terms of immunology 
components, Fcγ Receptor-mediated phagocytosis (module 12; innate immunity) can be found here, 
while the major parts are contributed by the mechanisms of cytokine signaling, especially interleukin-
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like ones (belonging to module 0). Those are released into the intracellular space during inflammation 
reactions and sensed by receptive cells. Additionally, MHC class II signaling (module 2) as the respective 
component in the adaptive branch of the immune system, adjoins here. These molecules are present 
primarely in professional antigen-presenting cells, like dendritic and B cells, providing antigens from 
phagocytosed proteins. In contrast, the MHC I cluster is located much more right within the MSM, 
showing less proximity to the core region. 
Close to module 0, but quite strictly separated, components of nucleus mechanics (module 6; nuclear 
pores, chromatids) appear, reflecting that downstream events of both growth factor signaling and 
immune system reactions include highly regulated transcription factor re-localization from cytoplasm 
to nucleus. 
 
Fig. 23 - Detail from the MSM's central region. Example for the relation between modules 0 (blue), 2 (violet), 3 (olive), 4 
(light blue), 5 (yellow), 6 (pink/magenta) and 7 (violet grey). 
 
However, there were some surprises when interpreting the MSM, e.g. when checking for the 
localization of cell adhesion-related molecules. Cadherins appear topologically separated from all 
other components from this superset (which form module 1 at the bottom left side of the MSM), 
located closer to WNT-related modules on the top right side. Biologically, this may underline the tight 
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mechanistic connection to WNT pathways (especially in development), as well as the dual function of 
cadherins as mechanical connectors and receptors/ligands for signaling.  
Also, when considering the WNT-related reactions, a separation into three major modules (8, 11, 13) 
was not expected. While module 13 may map properly to the WNT ligand biogenesis und trafficking 
pathway, the modules 8 and 11 share larger intersections. In more detail, module 8 appears like 
integrating all WNT-related functions including the downstream link to nuclear factors (transcription 
factors, β-Catenin, Demethylases, histones; also assigned to Signaling by Rho GTPases pathway). 
Module 11’s connection to the RAF/MAP kinase pathway remains functionally unclear (G-protein 
receptors, voltage-gated potassium channels). 
Most interestingly, EGFR as Cetuximab target molecule and consequently the starting point of all 
literature research on connected molecular mechanisms, appeared right in the middle of the MSM. 
Obviously, as it belongs to the central growth factor signaling representing module 0, it was not 
expected to be located in any corner of the map. But from a functional point of view, for the given 
subset it takes a literally central role, as in contrast to e.g. receptors for foreign molecules (TLRs, LRRs), 
there it not only a downstream side from the receptor, but also a number of regulative mechanisms 
on the ligand side, pointing to EGFR. Considering that the receptor knows a number of related but 
different endogenous ligands (EGF, HB-EGF, … [Wells 1999]), it is not a simple starting point of a cellular 
reaction, but central switch of multiple regulative cycles, obviously pulling the respective node into the 
MSM core. 
Apart from biological interpretation, there is a technical side on the MSM’s implementation in 
Cytoscape. During development some technical limitations were experienced, mainly due to the 
amount of data – although highly connected nodes (e.g. rhodopsins, immune chains) were removed 
beforehand during pathway merging. In terms of performance, especially the heavy usage of main 
memory is grave: while up to eight gigabytes are used by Cytoscape in the given setting, usual desktop 
computers with less than 16 GB of RAM might struggle. Here, the user’s experience might be rough. 
Ultimately, for this reason, excessively connected subsets of nodes were removed from the initially 
loaded pathways (comp. Subsection 2.7.1 and Tab. 4), reducing objects (nodes and edges) to a number 
operable by Cytoscape. 
Furthermore, by observation somehow connected to the memory consumption, sessions in Cytoscape 
might loose contents (e.g. plotting styles, edge annotations fetched from ReactomeFI) or 
functionalitites (e.g. right-click menu in the main panel, with all its functions). Also freezes of the whole 
workbench were faced, and saving sessions takes several seconds to finish for sessions containing 
many objects.  
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Independent of those issues, the statement has to be made that in terms of usability and non-expert 
user motivation, Cytoscape as an interface is still a de facto standard for graph data. 
In summary, the MSM idea of integrating functional interaction data works, at the model follows the 
annotated biological subject, designating the MSM as a valid basis for the analyses which incorporate 
the NGS-derived variation data. 
 
4.3 Final gene candidates and interpretation 
When reviewing the results of the performed analyses on the exome data from a systemic perspective, 
for Sets 1 and 3, representing those which still include the majority of variants being designated by 
SNPeff as low impact, no eye-catching distribution pattern could be observed.  
In contrast, the restriction to medium or high impact variants in both Set 2 and 4 revealed a small 
number of remaining genes, suitable for manual review within the MSM itself as well as further 
knowledge bases like GeneCards13 [Rappaport et al. 2017], dbSNP [Kitts et al. 2013]14, PubMed15 and 
others. For those candidates, the following subsections introduce findings and, where applicable, basic 
hypotheses on how the variant may explain the Cetuximab-related skin rash phenomenon. 
Taken together, the Sets 2 and 4 provide eleven candidate genes, of which ten are discussed the 
following Subsections 4.3.1 to 4.3.10. With KISS1, extracted from the NGS data variation analysis, but 
missed by the MSM design, another gene will be discussed in Subsection 4.3.11.  
  
4.3.1 C3 
C3 plays a central role in activating the complement system, which works in balanced cascades of 
proteolytic steps and potentiates antimicrobial responses of both humoral and cellular nature [Merle 
et al. 2015a; Merle et al. 2015b]. Mechanistically, three sensoring pathways (classical, alternative and 
lectin pathway) join in C3’s amplification loop, finally initiating the terminal pathway and its membrane 
attack complex [Merle et al. 2015a]. In recent years the complement system’s role has been recognized 
as being more than microbial defense [Mastellos et al. 2016]. It plays a central role for tissue 
homeostasis, also via the recognition of diseased and damaged cells of the host itself, together with 
other immune mechanisms [Ricklin et al. 2010]. An important cleavage product is C3b, acting as 
opsonizing factor, tagging cells for decay and recruiting phagocytotic cells; C3a meanwhile acts as 
                                                          
13 http://www.genecards.org  
14 https://www.ncbi.nlm.nih.gov/SNP/  
15 https://www.ncbi.nlm.nih.gov/pubmed/  
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anaphylatoxin, triggering potent inflammatory responses in the local tissue [Janeway 2001]. 
Interestingly, in cancer settings, C3 is described to be elevated in the tumor microenvironment, and 
having an anti-angiogenic effect [Pio et al. 2014]. Meanwhile, lowered C3b levels seem to be correlated 
with an improved escape of the tumor from immunosurveillance [Pio et al. 2014]. In human, but not 
mouse skin, keratinocytes treated with EGFRIs showed elevated expression and activation of 
complement components, together with improved recruitment of neutrophils, implicating a 
chemotactic effect [Holcmann & Sibilia 2015; Abu-Humaidan et al. 2014], leading to inflammation and 
rash [Holcmann & Sibilia 2015]. Since more than thirty years, the relation between C3 polymorphisms 
and Crohn’s disease, a chronic inflammatory bowel disease (IBD) is documented [Elmgreen et al. 1984].  
In the given SR setting, C3 occurred to be hit homozygously by a variant altering a splice site in the SR-
positive patient group. As the minor allele frequency (MAF) was given with 0.73, in fact, the reference 
genome is carrying the less frequent variant, finally switching relations: the SR-negative patient group 
carries in eight out of eleven cases the less frequent allele of a variation site. In contrast to the dbSNP 
information used in the data processing/annotation, this variant (rs2287845) has already been 
switched to the described opposite case in dbSNP online, with a MAF of 0.27. Furthermore, it is tagged 
with a clinical relevance, pointing to C3 deficiency (NCBI MedGen ID C1332655). The ClinVar entry16 
states ‘benign’ for the more common allele (which is present in the SR-positive group). In this context 
it is announced that patients with a C3 deficiency may show systematic lupus erythematosus (SLE; 
[Tsukamoto et al. 2005]). SLE, also inducible by drugs, shows a similar phenotype to the observed 
Cetuximab-induced skin rash [Antonov et al. 2004].  
Interestingly, Chowdhury et al. 2015 already reported a C3 polymorphism to have a significant 
influence on a treatment. Despite the fact that this publication is about a coding variant and hepatitis 
C, it hits quite fair the pharmacogenomics principle, which is part of the working assumptions of this 
thesis. In another study referenced at MedGen, there are three coding variants reported affecting the 
exons 24 (frameshift) and 26 (premature stop codon, nonsense mutation), respectively [Kida et al. 
2008]. An additional study reported about a splice site mutation, leading to a skip of exon 27, 
compromising a functional domain, and ultimately leading to a complete C3 deficiency [da Silva et al. 
2016]. In turn, the patient reported in [Tsukamoto et al. 2005] was identified with an acceptor site A-
to-G transition in intron 38, which leads to skipping exon 39. The parents and two sibblings were 
heterozygous for this mutation and showed reduced levels of C3 hemolytic activity. Taken together, a 
number of clinically relevant C3 variants are known. 
                                                          
16 https://www.ncbi.nlm.nih.gov/clinvar/variation/330297/  
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For the variant rs2287845 detected in the given skin rash setting, neither a clinical phenotype nor an 
elevated interest has been reported yet. Here, the affected donor splice site reported by SNPeff is 
located after exon 22. Assuming the splice out signal is impaired, the intron region up to exon 23 would 
remain part of the mature mRNA, getting finally translated into an amino acid sequence. As the 
additional region of 127 bp is not divisible by three, the subsequent nucleotide sequence would be 
affected by a frame shift event. As shown in Box 12, 14 deviating amino acids would be coded until a 
premature stop codon terminates the translation. 
Box 12 - Predicted sequence change in C3 due to rs2287845. The original sequence of the mature mRNA contains the 
transcribed information from exons 22 (yellow highlight) and 23 (cyan highlight), being translated into the reference amino 
acid sequence (as shown in bold green). With the reference “c” in intron 22 (lower case subsequence; highlight in grey) 
converted to a “t” (highlighted in red), the resulting mutation event “NG_009557.1:g.29066C>T” causes a disruption of the 
donor splice site as predicted by SNPeff. Thus, the intron is probably not spliced out.  
Consequently, the amino acid sequence is also changed. In the reference sequence of the mature mRNA17, the codon “GAA” 
starting from position 2957 (underlined) is assembled of one base from exon 22 and two bases from exon 23. It codes for 
glutamic acid (“E”) at position 956 of the reference protein sequence18. When translating the not spliced out intron, the amino 
acid sequence would start deviating with a frameshift from the reference (red bold), introducing a mutation p.E955G (with 
“G” coded by new codon “Ggt”; underlined). The 14th following triplett would finally code for a new stop signal (‘*’), 
terminating the translation here. Taken together, the modern HGNC nomenclature would code the event on the protein level 
as “NP_000055.2:p.(Glu955GlyfsTer969)”. Note: DNA sequence is the reverse complement of the reference, as C3 is coded 
on the reverse strand. 
 
 
Considering the position of the variation at ~60% of the 1,663 bp coding sequence of C3, a truncated 
version of the protein as considered in Box 12 may be regarded as too strong. The SR-negative patients 
show the variant homozygously, and are not described as phenotypically different to other patients 
before treatment. C3 is a central player in all three complement cascade pathways and the SLE-like 
phenotype of complete C3 deficiency as announced by [Tsukamoto et al. 2005] has not been 
documented for the given CRC patients. Consequently, it would be reasonable to assume a new donor 
                                                          
17 https://www.ncbi.nlm.nih.gov/nuccore/NM_000064  
18 https://www.ncbi.nlm.nih.gov/protein/NP_000055  
original mRNA sequence 
2890 CCGGAAGGAATCAGAATGAACAAAACTGTGGCTGTTCGCACCCTGGATCCAGAACGC 2947 
 933  P  E  G  I  R  M  N  K  T  V  A  V  R  T  L  D  P  E  R   952 
2948 CTGGGCCGTGAAGGAGTGCAGAAAGAGGACATCCCACCTGCAGACCTCAGTGAC    3000 
 953  L  G  R  E  G  V  Q  K  E  D  I  P  P  A  D  L  S  D      969 
 
modified sequence after splice site disruption 
2890 CCGGAAGGAATCAGAATGAACAAAACTGTGGCTGTTCGCACCCTGGATCCAGAACGC 2947 
 933  P  E  G  I  R  M  N  K  T  V  A  V  R  T  L  D  P  E  R   952 
2948 CTGGGCCGTGgtgagttggctgcagggggaggggctgaggggctggcagggtaaggg    ? 
 953  L  G  R  G  E  L  A  A  G  G  G  A  E  G  L  A  G  *  G     ? 
   ? gggtaaatgacctgggtttagtgaggtaggatagggcgggagggagctagagccatc    ? 
   ?  G  *  M  T  W  V  *  *  G  R  I  G  R  E  G  A  R  A  I     ? 
   ? ggtatctctcactcaccctgcagAAGGAGTGCAGAAAGAGGACATCCCACCTGCAGA    ? 
   ?  G  I  S  H  S  P  C  R  R  S  A  E  R  G  H  P  T  C  R     ? 
   ? CCTCAGTGAC 
   ?  P  Q  * 
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splice site appearing in the unspliced intron region before the newly introduced stop codon. The 
resulting protein would accordingly not lack major parts, but show a change in its threedimensional 
conformation, as additional amino acids would occur compared to the wildtype form. From a 
functional domain point of view, NCBI’s Conserved Domain Database search engine19 (CDD; [Marchler-
Bauer et al. 2017]) reports a ‘complement_C3_C4_C5’ domain20 starting just 31 amino acids after the 
affected position (Fig. 24). The respective domain is central for C3, as it contains four important 
features (active site, thioester region, surface patch and specificity-defining residues) central for 
binding of and reaction with other proteins. Presumably, while still present and intact, the domain 
might be suboptimally oriented within C3’s three-dimensional structure, affecting e.g. the binding to 
factors B or H, the cleavage or the probability to exhibit the thioester site during ‘tick-overs’ (see down 
below). 
 
 
Fig. 24 - Conserved Domain Database (CDD) view on C3's protein sequence. The broader red box marks the 
‘complement_C3_C4_C5’ domain, which follows shortly after the altered region in which an unspliced intron potentially 
introduces additional amino acids an a frameshift (red bracket). Top half: full domain-centric view onto protein sequence; 
bottom half: zoom to region of interest. Amino acids printed in bold carry dedicated functions in 3D space. 
 
In a nutshell, for the SR-negative patients showing the rs2287845 alternate allele, C3 is probably 
somatically slightly impaired, but not completely dysfunctional. On the one hand, this would imply 
changes in the regulative potential due to altered conformation may trigger large-scale changes in 
immune reactions overall: C3 is modulatory active on both adaptive and innate immune responses, 
affecting human pathophysiology via diverse biological processes [Mastellos et al. 2016]. On the other 
hand, a highly regulated and usually robust biological system like immunity characterizes itself by 
deploying adequate mechanisms [Azeloglu & Iyengar 2015], constantly balancing between minimizing 
damage by pathogens and autoimmunity [Bergstrom & Antia 2006; Eberl 2016]. Feedback control and 
                                                          
19 https://www.ncbi.nlm.nih.gov/Structure/cdd/docs/cdd_search.html  
20 https://www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi?uid=cd02896  
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redundancy are just two well-known examples described in several signaling cascades and pathogen 
elimination strategies [Bergstrom & Antia 2006]. In fact, for the complement system a clinically 
relevant long-term compensation for primary deficiencies in C3 has been reported: while those 
individuals show an increased risk for infections at young ages, in adulthood this effect subsides, 
suggesting a yet unknown mechanism [Reis et al. 2006]. Thus, investigations on the medical history of 
SR-negative patients may be informative. 
For a mechanistic overall hypothesis regarding C3’s role in the SR setting, it should be noticed that 
EGFR inhibition leads to an elevation of C3 levels in keratinocytes [Abu-Humaidan et al. 2014]. In the 
skin, which is in a regular contact to the microbial environment, inflammatory cascades are triggered 
constantly via the alternative pathway. Simultaneously, the activating forces are counteracted by 
inactivation processes, keeping the whole system in a delicate balance [Zipfel 2001]. Usually, this 
dynamic equillibrium resides on a low level, providing homeostasis under physiological conditions 
[Harris et al. 2012]. When due to Cetuximab’s induction, C3 molecules are more abundant than in a 
non-treatment setting, its higher concentrations may lead to more molecules being initially activated 
(Fig. 25). As consequently more units of the cascades subsequent steps are present, the probability for 
the whole complement cascade to ‘fall over’ would increase, effectively pushing the homeostasis to 
inflammation [Harris et al. 2012]. This would finally trigger and amplify immune cell recruiment and 
cytokine actions, resulting in skin rash [Holcmann & Sibilia 2015].  
In consequence of C3’s role in homeostasis, pathogenesis of a wide spectrum of inflammatory diseases 
is closely related to dysregulation of the complement system, mostly described as overactivation and 
including some individuals showing a skin rash phenotye similar to SLE [Ricklin & Lambris 2013; 
Truedsson et al. 2007]. Regarding therapeutic intervention, silencing of hypersensitive complement 
cascade reactions by blocking C3 as central component, is already subject to ongoing studies [Ricklin 
& Lambris 2016]. In the given CRC treatment setting, for C3 wildtype patients this overreaction may be 
triggered exogenously by systemically applied Cetuximab, elevating the levels of cleavable C3. As a 
result, the immune equilibrium of the skin gets massively disturbed, leading to a pathogenic state 
[Eberl 2016]. 
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Fig. 25 - Simplified model of C3's hypothetical role in skin rash phenomenon via the alternative pathway (AP). In the AP, C3 
molecules (blue) spontaneously convert to bioactive C3(H2O). This hydrolysis is known as ‘tick-over’ [Merle et al. 2015a]) and 
is the starting point for the AP initiation (green area). Hydrolized C3 is structurally different, effectively exposing a binding 
site for Factor B (black). Bound Factor B in turn gets cleaved by Factor D, leaving C3(H2O)Bb, which is capable of binding 
stabilizing Factor P (violet). The initial C3 convertase of the alternative pathway (AP) irreversibly cleaves a number of C3 
molecules, which again interact with Factor B, making up an amplification loop (red area; [Lachmann 2009]). During 
activation, most steps forward (red solid arrows) are counteracted by Factor H and FHL-1, representing a competing 
inactivation process (green solid arrows), effectively creating a dynamic equillibrium between activation and inactivation. For 
the later, the non-reversible exit point for C3b is the cleavage by Factor I, resulting in iC3b (both in initiation and amplification). 
In contrast, upon sufficiently high turnover rates, C3 convertases in the amplification loop bind free C3b, resulting in 
C3bBbC3b complexes (the C5 convertase of the AP). Those finally trigger the immunologically effective terminal pathway. 
When considering Cetuximab’s effect to increase C3 expression, both initiation and amplification of the AP could be assumed 
to be promoted, as turnover rates get increased and the equillibrium gets influenced in favor of the system’s forward 
direction. A general shift to activation would be the consequence for SR-positive patients, leading to inflammation (rash). 
Considering a slightly impaired C3 variant in the SR-negative patients, protein interactions on all steps of the cascade could 
be affected, presumably causing a reduced reaction speed in the progression to inflammation (interaction with Factors B, D 
or P). Consequently, the equillibrium gets shifted backward to inactivation and no inflammation (no rash). Illustration and 
general mechanistic description following [Zipfel 2001] and G. Hegasy21. 
 
  
                                                          
21 http://www.hegasy.de (Downloads > Komplement System) 
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For the tumor, the complement systems comes into play with contrasting positions; acute 
inflammation, lysis, chemotaxis and other mechanisms control tumor activities, while chronic 
inflammation promotes immunosuppression in the tumor’s microenvironment, angiogenesis and 
progression [Khan et al. 2015]. Especially for the colon, connections have been drawn between chronic 
inflammation (inflammatory bowel disease; IBD) and an increased risk of cancer (colitis-associated 
cancer; CAC). Here, the balance shift from physiological (acute) to pathological inflammation (chronic) 
is ground-laying for a tumor-supportive microenvironment [Danese et al. 2011]. Considering the colon, 
and especially the colonic tumor [Pabla et al. 2015], as EGFR-expressive tissues [Wells 1999; Cohen 
2003], elevated C3 levels in response to EGFR shutdown [Abu-Humaidan et al. 2014] would lead again 
to a homeostasis shift of the complement system’s alternative pathway in favor of acute inflammation, 
like for the skin’s keratinocytes. In the first line, a result would be a more sensitive recognition of 
malignant cells, supporting the anti-tumor forces of the immune system [Pio et al. 2014]. A report on 
Cetuximab’s activity to be significantly higher when the de-activating Factor H was genetically 
downregulated, supports this model (study in lung cancer; [Hsu et al. 2010]). Moreover, the same 
authors reported a general anti-tumor activity of Cetuximab being linked to complement activation via 
the classical pathway, resulting in increased production of cytolytic C5b-C9 complex (endpoint of the 
complement system’s terminal pathway). Consequently, apart from the alternative pathway’s 
influence described above, especially for the tumor context the complement’s classical pathway has 
to be considered relevant for the skin rash phenomenon (Fig. 26). 
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Fig. 26 - Simplified model of C3's hypothetical role in skin rash phenomenon via the classical pathway (CP). In the CP, no 
spontaneous activation occurs: initiation (orange area) is triggered by the recognition of foreign patterns by antibodies of the 
IgM or IgG type. The antibodies Fc terminus is subsequently detected by the C1 complex (golden hexameric structure), which 
gets activated and cleaves both C2 and C4 [Merle et al. 2015a]. C4b and C2a assemble to the CP C3 convertase, which like the 
alternative pathway (AP) C3 convertase irreversibly cleaves a number of C3 molecules. This finally starts up the C3 
amplification loop (red area), like described in Fig. 25. Both CP and AP C3 convertases bind free C3b, resulting in both 
C4bC2aC3b (the C5 convertase of the CP) and C3bBbC3b (the C5 convertase of the AP), which finally trigger the 
immunologically effective terminal pathway. Again, iC3b, but also iC4a, offer a permanent exit from the reaction chains, 
effectively supporting down-regulation. 
When considering Cetuximab as a therapeutic antibody of the IgG type, it must be suggested that the C1 complex binds to it, 
triggering the complement CP wherever it binds to EGFR (comp. green antibodies in figure). While at the same time the 
sensitivity of the subsequent C3 amplification loop is increased due to Cetuximabs increasing effect on C3 itself, the C5 
convertase-mediated activation of the terminal pathway should be considered. Consequently, acute inflammation should be 
suggested to occur at EGFR-expressing tissues (skin, colon, tumor). Again, given a suboptimally working C3 molecule due to 
the rs2287845 variant in several SR-negative patients, the effects of Cetuximab would be attenuated, as the CP triggers get 
not as strongly amplified like with wildtype C3 (no rash, no effectiveness against the tumor). Illustration and general 
mechanistic description following [Zipfel 2001] and G. Hegasy22. 
 
  
                                                          
22 http://www.hegasy.de (Downloads > Komplement System) 
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Taken together, the detected C3 variant offers a chance to generate a mechanistic model, potentially 
explaining the difference between patients being positive or negative for predictive skin rash upon 
Cetuximab treatment. The model (Fig. 27) includes two effects of Cetuximab: an increased C3 
concentration (promoting both the alternative pathway initiation and the amplification loop) as well 
as the antibody’s activation of the classical pathway. Consequently, the probability for the subsequent 
terminal pathway of the complement system to switch over to inflammation increases. As local tissue 
changes occur for the majority of patients, this leads to an overreaction in the skin (rash) and increased 
surveillance/destruction of the colonic tumor (survival).  
 
 
Fig. 27 - Overall model of C3-centric Cetuximab mechanisms causing rash in SR-positive patients. Cetuximab application 
triggers both the activation of the Classical Pathway (CP; yellow box) of the complement system and higher expression of the 
complement factor C3. The latter potentially promotes both the (constantly active) alternative pathway (AP; green box) and 
the amplification loop (red box). In sum, the gradual signal feeding the terminal pathway is elevated compared to no 
application of Cetuximab, leading to the activation of the terminal pathway. This switches the whole system to inflammation 
(orange boxes), causing the tissue effects in skin and colon/tumor (grey boxes). 
 
In contrast, for SR-negative patients with rs2287845, C3 is altered and although principally functional, 
considered to be less active at least in the amplification loop. Speaking of the switch from a balanced 
steady state to massive immunologic cascades forcing local anti-tumor effects, the probability might 
consequently be lowered overall, leaving those patients less sensitive to associated immune triggers 
as Cetuximab in the given setting. Higher levels of (slightly impaired) C3 may be necessary to trigger 
both the adverse effect (skin rash) as well as the anti-tumoral effects, leaving Cetuximab with an 
undesirably low efficacy at usual therapeutical dosage levels. A similarely delayed signal switch upon 
an increasing gradual signal has already been simulated for the MAPK signaling cascade [Veitia 2004]).  
Interestingly, the model of Cetuximab’s effects via the complement system simultaneously covers the 
observation by [Chung et al. 2005] that Cetuximab therapy may also show anti-cancer activity in those 
patients whose tumors do not express EGFR. Also in those cases, although for the lack of molecular 
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targets the antibody recognition by the classical pathway may fail, the antibody’s activating effect on 
the complement system at least via the alternative pathway would remain – given C3 is fully functional. 
 
4.3.2 CCNK 
CCNK codes for a member of the transcription cyclin family, cyclin K (CycK). Cyclins in general regulate 
the cell cycle both positively and negatively by interacting with Cyclin-dependent Kinases (CDKs). For 
a subgroup of CDKs, transcription-regulating functionalities have been described [Bartkowiak & 
Greenleaf 2011]. These are facilitated by phosphorylation of the C-terminal domain (CTD) of RNA 
polymerase II (Pol II). For CycK, two binding partners are known, namely CDK12 and CDK13 [Bartkowiak 
& Greenleaf 2011; Kohoutek & Blazek 2012]. While for CDK13 there is little specific knowledge, the 
Cyclin K/Cdk12 complex has been described to maintain genomic stability via the regulation of 
expression of DNA damage response genes [Blazek et al. 2011]. Also, central functions during 
development are controlled by the complex. Moreover, links to tumorigenesis have been drawn: in 
high-grade serous ovarian cancer (HGSOC), loss-of-function mutations of CDK12 have been described, 
predominantly leading to an inability to properly bind CycK [Ekumi et al. 2015; Joshi et al. 2014], 
ultimately leading to genomic instability. Meanwhile, in HER2-amplified breast tumors, overexpression 
of CDK12 and an association with high tumor grades occurs, offering a dual role as both tumor 
suppressor and oncogene for CDK12, and making it a potential pharmacological target [Paculová & 
Kohoutek 2017]. Cyclin K itself has been described as oncogenic in myeloma, with inhibitory effects on 
cell migration [Marsaud et al. 2010], and both proliferative and anti-apoptopic in prostate cancer, 
associating with poor recurrence-free survival [Schecher et al. 2017]. In terms of regulation, CycK has 
been suggested as a direct transcriptional target of the p53 tumor suppressor [Mori et al. 2002]. 
Regarding anti-cancer treatments, cyclin K expression has been detected to be down-regulated upon 
application of NS-398, a nonsteroidal anti-inflammatory drug associated with decreasing mortality in 
colorectal cancer [Zhang & DuBois 2001].  
In terms of variation in the given dataset, CCNK shows with rs2069492 a quite common SNP (MAF1KG = 
0.447), although homozygously and exclusively assigned to the SR-positive group. Being located 
immediately upstream of exon 3, a splice region is annotated to be affected. Taking the interaction 
with CDK12 to be crucial for cell viability, slight variations in binding capabilities of cycK might 
predispose to human disease, as suggested by Bösken et al. 2014. 
From the MSM’s perspective, CCNK is connected to EGFR exclusively via SMAD2/3/4, each edge 
annotated as ‘catalyze’. SMADs are direct downstream components of TGF-β signaling, which has been 
described to interplay with RTKs like EGFR in tumor development [Shi & Chen 2017]. However, 
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PubMed23 does not reveal provide any evidence for CCNK’s connection to SMADs. Moreover, neither 
CDK12 nor CDK13 are part of the MSM. While interactions to these two proteins have recently been 
added to Reactome according to the web portal24,25, they were not listed in the functional interaction 
data provided by the ReactomeFI plugin within Cytoscape at the time of building the MSM. Functional 
interactions are updated once a year [Wu et al. 2014].  
Taken together, the rs2069492 variant in CCNK might be a candidate of interest to check for in more 
patients, but should be regarded rather as a factor than a cause for the SR phenomenon.  
 
4.3.3 CD86 
CD86 (or B7-2), expressed by antigen-presenting cells, is a co-stimulatory transmembrane molecule 
regulating the balance between anergy and immunity of T lymphocytes. Known binding partners are 
CD28 and CTLA-4 [Pentcheva-Hoang et al. 2004], the latter being primarely expressed in CD8+ 
(cytotoxic) T cells. In cancer settings, CTLA-4 has an important role when considering immune evasion 
in the tumor’s microenvironment [Webb et al. 2017], as it mediates the activation of T effector cells 
by negatively regulating their proliferation [Brunner et al. 1999]. While in EGFR-mutant non-small cell 
lung cancer CTLA-4 levels were negatively associated with overall survival [Soo et al. 2017], for 
metastatic melanoma an FDA-approved anti-CTLA-4 antibody, Ipilimumab, is available [Lipson & Drake 
2011]. For this drug, similar to EGFRIs, skin rash was reported as a possible adverse effect [Dika et al. 
2017]. Regarding genomic variants, with rs17281995 a UTR-3’ region SNP has been described altering 
the binding of five different miRNAs, effectively influencing post-transcriptional regulation [Landi et al. 
2012]. 
In the given Cetuximab-treated patient cohort, with rs2681417 a missense variant has been detected 
to be homozygously unbalanced between the patient groups. The variant’s alleles refer to isoleucin or 
valin in the protein sequence, both being unpolar amino acids at slightly different sizes and structure 
in CD86’s immunoglobulin domain. Accordingly, the protein’s 3D structure might be varied, and as the 
domain facilitates binding functions [Bork et al. 1994], a change in strength of binding to CTLA-4 or 
CD28 appears possible. Ultimately, this would affect the regulative balance of T cell anergy and 
activation. Similar to other candidate genes, e.g. C3 or P3H3 (comp. Subsections 4.3.1 and 4.3.8, 
respectively), these regulative differences according to genetic variation might not be striking under 
physiological conditions, while under cancer treatment, balance outcomes might be discriminative. 
                                                          
23 https://www.ncbi.nlm.nih.gov/pubmed  
24 http://www.reactome.org/content/detail/R-HSA-6797090  
25 http://www.reactome.org/content/detail/R-HSA-6797100  
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In terms of SR group assignments, the alternate allele appears to be the most common one. In turn, 
the minor, reference allele with an allele frequency of 0.132, is assigned to the SR-negative group. 
Assuming the minor allele is associated with a balance shift to anergy, both observations as well as the 
reduced anti-tumor efficacy in this patient group could be supported. Cytotoxic T cells are a central 
resource of inflammation (reduced or missing skin rash), and in the cancer context, they are able to 
identify and kill tumor cells [Martínez-Lostao et al. 2015], designating them to be an important 
biomarker in cancer research, especially in CRC [Deschoolmeester et al. 2010]. 
Taken together, CD86 deserves further study, presumably with immunostaining experiments or 
approaches on the composition and activity of cytotoxic T cells. 
 
4.3.4 CDH11 
Cadherin-11 (CDH11) is a cell adhesion molecule regulated by the Wnt pathway [Li et al. 2012] and 
TGF-β [Torres et al. 2013]. In turn, it regulates collagen and elastin synthesis [Row et al. 2016]. 
Although mainly expressed in bones26 and brain27, but also aorta, bladder and skin [Row et al. 2016], 
several observations for CDH11 have been observed in cancer settings. Several reports describe 
epigenetic silencing of CDH11 in metastasizing cancers (e.g. [Carmona et al. 2012]). While CDH11 has 
been described as pro-apoptotic tumor suppressor [Li et al. 2012] and for osteosarcoma patients, 
CDH11 expression was associated with survival [Nakajima et al. 2008], contradictory reports also exist. 
In CRC, CDH11 expression was markly increased in tumor tissue [Bujko et al. 2015], and in terms of 
statistic evaluation, a correlation with tumor invasiveness has been published very recently [Zhu et al. 
2018]. Overall, the reports indicate for a dependency on the tissue type or other molecular factors like 
CALU [Torres et al. 2013], but leave the big picture contradictory. 
Mechanistically, no direct association with EGFR signaling could be found: neither the literature, nor 
the MSM revealed a functional connection. When reviewing the shortest path between CDH11 and 
EGFR, ubiquitin-driven protein degradation turns out to be the connective element.  
The variant c.1319C>T itself has been annotated as being a p.255P>M missense event. Regarding 
potential functional impacts on the protein level, it is located in an extracelluar cadherin domain, but 
without immediately influencing the Ca2+-binding site amino acid positions28. 
                                                          
26 http://www.genecards.org/cgi-bin/carddisp.pl?gene=CDH11  
27 http://www.uniprot.org/uniprot/P55287  
28 https://www.ncbi.nlm.nih.gov/protein/NP_001788.2  
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Summing up, the findings leave no space for a mechanistic model linking the detected SR-negative 
associated CDH11 variant to the skin rash phenomenon. 
 
4.3.5 COL4A4 
COL4A4 codes for one of the six known chains of the collagen IV multi-meric molecule, which is the 
major structural component of the basement membranes ([Kalluri 2003]; for general details on 
collagens refer to Subsection 4.3.8 and Fig. 31) and is associated with diseases of the eye and the 
kidneys29. In terms of cancer, collagen IV plays a central role in the tumor microenvironment, providing 
signals regulating tumor growth and metastasis [Tanjore & Kalluri 2006]. In the same journal issue, 
Ikeda et al. reported expression levels of COL4A5/COL4A6 to be decreased in tumors by 
hypermethylation of the promotor regions, effecting a disrupted basement membrane. 
For the coding variation position encoded by rs1800517, four alleles are known. Again, the reference 
allele is not the major one. In fact, the alternate allele ‘A’, detected in all SR-positive patients except 
one, is most common with a MAF of 0.547. For rs1800517, a clinVar entry exists, designating the 
alternate allele to be the benign one. The associated disease is the Alport syndrome, affecting the eye.  
Anyhow, for none of the patients, relevant alterations of eyes or kidneys were reported. Also, several 
of the patients were detected with heterozygous variants, relativizing effects if given. Homozygous 
patients could be located in both groups. Together with lacking evidence for connections of rs1800517 
to inflammation or cancer, COL4A4 was considered to be no promising candidate for further 
investigations in the given setting. 
 
4.3.6 GRIP2 
GRIP2, assigned to neurons as part of a multiprotein signaling complex30, could not be related to either 
inflammation or cancer in a functional or mechanistic way. Anyhow, one report on prediction of colon 
cancer recurrence and prognosis stated GRIP2 as part of a signature of 15 differentially expressed 
genes, derived from a support vector machine (SVM) approach [Xu et al. 2017]. 
Regarding the detected variant rs9845816, dbSNP’s web interface declares its effect on the protein 
level to be silent, as both reference and alternate allele code for the same amino acid. This is in contrast 
                                                          
29 https://www.genecards.org/cgi-bin/carddisp.pl?gene=COL4A4  
30 https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRIP2  
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to the results calculated offline (stating missense effects) and assumed to be according to recent 
reference sequence updates. 
Taken together, GRIP2 appears of limited interest for further investigations. 
 
4.3.7 NUP210 
NUP210 encodes the nuclear pore glycoprotein 210 (Nucleoporin 210 kDa or gp210), which is a major 
structural compound of the nuclear pore complex [Greber et al. 1990]. NUP210 gets phosphorylated 
in the course of mitosis, when the pore complex gets disassembled. In the MSM, this is depicted e.g. 
by the edge to CDC42, which is on a shortest path to EGFR. 
Although no mechanism is known yet, NUP210 has been reported to occur in risk studies on CRC [Landi 
et al. 2012; Cipollini et al. 2014], expression profiling of cervical cancer [Rajkumar et al. 2011] and an 
RNAseq analysis of lung adenocarcinoma [Kikutake & Yahara 2016], indicating a role in tumorigenesis. 
In the CRC-related studies, with rs354476 a UTR-3’ variant has been described, in which the reference 
allele ‘T’ is recorded to be reduced expression of the gene if homozygous. In turn, the alternate ‘A’ 
allele is associated with an increased CRC risk. The authors draw the connection to post-transcriptional 
regulation via miRNAs, which hybridize with subsequences of the UTR 3’ region, counteracting the 
translation to proteins. Interestingly, in primary biliary cirrhosis (PBC), a significant association could 
be drawn between anti-gp210 antibody production and a SNP in CTL-4 [Aiba et al. 2011], which is a 
binding partner of CD86 (comp. Subsection 4.3.3) and therefore potentially links NUP210 to T cell 
immunity. 
In the given SR use case, four imbalanced variants could be found in NUP210 (Fig. 28). Among them, 
rs354478 is the only heterozygous one. Here, the reference, but minor allele ‘C’, is assigned to the SR-
negative patient group. Although annotated to trigger a missense mutation p.1787Val>Met, both 
amino acids are unpolar, presumably not disturbing the local transmembrane region31 of the protein. 
All three homozygous variants (rs2280084, rs2271504, rs2271509) occur exclusively in the same SR-
negative patients, although showing distances of around 10 kB to each other. This makes them 
independent from individual short reads. Anyhow, just rs2280084 is declared to be a missense variant 
(Arg786Leu).  
 
 
                                                          
31 http://www.uniprot.org/uniprot/Q8TEM1#subcellular_location   
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Fig. 28 - Overview on imbalanced variants in NUP210. Except rs354478 (orange), all variants occur homozygously and in the 
same patients. As NUP210 is located on the reverse strand of chromosome 3, the first variant in order is rs2280084 (red) in 
the beginning of exon 17. While rs2271504 (green) and rs2271509 (blue) are annotated to cause synonymous amino acid 
exchanges, the other two variants are labeled to be missense. For details compare Tab. 12 and Tab. 14. Screenshot from 
NCBI’s Genome Data Viewer32. 
 
Anyhow, considering MAFs, impacts or patient group assignments (rs2280084 and rs2271504 both 
appear with the minor allele as being reference), in terms of causing the SR phenomenon all these 
candidate SNPs appear of limited interest.  
Consequently, NUP210, although tagged with several variants (also comp. Tab. 10), appears of no 
deeper interest. 
 
4.3.8 P3H3 
Prolyl 3-hydroxylase 3 (P3H3; also known as LEPREL2 or GRCB) is an enzyme of the leprecan family, 
modifying collagen chains post-transcriptionally. It is part of a hydroxylation complex, which is located 
in the endoplasmatic reticulum (ER; [Heard et al. 2016]). 
In breast cancer, P3H3 is a frequent target to epigenetic silencing by methylation and has been linked 
to carcinogenesis via association with higher tumor grades and Nottingham Prognostic Index [Shah et 
al. 2009]. On the one hand, this is in line with reports on silenced collagen-related genes, e.g. P3H2 
[Shah et al. 2009], COL4A5/A6 (being major substrates the P3H family; [Ikeda et al. 2006]) and COL1A2 
(the most frequent collagen; in primary CRC [Sengupta et al. 2003]). 
In the given investigation, seven SR-negative patients were tagged with a frameshift mutation 
rs57050687 at the end of exon 1 (comp. Fig. 29). Consequently, major parts of the protein should be 
assumed to be dysfunctional. 
                                                          
32 https://www.ncbi.nlm.nih.gov/genome/gdv/browser/?context=gene&acc=23225  
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Fig. 29 - Detail view on rs57050687 in NCBI dbSNP (Genome Viewer). The green horizontal line depicts the mRNA of P3H3, 
with boxes representing exons. The green vertical line marks the position of the frameshift mutation rs57050687 at the end 
of exon 1, affecting the sequence to the right, probably hardly affecting the protein’s amino acid sequence, structure and 
functionality. Viewer screenshot from dbSNP33. 
 
Confusingly, according to the Thousand Genomes Project (1KG as used in the pipeline) as well as 
ExAC34, the references allele could not been observed in these cohorts34, thus the MAF is 0 (and 1 for 
the alternate allele with an inserted ‘G’). Only in GO-ESP35, 22 individuals were detected with the 
particulary rare allele ‘-‘ (= no ‘G’), resulting in a MAF of 0.0045. Although this may be due to the fact 
that 70 % to 80 % of the human reference genome originate from one individual [Osoegawa et al. 
2001], in the given setting this implies that all SR-positive patients carry a quite rare variant. However, 
as coverage of the locus is low in the analysis, P3H3 is poorly studied and simultaneously highly 
interesting in the context of the use case, the gene was further studied, assuming a frameshift event, 
marking a difference between the SR patient groups. 
Hydroxylation on pro-collagens is the most important modification during maturation, occurs on both 
proline and lysine residues after and even during translation, providing binding sites and consequently 
stability [Hudson et al. 2015]. This holds both for the formation of the quaternary structure of the 
collagen typical triple helix in fibrillar types (prolines) as well as for the higher order network-like 
assemblies in the extra-celluar matrix (ECM; lysines) [Hudson et al. 2015]. Overall, 28 different collagen 
types with various functions are known to date [Cescon et al. 2015]. Referring to this variety, the 
abundance (~30% of the whole-body protein content [Lehninger 1975]) and the complexity of proper 
maturation, a number of diseases is rooted in collagen-related pathology [Parvizi & Kim 2010]. 
Prolyl hydroxylases subdivide into two classes, depending on the targeted proline sites. While patterns 
of the form Gly-X-Y occur ubiquitously in collagens (with X und Y being any amino acid, but mostly 
proline), hydroxylases work either on the Y position (P4H) or the X position (P3H) and convert proline 
to 4-hydroxyproline (4Hyp) or 3-hydroxyproline (3Hyp), respectively. In quantitative terms, one in four 
amino acids in the ~1000 residue long collagen chains is a proline residue, of which about 40% are 4-
                                                          
33 https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=57050687  
34 http://exac.broadinstitute.org  
35 http://evs.gs.washington.edu/EVS/  
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hydroxylated, but just up to 10 sites are 3-hydroxylated (depending on collagen type) [Hudson et al. 
2015]. However, at least the latter is found to be highly conserved in the whole animal kingdom 
[Hudson & Eyre 2013; Weis et al. 2010]. 
Unfortunately, in comparison to P4H, the general role and particular function remains largely unknown 
for the P3H family [Weis et al. 2010]. The family overall consists of three homologous hydroxylases 
P3H1 (LEPRE), P3H2 (LEPREL1) and P3H3 (LEPREL2) plus two non-enzymatic, highly homologous 
paralogs CRTAP (LEPREL3) and SC65 (LEPREL4) [Hatzimichael et al. 2012; Gruenwald et al. 2014]. P3H1 
(LEPRE1) has been linked to the specific 3-hydroxylation of Pro986 in collagen type I chains and, in the 
case of biallelic mutations in either P3H1 itself or its complex partners CRTAP and CypB, with recessive 
forms of osteogenesis imperfecta [Marini et al. 2014]. In contrast, P3H2 targets multiple sites in at 
least collagen types I, II, IV and V [Hudson et al. 2015]. Here, in terms of disease, connections to myopia 
have been drawn (e.g. in [Mordechai et al. 2011]). Solely for P3H3, substrate as well as disease-
associated mutations still remain unknown [Hudson et al. 2017]. Meanwhile, at least the P3H3 complex 
formation with SC65 and, potentially, CypB and lysyl hydroxylase-1 (LH1) has been discovered [Hudson 
et al. 2017]. While CypB is the same protein like in the P3H1 complex, the reported interaction with 
LH1 revealed an interesting relation between the two most common post-translational modifications 
of collagens: primarely for SC65-/-, but also for P3H3-/- mice, the major physiological collagens (types I, 
II, IV and V; type III is known to contain no 3Hyp at any site [Weis et al. 2010]) were clearly under-
hydroxylated on lysine residues - but not on any of the known proline 3-hydroxylation sites [Hudson 
et al. 2017]. The former observation effectively phenocopied the Ehlers-Danlos syndrome (EDS) type 
VIA (six A; caused by loss the PLOD1 gene encoding LH1 [Steinmann et al. 2003]). The helical domain 
cross-linking sites of collagen type I, especially in the skin, appeared to be under-hydroxylated. 
However, the skin’s resulting lack in structural integrity could only be detected on lab methods, rather 
than on physical appearance compared to wild type mice. Interestingly, heterozygous P3H3+/- mice did 
not reflect the described phenotype [Hudson et al. 2017], indicating loss of function just for 
homozygous variations. Similarely, P3H3 variations detected in the given SR setting also appeared 
exclusively homozygous.  
The much more interesting observation from the recent study of [Hudson et al. 2017]is that for the 
major collagens of types I, II, IV and V no change in proline 3-hydroxylation could be recorded, although 
for both SC65-/- and P3H3-/- mice the P3H3 complex could not have formed. In other words: on major 
collagens, the prolyl 3-hydroxylation 3 complex is essential for hydroxylation of lysyls, but not for 
prolyls. The authors provide two explanations: on the one hand, and in line with the suggestion on 
collagen-modifying proteins to provide a dual function as both enzymes and chaperones [Ishikawa et 
al. 2009], P3H3 may have lost its hydroxylation functionality in the course of evolution, retaining the 
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LH1-supporting chaperone functionality. On the other hand, simply the proline substrate of P3H3 is 
still unknown, as the number of collagens goes far beyond the tested major types. 
At this point, the look back to the MSM turns out to be helpful. As depicted in Fig. 21 and Fig. 22, all 
shortest pathes of functional interactions from P3H3 to EGFR (the target of Cetuximab) run across 
nodes belonging to five different collagen types: IV (COL4A[1-5]), VI (COL6A[1-3,5,6]), IX (COL9A[1-3]), 
XVII (COL17A1) and XVIII (COL18A1). As type IV has already been excluded to be a target of P3H3, 
investigations could be concentrated to just four out of 23 remaining types of collagens. 
Collagen type VI is unusal compared to other fibrillar types due to its intracellular complexation going 
beyond trimerization of the helix structure. Rather more, tetramers of heterotrimeric helices of chains 
α1 (COL6A1), α2 (COL6A2) and α3 (COL6A3) are generated in a highly regulated assembly sequence 
and secreted afterwards. In terms of function, collagen type VI has been described as mechanically 
relevant due to cross-linkage with various ECM proteins (perlecan, collagens type I, II, IV and other), 
but also important for tissue homeostasis, e.g. by interaction with several membrane receptors linked 
to intracellular signaling pathways [Cescon et al. 2015]. In a not yet fully understood tissue-specificity, 
α3(VI)’s position may be occupied by alternative chains α4 (COL6A4), α5 (COL6A5) and α6 (COL6A6), 
suggesting different roles of COLVI variants in distinct tissues [Gara et al. 2011; Cescon et al. 2015]. In 
the skin, where collagen VI is expressed by fibroblasts, it is present in the dermis, abundant in the 
basement membrane, but absent in the epidermis [Gara et al. 2011]. Although several skin related 
abnormalities have been described [Lettmann et al. 2014], none of them resembles the SR phenotype. 
In terms of cancer, a set of cytoprotective functions is interesting: inhibition of apoptosis and oxidative 
damage, regulation of autophagy and cell differentiation, maintanance of stemness, and finally 
promotion of tumor growth, cancer progression and drug resistance [Cescon et al. 2015; Chen et al. 
2013a]. Taken together, collagen VI contributes to at least five of the cancer hallmarks [Hanahan & 
Weinberg 2011]. When considering collagen type VI as substrate for P3H3, at least for a mechanistic 
model explaining the SR phenomenon, the potential of the candidate from both the skin and tumor 
perspective is given. Anyhow, the available information is insufficient, as no connection could be drawn 
to either EGFR or Cetuximab: neither integrins (ITGB3, ITGAV), nor platelet-derived growth factor 
(PDGFA, PDGFB) offered further meaningful interpretations of connections to EGFR. 
Collagen type IX has been described as distinct component of cartilage and expressed in joionts, spinal 
disks and the eye’s vitreous body [Olsen 1997]. Therefore, it is also unsupportive for a model explaining 
the SR-phenomenon. 
Collagen type XVIII is ubiquitously expressed in different basement membranes of the whole body 
[Seppinen & Pihlajaniemi 2011] and maintains its integrity [Bager & Karsdal 2016]. Collagen XVIII is the 
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prime example for a functional dualism: the intact form holding structural properties, while signaling 
capabilities come into play upon degradation [Bager & Karsdal 2016]. This second function is provided 
by the C-terminal fragment, endostatin. It can be proteolytically cleaved, revealing anti-angiogenic 
effects [Marneros & Olsen 2005] and an inhibition of tumor growth by restiction of proliferation and 
migration as well as induction of apoptosis in epithelial cells [Seppinen & Pihlajaniemi 2011]. Anyhow, 
in the course of SR model generation, collagen type XVIII turns out not to be supportive. On the one 
hand, the defects in this collagen type are associated with abnormalities of the eye [Bager & Karsdal 
2016], while none of those have been reported for SR-negative patients. On the other hand, like for 
collagen type VI, no connection to EGFR or Cetuximab could be drawn. 
Collagen type XVII, also known as BP180, BPA-2 or BPAG2, revealed to be the most interesting 
molecule for a model connecting altered P3H3 in the sense of the SR phenomenon. This is in a nutshell 
due to the abundance at the skin’s basement membrane, a functional dualism offering a direct link 
between cell adhesion and immunity, and a bi-directional regulative connection with EGFR supported 
by literature. 
The molecule itself is a type II transmembrane protein (Fig. 30A), spanning the lamina lucida and 
projecting into the lamina densa of the epidermal basement membrane [Ujiie et al. 2010]. Structurally, 
it is a major component of the hemidesmosome (HD) type I (Fig. 30B), but not in type II [Moilanen et 
al. 2015]) complex, and crucial for stable adhesion of dermis and epidermis.  
For collagen XVII, no investigations on 3Hyp sites have yet been reported. Anyhow, two closely similar 
and conserved motifs have been published from the collagen α1(I) chain (GLPGPIGPPGPR; 
hydroxylated proline highlighted) and collagen type II (GIPGPIGPPGPR; LI conversion in italics) [Weis 
et al. 2010]. A BLAST search on the amino acid sequence of collagen XVII using these motifs revealed 
some imperfect hits (Tab. A1), providing hints on where such motifs could occur in the collagenous 
domains (Box A1). In any case, published knowledge on 3Hyp and its mechanisms is sparse, leaving 
space for experiments investigating on the yet hypothetical modification of collagen XVII by P3H3. 
Defects in the HD proteins are associated with chronic skin fragility and blistering [Bruckner-Tuderman 
& Has 2012]. In turn, for e.g. tissue repair and immune cell invasion, but also keratinocyte migration, 
disassembly of hemidesmosomes is required [Löffek et al. 2014]. Growth factors like EGF are capable 
of triggering this effect by phosphorylating α6β4 integrin [Margadant et al. 2008]. As disassembly is 
mostly transient, HD stability has been suggested to be viewed as a dynamic equilibrium, with its 
components (primarely α6β4 integrin) in rapid turnover [Wells 2006]. In cancer settings, this 
equilibrium may be shifted towards migration, facilitating tissue invasion and metastasis [Löffek et al. 
2014]. 
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Fig. 30 - Collagen XVII molecular structure and as component of the hemidesmosome. A: Collagen XVII (according to [Giudice 
et al. 1992]; there named BP180) as type II transmembrane protein consists of a C-terminal extracellular part, one trans-
membrane domain and a N-terminal intracellular part. The authors numbered 15 collegenous domains (COL1 to COL15) 
starting from the C terminus, interrupted by 14 numbered non-collagenous (NC) domains. The last domain NC16 divides into 
the sub-domains a (juxta-membraneous), b (membrane-spanning) and c (containing four tandem repeats). B: Classical type I 
hemidesmosomes (according to [Walko et al. 2015]) are cell-matrix junction complexes, besides collagen XVII/BPAG2 
consisting of transmembrane α6β4 integrin and CD151, intracellular BP230/BPAG1e and plectin. While the extracelluar 
components bind to laminin-332 and collagen IV [Nishie et al. 2011] in the basement membrane (BM), the intracellular side 
binds to the intermediate filament (IF) cytoskeleton (Keratins K5 and K14).  
 
  
A B 
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As indicated by the MSM, the connecting nodes between EGFR and collagen type XVII are the closely 
related sheddases ADAM10 and ADAM17 (comp. Fig. 21, Fig. 22), which generally show overlapping 
substrate specificity [Gooz 2010]. Interestingly, this connection discriminates the COLXVII node from 
all other shortest path nodes indicating for collagens of types IV, VI, IX and XVIII: those connect via cell 
adhesion molecules (NCAM1, IGTB3, ITGAV) or the growth factors PDGF[A/B].  
Sheddases, in particular ADAMs, both constantly and upon signaling, cleave various membrane-bound 
proteins on the extracellular domain, often initiating further reactions by the cleavage products 
[Giebeler & Zigrino 2016]. In fact, both collagen type XVII [Nishie et al. 2011] and membrane-bound 
EGF (e.g. amphiregulin by ADAM10 [Lao & Grady 2012], HB-EGF by ADAM17 [Yin & Yu 2009]) are 
constitutively shed from the cell surface in physiological processes and thereby released into the 
intracellular space. Interestingly, in particular levels of ADAM17 are elevated in human colorectal 
tumors [Arribas & Esselens 2009], designating it as target for combination therapies with EGFRIs 
[McGowan et al. 2013]. While ADAMs act on the extracellular domains of proteins, it can assumed that 
collagen type XVII molecules bound to hemisdesmosomal complexes are sterically inaccessible and 
consequently uncleavable. Similarely, lipid rafts seem to play a role in regulating shedding, as collagen 
XVII and α6β4 integrin as HD components locate to those special areas of the cell membrane [Zimina 
et al. 2005], while ADAM10 and ADAM17 are excluded [Murai 2012]. While sheddase activity on EGF 
family members trans-activates the EGFR and the subsequent pathway down to growth [Tanida et al. 
2004], shedding of collagen type XVII triggers its secondary function. Like described for collagen XVIII 
above, collagen XVII comes with a dualism beyond mechanic stability. In fact, the shedding of 
extracellular domains (ecto-COLXVII; [Nishie et al. 2011]) triggers local immune reactions (complement 
activation, mast cell degranulation and neutrophil infiltration [Panelius & Meri 2015]) as well as cell 
migration [Parikka et al. 2003]. Besides the physiological fragment, at least two disease-related ones 
are known (LAD-1, LABD97; [Hirako et al. 2003]). Although antibodies are assumed, the binding partner 
of the soluble fragment in terms of immunologic reactions remains unknown [Nishie et al. 2011; Nishie 
et al. 2015; Moilanen et al. 2015].  
Thus, the hemidesmosomal form might be referred to as adhesion-related, while the unbound form is 
more dedicated to signaling. From a tissue point of view this makes sense, as inflammation goes along 
with decreased cell-cell adhesion, providing a tissue structure permissive for recruited immune cells. 
The other way round, healthy tissue in homeostasis benefits from tight cell-cell interactions, especially 
for those layers intended to be a impermeable layer to ‘non-self’ (i.e., the skin’s microbiome). 
Immunologically, collagen XVII has been reported to have an attenuating effect on interleukin 8 (IL-8) 
via NFκB [van den Bergh et al. 2012]. IL-8 is an immunological key factor, promoting neutrophil 
recruitment, angiogenesis and inflammation [Janeway 2001], but also growth, e.g. by trans-activating 
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EGFR trough ADAM10 [Tanida et al. 2004]. This trans-activation mechanism in fact is induced by IL-8 
itself [Itoh et al. 2005], offering a signaling link between collagen XVII and EGFR as indicated by the 
functional interaction data behind the MSM. To this point, the MSM could only deliver statements on 
independent, pairwise interactions between molecules of the given shortest pathes, not necessarely 
acting together in one scenario.  
Taken together, for P3H3 a hypothetical model of action could be constructed, potentially explaining 
the SR phenomenon in Cetuximab-treated CRC patients (Fig. 31). 
In the skin of untreated individuals with wildtype P3H3, collagen XVII gets regularely modified on its 
secretion to the cell membrane. EFGR pathway activity is well balanced and decreases with the 
keratinocytes developmental progress, during which they undergo maturation on the way from the 
skin’s basal membrane to the body surface [Candi et al. 2005]. With progress in maturation, the grade 
of differentiation increases, and motility decreases [Fuchs & Raghavan 2002]. Regarding the balance 
between collagen XVII’s oposing states, EGFR triggers hemidesmosomal disassembly preferrably in 
early stages, promoting cell migration [Walko et al. 2015]. The weaker EGFR signaling gets, the more 
the balance of collagen XVII states shift to adhesion via assembly of hemidesmosomes, triggering 
linkage to collagen IV and laminin of the intercellular space. Simultaneously, growth signaling is 
attenuated by a negative feedback inhibition on the downstream pathway being linked to collagen 
XVII’s state (HD-bound or not), which may be related to the increasing inhibition of IL-8 via NFκB, 
effectively lowering the activity of sheddases [van den Bergh et al. 2012]. 
In a Cetuximab treatment of P3H3 wildtype individuals, the systemically applied therapeutic antibody 
reaches the skin and silences EGFR, consequently disturbing the dynamic equillibrium of skin 
maturation processes. Molecularely, in such a setting the balance of collagen XVII states would be 
affected, shifting the balance in favor of the hemidesmosomal conformation, leading to a premature 
differentiation of keratinocytes. Consequently, the skin barrier gets impaired, ingesting bacteria from 
the skin surface into deeper layers [Holcmann & Sibilia 2015]. Here, immune cells, but also epithelial 
cells, detect microbe-associated molecular patterns (MAMPs) like lipopolysaccharides (LPS; by TLR4 
[Ray et al. 2013]) or flagellin (by TLR5 [Miller et al. 2005]). Recognition of those molecules triggers 
proinflammatory immune responses e.g. via interleukin (IL-)8 expression [van den Bergh et al. 2012; 
Fraser-Pitt et al. 2011]. As many bacteria at a time infiltrate the skin, immune reactions can be 
expected to be strong, leading to local, visible inflammation, i.e. skin rash. Simultaneously, early and 
modest immune reactions invoking collagen XVII’s shed extracellular domain are impaired, as 
sheddable collagen XVII molecules outside hemidesmosomes are rare. 
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Fig. 31 - Model on P3H3, collagen XVII and ADAM-driven shedding mechanisms. Collagen XVII (red rod; for an amino acid-
level depiction comp. Box A1), synthesized in the endoplasmatic reticulum, gets post-translationally modified by various 
enzymes, including P3H3, which is organized in a hydroxylation complex [Heard et al. 2016]. Through the endomembrane 
system it reaches the cell’s outer membrane. The extracellular region, containing 15 collagenous domains, binds to collagen 
IV and laminin-332 [Nishie et al. 2011]. In a dynamic equilibrium the molecule toggles between it’s adhesion-related, lipid 
raft-located, hemidesmosome-bound state (promoting keratinocyte differentiation) and an unbound state, which is signaling-
related. Disassembly of the hemidesmosome (HD) is promoted by protein kinase C (PKC; [Kitajima et al. 1992]) and can be 
induced by growth factors like EGF [Oliva et al. 2005]. Upon leaving the lipid raft, collagen XVII gets exposed to ADAMs. If, 
ADAM10 or -17 (the later also named TACE) sheds the extracellular domain in the juxta-membranous region [Nishie et al. 
2011], given that such cleavage is not hindered due to target phosphorylation by CK2 [Zimina et al. 2007]. Shedding enables 
pro-inflammatory signaling and promotes cell migration, as the molecule is not available for HD re-assembly anymore. 
Presumably, at least major parts of the observed immune reactions are based on release of IL-8, as collagen XVII’s attenuating 
effect (through NFκB pathway [van den Bergh et al. 2012]) is lost. Also IL-8 [Itoh et al. 2005], and additionally EGFR ligands 
(HB-EGF, AREG; [Lao & Grady 2012; Yin & Yu 2009]), get shed by ADAMs, leading to activation of EGFR signaling, promoting 
growth and closing the cycle to PKC (leading to further HD disassembly). As the IL-8 receptor (IL8R), like several other G 
protein-coupled receptors (GPCRs; [Wang 2016]) transactivates EGFR via ERK1/2 and increased ADAM-related sheddase 
activity [Yin & Yu 2009], a second, potentially amplifying cycle may be considered here. 
 
  
85 
 
In the colon, collagen XVII is supposed to be generally more dedicated to signaling and cell migration 
rather than adhesion and tissue integrity [Moilanen et al. 2015], which would significantly support 
tissue invasion in the case of carcinoma cells. In fact, collagen XVII expression has been reported as 
significantly associated with higher TNM stage, decreased disease-free and cancer-specific survival 
[Moilanen et al. 2015]. Anyhow, EGFR signaling is expected to influence hemidesmosomal integrity, as 
activation also causes the cytoplasmic phosphorylation and dissociation of integrin α6β4 integrin, 
being part of the hemidesmosomal complex type II [Mariotti et al. 2001], which is found in simple 
epithelia of the intestine [Walko et al. 2015]. 
When considering SR-negative patients carrying the rs57050687 variant and consequently impaired 
P3H3, a suboptimal post-translational modification of COLXVII in might occur in terms of prolyl 3-
hydroxylation. Unfortunately, collagen XVII has not yet been examined for such positions, designating 
it still as a hypothetical target to P3H3 (while to date not a single target is known [Gjaltema & Bank 
2017]). In terms of proline residues suitable for 3-hydroxylation, literature revealed just two explicit 
similar P3H motifs being conserved across vertebrate species, although generalized evolutionary 
studies exist [Hudson et al. 2014]. In human collagen type I this is GLPGPIGPPGPR, and GIPGPIGPPGPR 
in human collagen type II [Weis et al. 2010]. For those, a BLAST search in collagen XVII’s sequence 
ended in ten positions with an expect value <= 0.01 (comp. Tab. A1), distributed over ten collageneous 
domains (COL5 to COL15; comp. Box A1). Considering at least one position being fact, an altered 
hydroxylation pattern can be assumed in the case of defect P3H3, affecting the final conformation of 
the collagen XVII protein. 
Taking into account the dual function of collagen XVII, adhesion and signaling, conformational changes 
might influence both. Referring to Fig. 31, two particular mechanisms may be affected: the assembly-
disassembly switch at the hemidesmosome (HD), as well as the shedding of the extracellular 
membrane, in both cases due to steric hindering during the interaction with other proteins (integrin in 
HDs and ADAMs at shedding). Overall, the equilibrium between adhesion and pro-inflammatory 
signaling would be affected. As SR-negative patients show less inflammation in the skin, a shift to the 
adhesion state can be assumed – potentially due to impaired shedding, removing less molecules 
permanently from the ‘pool’ of those available for HD assembly. On the other hand, regarding HDs 
adhesion to molecules in the extracellular matrix (ECM), proper binding of collagen XVII to either 
collagen IV or laminin-332 [Nishie et al. 2011] appears questionable. Thinking of impaired expression 
of at least type IV collagen to be an early event for invasive phenotypes [Ikeda et al. 2006], altered 
tissue behaviour in the tumor and effects on survival should be considered. In terms of collagen XVII’s 
immunological role, considered to be negatively influenced by P3H3 failure, tumor surveillance could 
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be simultaneously lowered. Consistently, direct anti-proliferative effects of active P3H3 have been 
reported at least in breast cancer settings [Shah et al. 2009].  
From a clinical point of view, individuals with sub-optimally processed collagen XVII due to P3H3 
failure would not necessarily show a phenotype in daily life. As reported for the P3H3-/- mouse model, 
skin outer appearance is unremarkable, although of reduced structural integrity upon mechanic lab 
examination [Hudson et al. 2017]. As stated earlier, mutations in P3H3 may be responsible for mild 
variants of the EDS VI [Heard et al. 2016]. For the SR-negative patients affected by the detected 
homozygous P3H3 mutation a simple clinical check for soft skin, lax joints and kyphoscoliosis may be 
helpful in order to proof or reject the hypothesis of P3H3 being causative. Also, mild changes in general 
hair development might be a visual marker ahead of therapy, as expression of collagen XVII is high in 
hair follicle stem cells [Gude 2011].  
In a nutshell, P3H3 deserves deeper investigations, particularly in the light of overall sparse knowledge 
on this protein and its functions. As a key point occur HD assembly and disassembly, as their exact 
dynamics remain elusive [Walko et al. 2015]. 
 
4.3.9 STUB1 
STUB1 (also known as CHIP or STIP1) is both a ubiquitin E3 ligase and co-chaperone, associated with 
heatshock proteins [Joshi et al. 2016]. Due to a variety of ubiquitylation targets there are several 
relations to biological mechanisms known, e.g. base-excision repair [Parsons et al. 2008], TGFβ 
signaling [Shang et al. 2014], T cell immunity activation [Chen et al. 2013b; Wang et al. 2013] and 
autophagy [Joshi et al. 2016]). Consequently, a role in multiple diseases has been described, e.g. 
ataxias [Heimdal et al. 2014], systemic lupus erythematosus [Guo et al. 2016]), Alzheimer’s and 
Parkinson’s disease [Joshi et al. 2016]. In terms of cancer, most prominent is STUB1’s tumor-
suppressing role, facilitated mainly through the LKB1-AMPK pathway [Gaude et al. 2012]. While LKB1 
is a master kinase controlling metabolism, growth and cell polarity, it is known to be inactivated 
through mutation during carcinogenesis [Shackelford & Shaw 2009]. In colon cancer settings, STUB1 
has also been reported to act as a tumor suppressor, repressing NFκB-mediated signaling [Wang et al. 
2014b]. In contrast, STUB1 also enhances angiogenesis, at least after cardiac infarcts [Xu et al. 2013]. 
Most interestingly, a direct regulative link between STUB1 and EGFR has been reported for cell culture 
[Chung et al. 2016] as well as pancreatic cancer [Wang et al. 2014a]. In the cell culture experiments, 
overexpressed STUB1 turned out to specificially ubiquitinate mutant EGFR, resulting in proteasomal 
degradation of the targeted receptor as well as inhibition of cell proliferation and xenograft’s tumor 
growth. As mutant EGFR is directly related to EGFR TKI resistance, the authors suggest STUB1 to be a 
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potential novel therapeutic target to overcome such settings. Without restricting these observations 
to mutant EGFR, in the pancreatic cancer setting the oberservations were made as well. Additionally, 
reduced tumor migration and invasion were reported. Not last, enhanced apoptosis induced by 
Erlotinib and a negative correlation of STUB1 expression with tumor differentiation and overall survival 
marked clinical significance. Similarely, in gastric cancer low STUB1 expression levels correlate with a 
clinically aggressive phenotype [Gan et al. 2012].  
Although for the patients in the SR setting EGFR is given in its wildtype form, the detected variants 
indicate for structural variations of STUB1 (Fig. 32). Again, the reference but less common allele, is 
assigned to the SR-negative group. SNPeff annotates these variations to be located within a splice 
region. The gene’s 3’ end codes for a protein’s carboxy terminus, which in the case of STUB1 is in fact 
the E3 ligase or U-box domain [Joshi et al. 2016], facilitating ubiquitylation and consequently protein 
degradation. An altered efficacy of STUB1 in consequence of slight structural modifications in this 
important domain should be considered. 
 
 
Fig. 32 - Location of detected SNPs in STUB1 gene structure. The position locates right after exon 6 in a stretch annotated 
to be a splice region. Screenshot from NCBI’s Genome Data Viewer36. 
 
Taken together, investigating the action of STUB1 in the cell offers chances for closer insights into the 
SR phenomenon. Measurements of expression and activity levels in both SR-negative and -positive 
patients appear necessary. 
                                                          
36 https://www.ncbi.nlm.nih.gov/genome/gdv/browser/?context=gene&acc=10273  
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4.3.10 TLR5 
Toll-like receptor 5 (TLR5) is a member of group of pattern recognition receptors (PRRs), which being 
part of the innate immune response detect a variety of microbial- (or pathogen-)associated molecular 
patterns (MAMPs/PAMPs) [Köllisch et al. 2005]. In the case of TLR5 this is bacterial flagellin, which is 
quite ubiquitously present at environmental contact surfaces like skin and colon. Apart from immune 
reactions, TLR5 takes part in the induction of epithelial cell responses including cell migration, wound 
repair, proliferation and survival [Shaykhiev et al. 2008]. Transactivation of EGFR via the release of 
TGF-α by sheddases (comp. Subsection 4.3.8) hereby is a central mechanism [Yu et al. 2012]. In terms 
of cancer, TLR5 has been described to modulate tumor development (mouse xenograft model of 
human colon cancer; [Rhee et al. 2008]). In several studies an altered T cell-related immunity was 
observed upon TLR5 activation (e.g. [Ogino et al. 2013]), with some reporting a metastasis suppressive 
activity on metastasis [Brackett et al. 2016] as well as tumor rejection [Marshall et al. 2012]. 
Interestingly, in a 5-fluorouracil (5-FU) application setting, a reduction of systemic toxicity, selectively 
for non-tumor cells, has been reported for Entolimod (an TLR 5 agonist; colon adenocarcinoma mouse 
model; [Kojouharov et al. 2014]). Similarely, a bioinformatic study revealed TLR5 to be one of six genes 
whose expressions were closely related to responsiveness to oxaliplatin treatment [Klahan et al. 2016]. 
Both drugs were applied (5-FU as Capecitabine in the CIOX study), additionally to Cetuximab. 
Several functional polymorphisms are known for TLR5, including connections to systemic lupus 
erythematosus (SLE; [Hawn et al. 2005]) and psoriasis [Loft et al. 2017]. The detected variation 
rs5744174 is not yet linked to a disease, but leads to a missense variant F616L, located witin the LRRCT 
region of the protein37. LRRCT is a binding interface domain intended to support dimerization of the 
receptor upon complexation with flagellin [Berglund et al. 2015]. Therefore, variations in this region 
potentially affect binding affinities and consequently downstream signaling. In the case of TLR5, 
besides EGFR this is such a downstream element, as well as the pro-inflammatory interleukin-8 
chemokine (IL-8; [Fraser-Pitt et al. 2011]). In fact, those two interact widely independent, with IL-8 
signaling being depended on the NFκB pathway [Gao et al. 2010]. Meanwhile, pro-inflammatory 
effects of TLR5 signaling are attenuated via a negative feedback loop; here, activated EGFR 
phosphorylates MUC1, whose cytoplasmic tail consequently associates with TLR5 [Kato et al. 2016], 
effectively competing with My88 as downstream signaling partner [Kato et al. 2012]. 
Anyhow, the minor missense variant appears to be enriched in the SR-positive patient group. 
Considering the low fraction of SR-negative patients, the TLR5 variant reported here might not be 
considered as causative. 
                                                          
37 http://www.uniprot.org/uniprot/O60602#family_and_domains  
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4.3.11 KISS1 
After all, one candidate missed by the MSM remains worth shortly mentioning: KISS1. SNPeff reported 
with rs71745629 a frameshift variant (MAF1kG = 0.222) due to an deleted ‘T’ (forward strand; ‘A’ in 
reading direction), which in dbSNP appeared immediately destructive for the stop codon at the end of 
the terminal exon 3 of the canonical transcript (p.139Ter>Trp). Consequently, the transcript would be 
elongated. In fact, although SNPeff reports one transcript, Ensemble knows two isoforms: KISS1-20138 
and a 21 bp longer form KISS1-20239. NCBI RefSeq40 reports the common length of 138 amino acids for 
the fully translated protein, and also mentions the polymorphic site encoded by rs71745629. 
Furthermore, it is thereby stated that in the case of the absence of the stop codon a downstream one 
is utilized instead, extending the protein for additional seven amino acid residues. Interestingly, several 
authors refer to either Lee et al. 1996 or West et al. 1998, stating a length of 145 amino acids for the 
protein. This difference in length of seven amino acids implies that the earliest publications describing 
KISS1 studied the less frequent isoform. As anyhow the gene product of KISS1 is a precursor being 
cleaved into active peptides41 (so-called kisspeptines (KP); comp. Fig. 33), which act as natural ligands 
for the G protein-coupled receptor GPR54 [Kotani et al. 2001].  
 
 
Fig. 33 - From KISS1 gene product to active peptides. The full length gene product has been described both to be composed 
of 138 and 145 amino acids, possibly referring two isoforms not being discussed in one common study yet. In any case, after 
cleavage of the full length precursor protein, KP-54 forms, with an amidated C-terminus at the RF motif (R = arginine, F = 
phenylalanine). All shorter peptides are formed by further cleavage, preserving the C-terminal end. A cleavage of the last 
three amino acids 119 to 121 by MMPs is possible, effectively inactivating the peptide [Takino et al. 2003]. Scheme from 
[Teles et al. 2011]. 
GPR54 (or KISS1R) appears overexpressed in triple negative breast cancer (no expression of estrogen 
receptor α, progesterone receptor and human epidermal growth factor receptor 2), promoting drug 
                                                          
38 https://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000170498;r=1:204190341-204196486;t=ENST00000367194 
39 https://www.ensembl.org/Homo_sapiens/Transcript/ProteinSummary?g=ENSG00000170498;r=1:204190462-204192876;t=ENST00000625357 
40 https://www.ncbi.nlm.nih.gov/protein/NP_002247.3  
41 http://www.uniprot.org/uniprot/Q15726#ptm_processing  
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resistance [Blake et al. 2017]. Several other authors, in contrast, reported the expression of the ligand 
precursor KISS1 to be an important anti-metastatic factor, setting disseminated cancer cells to a 
dormant state [Beck & Welch 2010], without affecting tumourigenicity or local invasiveness [Miele et 
al. 1996]. Complementary, methylation of KISS1 and decreased expression level correlate with higher 
tumor stages and grades, shorter survival and recurrence in colorectal cancer [Moya et al. 2013; 
Okugawa et al. 2013; Huo et al. 2018], but also other cancer entities [Tng 2015]. Anyhow, in further 
reports, e.g. for patients with colorectal adenocarcinoma, contradictory observations were reported: 
levels of KISS were higher in larger tumors and stage III/IV cancers, and patients with greater KISS1 
levels had worse prognosis [Kostakis et al. 2015]. There, GPR54 could not be detected in either normal 
or the malignant colonic epithelial cells. 
Functionally, for kisspeptine-expressing cells, both inhibition of chemotaxis and cell invasion could be 
observed [Mead et al. 2007], possibly mediated by downregulation of matrix metalloproteases (MMPs) 
by KPs [Hesling et al. 2004]. KP-driven regulation of MMPs may occur on both the transcriptional and 
protein level. While nuclear factor-κB binding to the MMP-9 promoter region has been reported to be 
reduced by KPs [Yan et al. 2001], stable complex formation has been described for the N-terminal 48 
amino acids of the KISS1 full length protein product and pro-MMP-2 or pro-MMP-9, yet without further 
knowledge on the actual physiological consequences of this interaction [Mead et al. 2007]. In turn, 
active MMPs are able to cleave the bond between Gly118 and Leu119 in KPs, leading to inactivation 
of KP and potentially representing a regulatory feedback mechanism between KP and MMPs [Takino 
et al. 2003]. Downstream signaling of the KISS1 peptide receptor, GPR54, seems to be a separate way 
of action, involving numerous molecular factors (like ERK1/2, MAPKs, PKC, PLC and several more; 
comp. Mead et al. 2007), potentially explaining the various physiologial roles described for 
kisspeptines, which also include endocrinologic functions in the brain [Oakley et al. 2009], pregnancy 
[Mead et al. 2007] and puberty [Teles et al. 2011].  
Interestingly, GPR54 has been reported to transactivate EGFR, promoting cell invasiveness in breast 
cancer [Zajac et al. 2011]. Transactivation of EGFR by peptide G protein-coupled receptors has been 
reported as important mechanism in cancer cell proliferation relatively recently [Wang 2016]. While 
agonists for such receptors may bypass EGFR blockade in EGFRI treatments, antagonists are supposed 
to potentially support treatment by increasing cytotoxicity of TKIs [Moody et al. 2016]. In fact, the 
clinical exploitation of KISS1 to treat metastases has already been claimed [Beck & Welch 2010]. 
However, neither for the skin nor for the colorectal tumors expression is yet known for GPR54. This 
anyhow leaves space for theories related to MMPs and modifications of the extracellular matrix. The 
core question is in fact, whether the additional seven amino acids of the less common KISS1 isoform 
shows a deviant mechanistic behaviour in cleavage or binding to either GPR54 or MMP precursors. 
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Although speculative, the mRNA of the less common might not be less stable, as the last exon also 
encodes the polyadenylation signal [Harms & Welch 2002]. 
In a nutshell, in terms of cancer mechanisms and epidemiology, KISS1 appears as interesting as 
contradictory, with its exact systemic modes of action remaining elusive. 
 
4.3.12 Further candidates and summary 
Due to the MSM filtering effect, some candidates from the initial list of SR-positive associated variants 
(comp. Tab. 9 and Tab. 10) have been cut. Among them several appear anyhow of low potential: for 
HNRNPK (Heterogeneous Nuclear Ribonucleoprotein K), an exceptional number of synonymous 
variations were detected in exons 9 and 13, of which only one could be linked to a dbSNP ID (rs code). 
Neither the gene, nor associated disease or predicted mechanistic variation effects offered a link to 
the SR phenomenon. Similarely, for CAPN11 (calpain 11, a protease; 3’ UTR variant) and MCPH1 
(microcephalin, a DNA damage response protein during cell cycle; missense event leading to a 
p.875Pro>Leu substitution) no links could be established. 
BAIAP3 (BAI1 associated protein) encodes a gene targeted by p53, has been described as a brain-
specific angiogenesis inhibitor and is associated with the KEGG pathway ‘Transcriptional misregulation 
in cancer’. The detected splice site variant rs2235632 might prevent splicing out during transcript 
maturation, but a mechanistic role for the clinical SR setting remains elusive. CRB2 (Crumbs 2, a cell 
polarity complex component), shows a missense event in exon 3, coding for a calcium-binding EGF-like 
domain42. However, an exchange of the two smallest amino acids p.159Gly>Ala may be considered to 
be largely without an effect. For this gene, no connection in terms of disease or general regulation 
could drawn. 
Considering those variants being linked to gene represented in the MSM, two appeared just being low 
impact (intronic; in CASK and MARK3). Even a medium impact, like the missense events in OBSCN 
(obscurin), does not imply a connection to the clinical seeting: OBSCN is related to muscular tissues. 
In a nutshell, these other candidates do not appear promising for further investigations. Accordingly, 
CCNK, CDH11, COL4A4, GRIP2, NUP210 and TLR5 could not be linked to the SR phenomenon by public 
knowledge.  
In summary, this results in a list of five genes to be considered as being potentially linked to the SR 
phenomenon: C3, CD86, P3H3, STUB1 and KISS1. 
                                                          
42 https://www.ncbi.nlm.nih.gov/protein/NP_775960.4  
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4.4 Conclusions 
Skin rash occurrence or absence upon Cetuximab treatment is used as predictive phenotypic 
biomarker, but still not understood in terms of the underlying molecular mechanisms. For some cases, 
polymorphisms of EGFR have been described as being relevant, as binding affinity of the therapeutic 
antibody might be negatively influenced [Jaka et al. 2014]. Also, for Fcγ receptor (FcγR) such 
polymorphisms have been reported and suggested for lowering the efficacy of antibody-dependent 
cell-mediated cytotoxicity (ADCC) [Bibeau et al. 2009]. Both conditions have been precluded for the 
patients underlying this work. 
However, given data with 23 exome datasets was sparse, reasoned i.a. by just two available clinical 
studies. The Cancer Genome Atlas (TCGA43) unfortunately does not offer clinical information on the 
skin toxicity grade. Hence, statistically a quite low sample size is opposed to a very high number of 
variables, which in this setting are the genomic variants. Consequently, just an exploratory analysis 
was possible, lacking validation by design [Bickel et al. 2009]. Also the imbalance criterion, assuming 
bionomial distributions, appears simple, but should be regarded as pragmatic, providing basic statistic 
grounds for primary selection of variants. In order to compensate, a clustering approach on the gene 
level was performed, taking into account the biological mechanisms of interest only and therefore 
acting as a filter. Simultaneously, graphical interactive presentation supports hypothesis generation by 
field experts, as the functional context is instantly visible. This method, implemented in Cytoscape, has 
been named ‘Molecular Systems Map’ (MSM) and is the technical core outcome of this work. Despite 
some technical shortcomings, the advantages of the MSM method could be demonstrated as filter, 
visualization and platform for graph algorithms. In contrast to initial considerations, no obvious 
enrichment of detected gene variants could be detected in domains of the MSM (comp. Fig. 19). 
Considering the central biomedical question, in this work five candidates overall could be named, 
associated with findings and provided with an hypothesis each: C3, CD86, P3H3, STUB1 and KISS1. This 
indicates them to be considerable for further investigations. According to the depth of the developed 
hypotheses, C3 and P3H3 (Subsections 4.3.1 and 4.3.8, respectively), appear most worth to be 
reviewed. For those, the respective mechanistic models should be considered as working hypotheses 
for future validation studies. These models include proteins being connected to either C3 or P3H3 
according to literature and therefore offer several molecular targets to measure. As both models imply 
balance shifts in regulation, quantitative experiments appear most supportive for determining the 
background of discriminative skin rash phenotypes upon Cetuximab treatment on a mid-term 
perspective. 
                                                          
43 http://cancergenome.nih.gov  
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For C3 (comp. Subsection 4.3.1), major implications concern immune system mechanisms. The protein 
is the regulative core element of the complement cascade, which is simultaneously, although 
accounted for innate immunity, tightly linked to adaptive immune systeme mechanisms. 
Consequently, a range of immobiochemistry assays might help to quantify the reactivity of C3 and its 
effects on complement cascade as well as T cell-mediated anti-tumor activity. 
For P3H3 (comp. Subsection 4.3.8), also immune system effects should be considered to be measured, 
but according to the enzyme’s proposed influence on collagen type XVII, cell culture-based assays 
should investigate on this yet hypothetical relation and its mechanistic role in hemidesmosome 
assembly and disassembly. If upon EGFR inhibition measureable differences occur depending on the 
P3H3 phenotype, other players of the proposed model (e.g. sheddases) might be interesting to 
considered as additional targets. 
In spite of everything, one has to consider the quite low number of individuals taken into account for 
this work. Still, these are just eleven patients of the group of interest (SR-negative), with limited quality 
of the underlying NGS data. Hence, a targeted re-sequencing of the claimed loci in more patients of 
both groups should be performed first for the sake of experimental validation. Therefore, for those 
loci a chip layout would have to be designed and applied on additional patients, of which some more 
are listed in the CIOX and FIRE3 study. In contrast, referencing public datasets like TCGA for validation 
appears difficult, as like stated above clinical information like survival times and especially the skin rash 
status are not available. 
Coming back to the methodology, one candidate revealed a usability issue in the current 
implementation of the MSM: while four candidates (C3, CD86, P3H3 and STUB1) have been located in 
the MSM, KISS1 has been missed; its identification depends on the list of imbalanced candidates only. 
Although this gene offers an interesting hypothesis, it was simply not contained in any of the broadly 
selected pathways underlying the skin rash MSM. However, it could be found in the most recent 
functional interaction list of Reactome. 
This observation points out one current drawback of the MSM: while the calling of imbalanced variants 
is completely automated, the generation of the target map still includes a series of manual steps. 
Consequently, the MSM particularly developed for this work remained static since the point where 
variants had been (semi-automatically) mapped to it. A higher degree of automation within the 
Cytoscape environment is therefore necessary and planned (comp. chapter 5). 
Summing up, the MSM principle appears well applicable for closing the gap between high-throughput 
genomic data (e.g. exome sequencing) and domain experts in the course of explorative analysis. This 
is primarely due to the biology-based restriction to the relevant contextes, but also to the use of a 
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graphical representation in an interactive environment. Projecting higher degrees of automation, even 
for non-computer scientists the use case-specific adaption of the MSM principle appears easy: 
choosing a formatted pathway database, picking the subsets of interest, remove undesired nodes or 
edges, and merge all networks to an MSM. As soon as the tasks can be reduced to these major points, 
ommitting all non-exporatory editing work in text files or the graphical workbench, any domain user is 
capable of performing hypothesis generation beyond scrolling annotated variant call or gene lists. 
Importantly, validation studies have to be considered. 
 
 
  
95 
 
5. Outlook 
Methodologically, the MSM implementation should be considered for improvements, especially in 
terms of automation. The example of KISS1 demonstrated that the manual multistep generation of the 
map from Reactome pathways may lead to update issues, as the integration of new knowledge is 
comparably cumbersome. Information on functional interactions are provided on an roughly annual 
basis [Wu et al. 2014], and a MSM generated once does not motivate to start the process from scratch 
when such an update is released. The main reason is the necessity to add attribute columns on origin 
to both the nodes and edges when iteratively merging the FI networks converted from Reactome 
pathways. While the process repeated clicking and labeling is not sophisticated at all, it it both error-
prone and annoying. In turn, this makes it well suitable for a programmatic solution. Cytoscape comes 
with a constantly growing application programming interface (API; [Ono et al. 2015]), offering the 
possibility for both automated data analysis and visualization workflows44 by interconnecting 
Cytoscape with Python45, Jupyter notebooks46 or RStudio47.  
Although the capabilities and limitations remain subject to further evaluation, Python as a 
programming language and Jupyter notebooks or RStudio as so-called interactive environments 
predestines the whole approach for integration into Galaxy [Afgan et al. 2016]. Galaxy is currently the 
most widely used workflow and already hosting the genomic variant calling workflow in the given use 
case. As a data processing platform for various high-throughput data, especially from the ‘omics field, 
also the mapping of other ‘omics-derived information should be considered to be mapped to the MSM. 
Furthermore, selecting subsets of the graph (i.e. genes of interest) may lead to continuative questions 
on further data, e.g. from other studies or public resources. These could be seemlessly treated in 
Galaxy, as the integrated interactive environments allow a backport of results. For the sake of 
reproducibility and documentation, the graph-related analyses can be saved as a notebook, being part 
of Galaxy workflow like the tools used in common ‘omics analyses (comp. Section 2.3). However, such 
advanced, notebook-based approaches might be primarely dedicated to computational biologists, 
bioinformaticians or data scientists. 
Alternatively, with Cytoscape.js48 a JavaScript implementation is available, allowing for less 
encapsulated, more straight-forward visualization of the MSM, suitable for biologists or clinicians. In 
such settings, graph-related processing steps could be implemented as classical Galaxy workflows of 
                                                          
44 http://apps.cytoscape.org/apps/cyrest  
45 https://www.python.org  
46 http://jupyter.org  
47 https://www.rstudio.com  
48 http://js.cytoscape.org  
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regular, configurable tools. In any case, the deeper integration and automation of the MSM principle 
desires attention, as it also opens the principle to a broader community in a user-friendly way. 
Correspondingly, it would further reduce the fields expert’s dependance on support by computer 
scientist. 
In terms of providing further biological information for hypothesis refinement an integrated 
connection to literature knowledge appears desirable. In fact, in the course of this work, such 
information had to be collected by browsing through portals like PubMed, GeneCards, dbSNP and 
others. This included the generation of queries, checking cross-references and comprehending 
information in various formats, including tables, figures and and full texts. Although this meets in parts 
the biologists classical way of dealing with such information and several knowledge sources already 
list particular evidences instead of just publication references, it appears time consuming. For sure, 
PubMed for example offers the possibility for restricting queries to findings in human experiments. 
However, a fully semantic search engine like SCAIview49 [Younesi et al. 2012] would also allow more 
precise filters like presenting publications with cancers of the gastrointestinal tract or skin, only. Also, 
cross-reading would be speeded up by class-specific entity highlighting. Modeling such public 
information again as networks (e.g. using the Biological Expression Language (BEL50); comp. Slater 
2014) offers chances for faster and deeper integration of knowledge as well as the identification of 
burried links. Consequently, this could add further support for hypothesis generation, as such networks 
could be interconnected with the MSM. 
Scientifically, the five candidates should be subject to deeper discussion with biomedical experts from 
oncology, immunology, cell biology and related fields. Targeted re-sequencing should be aimed, 
starting with the identification of suitable patients offering both biomaterial and clinical information 
on treatment and adverse effects. If a relevant collective can be assembled, a chip design for the loci 
of interest would have to be created, enabling deep sequencing e.g. on an Illumina MiSeq platform. 
From this, the developed workflow could be principally re-used. Anyhow, variant calls from other 
platform like Ion Torrent PGM/Proton are also applicable, but might require appropriate setup of an 
adequate workflow. 
Generally, the MSM principle is assumed to have the potential to serve as helpful tool in biomedical 
research for such settings where outcomes of untargeted approaches do not provide hypotheses for 
further investigations. As the presented principle depends on genes of interest (e.g. those attributed 
with called variants) and pathways being assembled to a functional interaction network in a usecase-
specific manner, it is not restricted to a certain particular field in biomedical research. Currently, an 
                                                          
49 http://academia.scaiview.com/academia/  
50 http://openbel.org  
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MSM is being set up for a usecase in neurodegeneration (amyotrophic lateral sclerosis; ALS), where 
prior analyses revealed a limited number of genes, for which mechanistic hypothesis on the mode of 
action are lacking. The MSM principle is suggested to bring these genes into a broader functional 
context. Nevertheless, the unvalidated status of the hypotheses generated in such way have to be 
taken into account, claiming for further lab work. 
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7. Appendix 
 
Tab. A1 - BLAST results for finding prolyl 3-hydroxylation motifs from collagens type I and II in collagen XVII's sequence.  
With GLPGPIGPPGPR and GIPGPIGPPGPR being queries and the full amino acid sequence of collagen XVII being the subject 
(database), in the latter eleven unique, although partly overlapping hits could detected with an expect (e-value) <= 0.01. 
Consequently, the proline residues highlighted in red are supposed to by potential 3Hyp sites and target to a referring P3H, 
presumably P3H3. Context to the overall sequence depicted in Box A1. 
Match score expect identities 
Query  3      PGPIGPPGPR  12 
              PGP GPPGPR 
Sbjct  1217   PGPPGPPGPR  1226 
27.8 bits(58) 2e-04 9/10 
Query  2     IPGPIGPPGP   11 
             IPGP GPPGP 
Sbjct  1213  IPGPPGPPGP   1222 
27.8 bits(58) 2e-04 9/10 
Query  1    GLPGPIGPPG    10 
            GLPGP GPPG 
Sbjct  885  GLPGPPGPPG    894 
Sbjct  1146 GLPGPPGPPG    1155 
26.5 bits(55) 6e-04 9/10 
Query  2     LPGPIGPPGPR  12 
             L GP GPPGPR 
Sbjct  855   LQGPPGPPGPR  865 
26.1 bits(54) 9e-04 9/11 
Query  3      PGPIGPPGP   11 
              PGP GPPGP 
Sbjct  673    PGPQGPPGP   681 
Sbjct  857     GPPGPPGPR  865 
Sbjct  862    PGPRGPPGP   870  
Sbjct  908    PGPPGPPGP   916 
Sbjct  995    PGPPGPPGP   1003 
Sbjct  1038   PGPPGPPGP   1046 
25.7 bits(53) 0.001 8/9 
Query  3      PGPIGPPGP   11 
              PGP GPPGP 
Sbjct  908    PGPPGPPGP   916 
Sbjct  995    PGPPGPPGP   1003 
Sbjct  1038   PGPPGPPGP   1046 
24.4 bits(50) 0.004 8/9 
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Box A1 - Protein sequence of collagen XVII. Grey = transmembrane domain, violet = recognition site for ADAM17, red = 
recognition site for CK2 (with bold ‘S’ marking serine dedicated to phosphorylation), green = collagenous domains. Bold 
underlined subsequences in collagenous domains mark putative 3’-hydroxylation patterns by similarity via BLAST (comp. Tab. 
A1), with double underlining or additional character strike out indicating for two or three overlapping patterns, respectively. 
Red ‘P’s mark the proline residues dedicated to 3’-hydroxylation (3Hyp positions). Sequence and domains according to 
Giudice et al. 1992, recognition sites according to Zimina et al. 2007. 
 
 
1 MDVTKKNKRDGTEVTERIVTETVTTRLTSLPPKGGTSNGYAKTASLGGGSRLEKQSLTHG   60 
61 SSGYINSTGSTRGHASTSSYRRAHSPASTLPNSPGSTFERKTHVTRHAYEGSSSGNSSPE  120 
121 YPRKEFASSSTRGRSQTRESEIRVRLQSASPSTRWTELDDVKRLLKGSRSASVSPTRNSS  180 
181 NTLPIPKKGTVETKIVTASSQSVSGTYDATILDANLPSHVWSSTLPAGSSMGTYHNNMTT  240 
241 QSSSLLNTNAYSAGSVFGVPNNMASCSPTLHPGLSTSSSVFGMQNNLAPSLTTLSHGTTT  300 
301 TSTAYGVKKNMPQSPAAVNTGVSTSAACTTSVQSDDLLHKDCKFLILEKDNTPAKKEMEL  360 
361 LIMTKDSGKVFTASPASIAATSFSEDTLKKEKQAAYNADSGLKAEANGDLKTVSTKGKTT  420 
421 TADIHSYGSSGGGGSGGGGGVGGAGGGPWGPAPAWCPCGSCCSWWKWLLGLLLTWLLLLG  480 
481 LLFGLIALAEEVRKLKARVDELERIRRSILPYGDSMDRIEKDRLQGMAPAAGADLDKIGL  540 
541 HSDSQEELWMFVRKKLMMEQENGNLRGSPGPKGDMGSPGPKGDRGFPGTPGIPGPLGHPG  600 
601 PQGPKGQKGSVGDPGMEGPMGQRGREGPMGPRGEAGPPGSGEKGERGAAGEPGPHGPPGV  660 
661 PGSVGPKGSSGSPGPQGPPGPVGLQGLRGEVGLPGVKGDKGPMGPPGPKGDQGEKGPRGL  720 
721 TGEPGMRGLPGAVGEPGAKGAMGPAGPDGHQGPRGEQGLTGMPGIRGPPGPSGDPGKPGL  780 
781 TGPQGPQGLPGTPGRPGIKGEPGAPGKIVTSEGSSMLTVPGPPGPPGAMGPPGPPGAPGP  840 
841 AGPAGLPGHQEVLNLQGPPGPPGPRGPPGPSIPGPPGPRGPPGEGLPGPPGPPGSFLSNS  900 
901 ETFLSGPPGPPGPPGPKGDQGPPGPRGHQGEQGLPGFSTSGSSSFGLNLQGPPGPPGPQG  960 
961 PKGDKGDPGVPGALGIPSGPSEGGSSSTMYVSGPPGPPGPPGPPGSISSSGQEIQQYISE 1020 
1021 YMQSDSIRSYLSGVQGPPGPPGPPGPVTTITGETFDYSELASHVVSYLRTSGYGVSLFSS 1080 
1081 SISSEDILAVLQRDDVRQYLRQYLMGPRGPPGPPGASGDGSLLSLDYAELSSRILSYMSS 1140 
1141 SGISIGLPGPPGPPGLPGTSYEELLSLLRGSEFRGIVGPPGPPGPPGIPGNVWSSISVED 1200 
1201 LSSYLHTAGLSFIPGPPGPPGPPGPRGPPGVSGALATYAAENSDSFRSELISYLTSPDVR 1260 
1261 SFIVGPPGPPGPQGPPGDSRLLSTDASHSRGSSSSSHSSSVRRGSSYSSSMSTGGGGAGS 1320 
1321 LGAGGAFGEAAGDRGPYGTDIGPGGGYGAAAEGGMYAGNGGLLGADFAGDLDYNELAVRV 1380 
1381 SESMQRQGLLQGMAYTVQGPPGQPGPQGPPGISKVFSAYSNVTADLMDFFQTYGAIQGPP 1440 
1441 GQKGEMGTPGPKGDRGPAGPPGHPGPPGPRGHKGEKGDKGDQVYAGRRRRRSIAVKP  1497 
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Box A2 - Short read data processing steps as executed by Galaxy (1). Pathes indicated by ‘[xyz_path]’ are system-specific. 
Dataset names are arbitrary, but refer to the workflow “036_new” in the ‘NGS-FabLab’ Galaxy instance [Schaaf et al. 2014]. 
 
FASTQ Quality Trimmer: 1x concat'ed forward + 1x concat'ed reverse reads 
 
python [repo_tool_path]/fastq_trimmer_by_quality.py 
'[dataset_path]/dataset_108445.dat' 
'[dataset_path]/dataset_147595.dat' -f 'sanger' -s '10' -t '1' -e 
'53' -a 'mean' -x '0' -c '>=' -q '20.0' -k 
 
 
bwa-mem v0.7.10: paired-end (forward + reverse reads) 
 
bwa mem -t "${GALAXY_SLOTS:-7}" -v 1 -T "30" -h "5" -M -R 
'@RG\tID:120410_HWUSI-
EAS632R_00054.3\tSM:036\tPL:ILLUMINA\tLB:Fire2_CIOX\tCN:LAFUGA\tDS:S
R negative, normal sample\tDT:2012-04-10\tPU:HWUSI-EAS632R' 
"[genome_path]/hg19.fa" "[dataset_path]/dataset_109015.dat" 
"[dataset_path]/dataset_109016.dat" | samtools view -Sb - > 
temporary_bam_file.bam && samtools sort -f temporary_bam_file.bam 
[dataset_path]/dataset_109017.dat 
 
 
Picard v1.136: ReorderSam 
 
_JAVA_OPTIONS=${_JAVA_OPTIONS:-'-Xmx2048m -Xms256m -
XX:ParallelGCThreads=7'} && export _JAVA_OPTIONS && ln -s "hg19" 
"localref.fa" && java -jar $JAVA_JAR_PATH/picard.jar ReorderSam 
INPUT="[dataset_path]/dataset_147597.dat" 
OUTPUT="[dataset_path]/dataset_147598.dat" 
REFERENCE="[genome_path]/hg19.fa" 
ALLOW_INCOMPLETE_DICT_CONCORDANCE="false" 
ALLOW_CONTIG_LENGTH_DISCORDANCE="false" 
VALIDATION_STRINGENCY="SILENT" QUIET=true VERBOSITY=ERROR 
 
 
Picard v1.136: MarkDuplicates 
 
_JAVA_OPTIONS=${_JAVA_OPTIONS:-'-Xmx2048m -Xms256m -
XX:ParallelGCThreads=7'} && export _JAVA_OPTIONS && java -jar 
$JAVA_JAR_PATH/picard.jar MarkDuplicates 
INPUT="[dataset_path]/dataset_147598.dat" 
OUTPUT="[dataset_path]/dataset_147600.dat" 
METRICS_FILE="[dataset_path]/dataset_147599.dat" 
REMOVE_DUPLICATES="false" ASSUME_SORTED="true" 
DUPLICATE_SCORING_STRATEGY="SUM_OF_BASE_QUALITIES" 
READ_NAME_REGEX='[a-zA-Z0-9]+:[0-9]:([0-9]+):([0-9]+):([0-9]+).*.' 
OPTICAL_DUPLICATE_PIXEL_DISTANCE="100" 
VALIDATION_STRINGENCY="SILENT" QUIET=true VERBOSITY=ERROR 
 
 
GATK2 v2.8.0: Realigner Target Creator 
 
python [repo_tool_path]/gatk2/gatk2_wrapper.py --stdout 
"[dataset_path]/dataset_147602.dat" -d "-I" 
"[dataset_path]/dataset_147600.dat" "bam" "gatk_input" -d "" 
"[metadata_path]/metadata_16756.dat" "bam_index" "gatk_input" -p ' 
java -jar "$GATK2_PATH/GenomeAnalysisTK.jar" -T 
"RealignerTargetCreator" -o "[dataset_path]/dataset_147601.dat" 
$GATK2_SITE_OPTIONS --num_cpu_threads_per_data_thread 1 --
num_threads ${GALAXY_SLOTS:-7} -R "[genome_path]/hg19.fa" ' 
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Box A3 - Short read data processing steps as executed by Galaxy (2). Continued from Box A2. 
  
GATK2 v2.8.0: Indel Realigner 
 
python [repo_tool_path]/gatk2/gatk2_wrapper.py --stdout 
"[dataset_path]/dataset_147604.dat" -d "-I" 
"[dataset_path]/dataset_147600.dat" "bam" "gatk_input" -d "" 
"[metadata_path]/metadata_16756.dat" "bam_index" "gatk_input" -p ' 
java -jar "$GATK2_PATH/GenomeAnalysisTK.jar" -T "IndelRealigner" -o 
"[dataset_path]/dataset_147603.dat" $GATK2_SITE_OPTIONS --
num_cpu_threads_per_data_thread 1 -R "[genome_path]/hg19.fa" -LOD 
"5.0" ' -p '--pedigreeValidationType "STRICT"' -p ' --
filter_bases_not_stored --filter_mismatching_base_and_quals ' -p '--
interval_set_rule "UNION"' -p '--interval_padding "0"' -p '--
downsampling_type "NONE"' -p ' --baq "OFF" --baqGapOpenPenalty 
"40.0" --defaultBaseQualities "-1" --validation_strictness "SILENT" 
--interval_merging "ALL" ' -d "-targetIntervals" 
"[dataset_path]/dataset_147601.dat" "gatk_interval" 
"gatk_target_intervals" -p ' --disable_bam_indexing ' 
 
 
GATK2 v2.8.0: Base Recalibrator 
 
python [repo_tool_path]/gatk2/gatk2_wrapper.py --stdout 
"[dataset_path]/dataset_147606.dat" -d "-I" 
"[dataset_path]/dataset_147603.dat" "bam" "gatk_input" -d "" 
"[metadata_path]/metadata_16762.dat" "bam_index" "gatk_input" -p ' 
java -jar "$GATK2_PATH/GenomeAnalysisTK.jar" -T "BaseRecalibrator" 
$GATK2_SITE_OPTIONS --num_cpu_threads_per_data_thread 
${GALAXY_SLOTS:-7} --no_standard_covs -R "[genome_path]/hg19.fa" --
out "[dataset_path]/dataset_147605.dat" -cov "ContextCovariate" -cov 
"CycleCovariate" ' -p '--
run_without_dbsnp_potentially_ruining_quality' 
 
 
GATK2 v2.8.0: Haplotype Caller 
 
python [repo_tool_path]/gatk2/gatk2_wrapper.py --stdout 
"[dataset_path]/dataset_147608.dat" -d "-I" 
"[dataset_path]/dataset_147603.dat" "bam" "gatk_input_0" -d "" 
[metadata_path]/metadata_16762.dat" "bam_index" "gatk_input_0" -p ' 
java -jar "$GATK2_PATH/GenomeAnalysisTK.jar" -T "HaplotypeCaller" -o 
"[dataset_path]/dataset_147607.dat" $GATK2_SITE_OPTIONS --
num_threads ${GALAXY_SLOTS:-7} -R "[genome_path]/hg19.fa" --BQSR 
"[dataset_path]/dataset_147605.dat" ' 
 
 
GATK2 v2.8.0: Print Reads 
 
python [repo_tool_path]/gatk2/gatk2_wrapper.py --stdout 
"[dataset_path]/dataset_147610.dat" -d "-I" 
"[dataset_path]/dataset_147603.dat" "bam" "gatk_input" -d "" 
"[metadata_path]/metadata_16762.dat" "bam_index" "gatk_input" -p ' 
java -jar "$GATK2_PATH/GenomeAnalysisTK.jar" -T "PrintReads" -o 
"[dataset_path]/dataset_147609.dat" $GATK2_SITE_OPTIONS --
num_cpu_threads_per_data_thread ${GALAXY_SLOTS:-7} -R 
"[genome_path]/hg19.fa" --BQSR "[dataset_path]/dataset_147605.dat" -
-disable_bam_indexing ' 
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Box A4 - Short read data processing steps as executed by Galaxy (3). Continued from Box A3. 
 
samtools v1.2: MPileup 
 
samtools mpileup -f "[genome_path]/hg19.fa" 
"[dataset_path]/dataset_147609.dat" -s --output 
"[dataset_path]/dataset_147611.dat" 2> 
"[dataset_path]/dataset_147612.dat" 
 
 
VarScan v2.3.5: InDels 
 
perl [tool_path]/varscan/varscan_mpileup.pl "COMMAND::java -jar 
$JAVA_JAR_PATH/VarScan.v2.3.5.jar mpileup2indel" 
"INPUT::[dataset_path]/dataset_147611.dat" 
"OUTPUT::[dataset_path]/dataset_147613.dat" 
"LOG::[dataset_path]/dataset_147614.dat" "OPTION::--min-coverage 4" 
"OPTION::--min-reads2 2" "OPTION::--min-avg-qual 13" "OPTION::--min-
var-freq 0.01" "OPTION::--min-freq-for-hom 0.75" "OPTION::--p-value 
0.95" "OPTION::--strand-filter 1" "OPTION::--output-vcf 1" 
"OPTION::--variants 1" 
 
 
VarScan v2.3.5: SNPs 
 
perl [tool_path]/varscan/varscan_mpileup.pl "COMMAND::java -jar 
$JAVA_JAR_PATH/VarScan.v2.3.5.jar mpileup2snp" 
"INPUT::[dataset_path]/dataset_147611.dat" 
"OUTPUT::[dataset_path]/dataset_147615.dat" 
"LOG::[dataset_path]/dataset_147616.dat" "OPTION::--min-coverage 4" 
"OPTION::--min-reads2 2" "OPTION::--min-avg-qual 13" "OPTION::--min-
var-freq 0.01" "OPTION::--min-freq-for-hom 0.75" "OPTION::--p-value 
0.95" "OPTION::--strand-filter 1" "OPTION::--output-vcf 1" 
"OPTION::--variants 1" 
 
 
VCFtools v0.1: Merge 
 
vcf-sort [dataset_path]/dataset_147607.dat > 0.vcf.sorted ; bgzip 
0.vcf.sorted ; tabix -p vcf 0.vcf.sorted.gz ; vcf-sort 
[dataset_path]/dataset_147615.dat > 1.vcf.sorted ; bgzip 
1.vcf.sorted ; tabix -p vcf 1.vcf.sorted.gz ; vcf-sort 
[dataset_path]/dataset_147613.dat > 2.vcf.sorted ; bgzip 
2.vcf.sorted ; tabix -p vcf 2.vcf.sorted.gz ; vcf-merge 
0.vcf.sorted.gz 1.vcf.sorted.gz 2.vcf.sorted.gz > 
[dataset_path]/dataset_147617.dat 
 
 
SNPeff v4.0 
 
SNPEFF_JAR_PATH=[repo_tool_path]/snpEff/ SNPEFF_DATA_DIR=`grep 
'^data_dir' $SNPEFF_JAR_PATH/snpEff.config | sed 
's/.*data_dir.*[=:]//'`; eval "if [ ! -e $SNPEFF_DATA_DIR/hg19 ] ; 
then java -Xmx6G -jar $SNPEFF_JAR_PATH/snpEff.jar download -c 
$SNPEFF_JAR_PATH/snpEff.config hg19 ; fi"; java -Xmx6G -jar 
$SNPEFF_JAR_PATH/snpEff.jar eff -c $SNPEFF_JAR_PATH/snpEff.config -i 
vcf -o vcf -upDownStreamLen 5000 -spliceSiteSize 1 -lof -stats 
[dataset_path]/dataset_147619.dat -chr "chr" -noLog hg19 
[dataset_path]/dataset_147617.dat > 
[dataset_path]/dataset_147618.dat 
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Box A5 - Shell commands for plotting the genomic position vs. quality of called variants. Values are retrieved from the 
VCF ‘POS’ and 'QUAL' columns. Graph plots generated for every chromosome of a patient each are combined iteratively. 
 
fire2="014 036 072 111 125 137 155" 
fire3="020 090 213 281 344 375 406 428 566 586 598 624 638 708 750 796" 
 
pair="start_vs_qual" 
mkdir "$pair" 
cd "$pair" 
for pat in `echo $fire2 $fire3` ; do 
 ~/project/gemini_plotter_v5.R \ 
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "start" -y "qual" \ 
  -G --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000" \ 
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\"" \ 
  --exonic-coloring; 
 gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
 gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \ 
   *$pat*$pair*chrM.png +append C.png 
 gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
  gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
  "All_"$pat"_"$pair".png" -append \ 
  "All_VC_all_pats_all_chr_"$pair".png" 
else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
 rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
 
pair="start_vs_qual(log)" 
mkdir "$pair" 
cd "$pair" 
for pat in `echo $fire2 $fire3`; do 
~/project/gemini_plotter_v5.R \ 
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "start" -y "qual" \ 
  -G -l "y" --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000" \ 
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\"" \ 
  --exonic-coloring; 
 gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \  
  *$pat*$pair*chrM.png +append C.png 
gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
 if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
  "All_"$pat"_"$pair".png" -append \ 
  "All_VC_all_pats_all_chr_"$pair".png" 
else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
 rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
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Box A6 - Shell commands for plotting the genomic position vs. the variant caller-specific quality of called variants. Values 
are retrieved from the VCF ‘POS’ column and the ‘GQ’ field within the ‘INFO’ column (accessed by GEMINI as ‘gt_quals’). 
Graph plots generated for every chromosome of a patient each are combined iteratively. As colors were used to separate 
variants from the particular calling tool, no exonic coloring has been used. 
 
fire2="014 036 072 111 125 137 155" 
fire3="020 090 213 281 344 375 406 428 566 586 598 624 638 708 750 796" 
 
pair="start_vs_gt_quals" 
mkdir "$pair" 
cd "$pair" 
for pat in `echo $fire2 $fire3` ; do 
 ~/project/gemini_plotter_v5.R \ 
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "start" -y "gt_quals" \ 
  -G --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000"  
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\""; 
 gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
 gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \ 
  *$pat*$pair*chrM.png +append C.png 
 gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
  gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
"All_"$pat"_"$pair".png" –append \ 
"All_VC_all_pats_all_chr_"$pair".png" 
else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
 rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
 
pair="start_vs_gt_quals(log)" 
mkdir "$pair" 
cd "$pair" 
for pat in `echo $fire2 $fire3`; do 
 ~/project/gemini_plotter_v5.R \ 
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "start" -y "gt_quals" \ 
  -G -l "y" --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000" \ 
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\""; 
 gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
 gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \ 
  *$pat*$pair*chrM.png +append C.png 
 gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
  gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
"All_"$pat"_"$pair".png" –append \ 
"All_VC_all_pats_all_chr_"$pair".png" 
 else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
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Box A7 - Shell commands for plotting the depth of coverage vs. the variant caller-specific quality of called variants (1). 
Values are retrieved from the ‘DP’ and the ‘GQ’ field within the VCF ‘INFO’ column (accessed by GEMINI as ‘gt_depth’ and 
‘gt_quals’). Graph plots generated for every chromosome of a patient each are combined iteratively. As colors were used to 
separate variants from the particular calling tool, no exonic coloring has been used. 
 
fire2="014 036 072 111 125 137 155" 
fire3="020 090 213 281 344 375 406 428 566 586 598 624 638 708 750 796" 
 
pair="gt_depths_vs_gt_quals" 
mkdir "$pair" 
cd "$pair" 
 
for pat in `echo $fire2 $fire3` ; do 
 ~/project/gemini_plotter_v5.R \ 
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "gt_depths" -y "gt_quals" \ 
  -G --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000" \ 
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\""; 
gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
 gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \ 
   *$pat*$pair*chrM.png +append C.png 
 gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
  gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
    "All_"$pat"_"$pair".png" -append \ 
    "All_VC_all_pats_all_chr_"$pair".png" 
 else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
 rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
 
pair="gt_depths(log)_vs_gt_quals" 
mkdir "$pair" 
cd "$pair" 
for pat in `echo $fire2 $fire3` ; do 
 ~/project/gemini_plotter_v5.R \ 
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "gt_depths" -y "gt_quals" \ 
  -G -l "x" --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000" \ 
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\""; 
gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
 gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \ 
   *$pat*$pair*chrM.png +append C.png 
 gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
  gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
  "All_"$pat"_"$pair".png" -append \ 
  "All_VC_all_pats_all_chr_"$pair".png" 
 else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
 rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
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Box A8 - Shell commands for plotting the depth of coverage vs. the variant caller-specific quality of called variants (2). 
Continued from Box A7. 
 
fire2="014 036 072 111 125 137 155" 
fire3="020 090 213 281 344 375 406 428 566 586 598 624 638 708 750 796" 
 
pair="gt_depths(log)_vs_gt_quals(log)" 
mkdir "$pair" 
cd "$pair" 
for pat in `echo $fire2 $fire3` ; do 
~/project/gemini_plotter_v5.R  
  -d ../../gemini_dbs/all_merged.decomposed.normalized.vcf.db \ 
  -f $pat -x "gt_depths" -y "gt_quals" \ 
  -G -l "xy" --no_local_titles --sample_global_titles \ 
  -w "qual != 'None' and qual >= 20 and qual < 10000" \ 
  --gt-filter "\"(gt_quals).(family_id = '"$pat"').(>=0).(any)\""; 
 gm convert `ls *$pat*$pair*chr{1..9}.png` +append A.png 
 gm convert `ls *$pat*$pair*chr{10..22}.png` +append B.png 
 gm convert *$pat*$pair*chrX.png *$pat*$pair*chrY.png \ 
   *$pat*$pair*chrM.png +append C.png 
 gm convert A.png B.png C.png +append "All_"$pat"_"$pair".png" 
    if [ -f "All_VC_all_pats_all_chr_"$pair".png" ]; then 
  gm convert "All_VC_all_pats_all_chr_"$pair".png" \ 
  "All_"$pat"_"$pair".png" -append \ 
  "All_VC_all_pats_all_chr_"$pair".png" 
 else 
  cp "All_"$pat"_"$pair".png" "All_VC_all_pats_all_chr_"$pair".png" 
 fi 
 rm "All_"$pat"_"$pair".png" 
done 
rm A.png B.png C.png 
cd .. 
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